FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Bagno, FF
   Godoi, LC
   Figueiredo, MM
   Sergio, SAR
   Moraes, TDS
   Salazar, ND
   Kim, YC
   Reyes-Sandoval, A
   da Fonseca, FG
AF Bagno, Flavia Fonseca
   Godoi, Lara Carvalho
   Figueiredo, Maria Marta
   Rodrigues Sergio, Sarah Aparecida
   Silva Moraes, Thais de Fatima
   Salazar, Natalia de Castro
   Kim, Young Chan
   Reyes-Sandoval, Arturo
   da Fonseca, Flavio Guimaraes
TI Chikungunya E2 Protein Produced inE. coliand HEK293-T Cells-Comparison
   of Their Performances in ELISA
SO VIRUSES-BASEL
LA English
DT Article
DE chikungunya virus; envelope protein 2; ELISA; heterologous expression;
   E; coli; HEK293-T cells
ID ENVELOPE PROTEINS; VIRUS; SERODIAGNOSIS; EXPRESSION; ENTRY; E1
AB Chikungunya virus (CHIKV) is a mosquito-borne pathogen that causes a disease characterized by the acute onset of fever accompanied by arthralgia and intense joint pain. Clinical similarities and cocirculation of this and other arboviruses in many tropical countries highlight the necessity for efficient and accessible diagnostic tools. CHIKV envelope proteins are highly conserved among alphaviruses and, particularly, the envelope 2 glycoprotein (CHIKV-E2) appears to be immunodominant and has a considerable serodiagnosis potential. Here, we investigate how glycosylation of CHIKV-E2 affects antigen/antibody interaction and how this affects the performance of CHIKV-E2-based Indirect ELISA tests. We compare two CHIKV-E2 recombinant antigens produced in different expression systems: prokaryotic-versus eukaryotic-made recombinant proteins. CHIKV-E2 antigens are expressed either inE. coliBL21(DE3)-a prokaryotic system unable to produce post-translational modifications-or in HEK-293T mammalian cells-a eukaryotic system able to add post-translational modifications, including glycosylation sites. Both prokaryotic and eukaryotic recombinant CHIKV-E2 react strongly to anti-CHIKV IgG antibodies, showing accuracy levels that are higher than 90%. However, the glycan-added viral antigen presents better sensitivity and specificity (85 and 98%) than the non-glycosylated antigen (81 and 71%, respectively) in anti-CHIKV IgM ELISA assays.
C1 [Bagno, Flavia Fonseca; Godoi, Lara Carvalho; Figueiredo, Maria Marta; Rodrigues Sergio, Sarah Aparecida; Silva Moraes, Thais de Fatima; Salazar, Natalia de Castro; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais UFMG, Ctr Tecnol Vacinas CT Vacinas, Parque Tecnol UFMG BH Tec, BR-31320000 Belo Horizonte, MG, Brazil.
   [Bagno, Flavia Fonseca; Silva Moraes, Thais de Fatima; da Fonseca, Flavio Guimaraes] Inst Ciencias Biol ICB UFMG, Dept Microbiol, Lab Virol Mol & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
   [Godoi, Lara Carvalho] Colegio Tecn Univ Fed Minas Gerais COLTEC, BR-31270901 Belo Horizonte, MG, Brazil.
   [Kim, Young Chan; Reyes-Sandoval, Arturo] Univ Oxford, Jenner Inst, Nuffield Dept Med, Henry Wellcome Bldg Mol Physiol, Roosevelt Dr, Oxford OX3 7DQ, England.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais UFMG, Ctr Tecnol Vacinas CT Vacinas, Parque Tecnol UFMG BH Tec, BR-31320000 Belo Horizonte, MG, Brazil.; da Fonseca, FG (corresponding author), Inst Ciencias Biol ICB UFMG, Dept Microbiol, Lab Virol Mol & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
EM flavia.bagno@gmail.com; lcarvalhogodoi@gmail.com;
   mariamartafigueiredo@gmail.com; sarsergio36@gmail.com;
   thais.moraes00@hotmail.com; natsalazar@gmail.com;
   young.kim@some.ox.ac.uk; arturo.reyes@ndm.ox.ac.uk;
   dafonsecaflavio@gmail.com
OI Godoi, Lara/0000-0003-3556-6701; Bagno, Flavia/0000-0003-1578-6678; Kim,
   Young Chan/0000-0003-2847-9407; Reyes-Sandoval,
   Arturo/0000-0002-2648-1696
FU CAPESCAPES; FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-03081-17 (EDITAL 001/2017-DEMANDA UNIVERSAL), CBB-APQ-04295-17
   (EDITAL 007/2017-PROGRAMA DE PESQUISA PARA O SUS/PPSUS)]; FINEPCiencia
   Tecnologia e Inovacao (FINEP); CNPqNational Council for Scientific and
   Technological Development (CNPq); UK Department of Health and Social
   Care through Innovate UK "New vaccines for global epidemics: development
   and manufacture" grant [972216]; ODA budget [Global Health (ODA)]
   [16/107/05]
FX This work was supported by CAPES, FAPEMIG, FINEP and CNPq. Grants from
   FAPEMIG were CBB-APQ-03081-17 (EDITAL 001/2017-DEMANDA UNIVERSAL) and
   CBB-APQ-04295-17 (EDITAL 007/2017-PROGRAMA DE PESQUISA PARA O
   SUS/PPSUS). A FINEP-ZIKA institutional grant was also important in the
   development of this work. FG da Fonseca is a CNPq fellowship recipient.
   For the proteins produced in mammalian HEK-293 cells, funding to A. R-S
   independent research was funded by the UK Department of Health and
   Social Care through Innovate UK "New vaccines for global epidemics:
   development and manufacture" grant No. 972216 (ARS), and also funded
   from an ODA budget [Global Health (ODA), 16/107/05-Design, development
   and GMP manufacture of a Zika vaccine].
CR Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799
   Baghban R, 2018, CURR PHARM BIOTECHNO, V19, P451, DOI 10.2174/1389201019666180718093037
   Bagno FF, 2019, J CLIN VIROL, V113, P27, DOI 10.1016/j.jcv.2019.02.006
   Banerjee Nilotpal, 2016, VirusDisease, V27, P1, DOI 10.1007/s13337-015-0293-5
   Campbell MJ, 2007, MED STAT TXB HLTH SC
   Cho B, 2008, YONSEI MED J, V49, P828, DOI 10.3349/ymj.2008.49.5.828
   Cifuentes-Munoz N, 2014, VIRUSES-BASEL, V6, P1801, DOI 10.3390/v6041801
   Erasmus JH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004119
   Fumagalli MJ, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1028-1
   Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005
   Goodman CH, 2014, J VIROL METHODS, V208, P66, DOI 10.1016/j.jviromet.2014.07.030
   Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049
   Jin J, 2015, CELL REP, V13, P2553, DOI 10.1016/j.celrep.2015.11.043
   Johnson BW, 2016, AM J TROP MED HYG, V95, P182, DOI 10.4269/ajtmh.16-0013
   KIM YC, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/v11050407
   Kost TA, 2016, ADV EXP MED BIOL, V896, P187, DOI 10.1007/978-3-319-27216-0_12
   Kr Verma A., 2014, BMC INFECT DIS, V14, pP65, DOI [10.1186/1471-2334-14-S3-P65, DOI 10.1186/1471-2334-14-S3-P65]
   Kumar P, 2014, J VIROL METHODS, V206, P67, DOI 10.1016/j.jviromet.2014.05.014
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lopez-Camacho C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040322
   Mendoza EJ, 2019, ZOONOSES PUBLIC HLTH, V66, P909, DOI 10.1111/zph.12641
   Metz SW, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-353
   Nigi Irene, 2017, Curr Protoc Protein Sci, V90, DOI 10.1002/cpps.44
   Ohuchi M, 1997, J VIROL, V71, P8377, DOI 10.1128/JVI.71.11.8377-8384.1997
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Prat CM, 2014, EMERG INFECT DIS, V20, P2129, DOI 10.3201/eid2012.141269
   Richardson JTE, 2011, STAT MED, V30, P890, DOI 10.1002/sim.4116
   Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172
   Shental-Bechor D, 2008, P NATL ACAD SCI USA, V105, P8256, DOI 10.1073/pnas.0801340105
   Spencer KA, 2007, VACCINE, V25, P5653, DOI 10.1016/j.vaccine.2007.02.053
   Sterner E, 2016, ACS CHEM BIOL, V11, P1773, DOI 10.1021/acschembio.6b00244
   Sun SY, 2013, ELIFE, V2, DOI 10.7554/eLife.00435
   Tripathi NK, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00420
   Tripathi NK, 2014, BIOENGINEERED, V5, DOI 10.4161/bioe.28336
   Tripathi NK, 2014, APPL MICROBIOL BIOT, V98, P2461, DOI 10.1007/s00253-013-5426-4
   United States National Center for Emerging and Zoonotic Infectious Diseases (CDC) Pan American Health Organization, 2011, PREP RESP CHIK VIR I
   Varki A., 2017, BIOL FUNCTIONS GLYCA
   Gomes AMV, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6020038
   VRATI S, 1988, VIROLOGY, V162, P346, DOI 10.1016/0042-6822(88)90474-6
   Weber C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005318
NR 41
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 939
DI 10.3390/v12090939
PG 12
WC Virology
SC Virology
GA OE8GI
UT WOS:000580761900001
PM 32858804
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Versiani, AF
   Martins, EMN
   Andrade, LM
   Cox, L
   Pereira, GC
   Barbosa-Stancioli, EF
   Nogueira, ML
   Ladeira, LO
   da Fonseca, FG
AF Versiani, Alice F.
   Martins, Estefania M. N.
   Andrade, Lidia M.
   Cox, Laura
   Pereira, Glauco C.
   Barbosa-Stancioli, Edel F.
   Nogueira, Mauricio L.
   Ladeira, Luiz O.
   da Fonseca, Flavio G.
TI Nanosensors based on LSPR are able to serologically differentiate dengue
   from Zika infections
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CAPPED GOLD NANOPARTICLES; ENVELOPE PROTEIN; VIRUS-INFECTION;
   ANTIBODIES; EPITOPES; NANOROD; GLYCOPROTEIN; IMMUNOASSAY; ENHANCEMENT;
   RECOMBINANT
AB The Flaviviridae virus family was named after the Yellow-fever virus, and the latin term flavi means "of golden color". Dengue, caused by Dengue virus (DENV), is one of the most important infectious diseases worldwide. A sensitive and differential diagnosis is crucial for patient management, especially due to the occurrence of serological cross-reactivity to other co-circulating flaviviruses. This became particularly important with the emergence of Zika virus (ZIKV) in areas were DENV seroprevalence was already high. We developed a sensitive and specific diagnostic test based on gold nanorods (GNR) functionalized with DENV proteins as nanosensors. These were able to detect as little as one picogram of anti-DENV monoclonal antibodies and highly diluted DENV-positive human sera. The nanosensors could differentiate DENV-positive sera from other flavivirus-infected patients, including ZIKV, and were even able to distinguish which DENV serotype infected individual patients. Readouts are obtained in ELISA-plate spectrophotometers without the need of specific devices.
C1 [Versiani, Alice F.; Cox, Laura; Barbosa-Stancioli, Edel F.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil.
   [Martins, Estefania M. N.] Ctr Desenvolvimento Tecnol Nucl CDTN CNEN, Lab Quim Nanoestruturas Carbono, Belo Horizonte, MG, Brazil.
   [Andrade, Lidia M.; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, Lab Nanomat, Belo Horizonte, MG, Brazil.
   [Pereira, Glauco C.] Fundacao Ezequiel Dias, FUNED, Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose Do Rio Preto, Dept Doencas Infecciosas & Parasitarias, Lab Pesquisa Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Versiani, Alice F.; Martins, Estefania M. N.; Andrade, Lidia M.; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, NanoBioMed Res Grp, Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio G.] Univ Fed Minas Gerais, Ctr Tecnol Vacinas, Belo Horizonte, MG, Brazil.
   [Versiani, Alice F.] Fac Med Sao Jose Rio Do Preto, Dept Doencas Infecciosas & Parasitarias, Lab Pesquisa Virol, Sao Jose Do Rio Preto, SP, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil.; da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Ctr Tecnol Vacinas, Belo Horizonte, MG, Brazil.
EM dafonseca@icb.ufmg.br
RI Nogueira, Mauricio L/B-7599-2012; Versiani, Alice/M-9782-2018; Andrade,
   Lidia/N-9552-2014
OI Nogueira, Mauricio L/0000-0003-1102-2419; Versiani,
   Alice/0000-0003-1378-5380; Barbosa-Stancioli, Edel/0000-0001-6584-4333;
   Andrade, Lidia/0000-0003-2594-4617
FU CAPESCAPES; FINEPCiencia Tecnologia e Inovacao (FINEP); CNPqNational
   Council for Scientific and Technological Development (CNPq);
   FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-03081-17 (EDITAL 001/2017), CBB-APQ-04295-17 (EDITAL
   007/2017)]; Rede Mineira de Pesquisa e Inovacao para Bioengenharia de
   Nanossistemas [RM PI-BEM-FAPEMIG-TEC-RED-00282-16]; FINEP-ZIKA
   institutional grant; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [13/21719-3]
FX We appreciate the scientific and technical support provided by R Freitas
   (Chemistry Department/UFMG), GS Trindade (Microbiology Department/UFMG),
   BM Silva (Department of Biological Sciences/UFOP), LV Cambraia
   (CTNano/UFMG), and EG Kroon (Microbiology Department/UFMG). We thank CA
   Furtado and AP Santos from the Centro de Desenvolvimento da Tecnologia
   Nuclear (CDTN) for encouraging the development of this project and for
   access to equipment and materials. We also thank FV de Oliveira for the
   artwork contributions. This work was supported by CAPES, FAPEMIG, FINEP
   and CNPq. Grants from FAPEMIG were CBB-APQ-03081-17 (EDITAL
   001/2017-DEMANDA UNIVERSAL), CBB-APQ-04295-17 (EDITAL 007/2017-PROGRAMA
   DE PESQUISA PARA O SUS/PPSUS) and Rede Mineira de Pesquisa e Inovacao
   para Bioengenharia de Nanossistemas (RM
   PI-BEM-FAPEMIG-TEC-RED-00282-16). A FINEP-ZIKA institutional grant was
   used in the development of this work. EF Barbosa-Stancioli, ML Nogueira,
   LO Ladeira and FG da Fonseca are CNPq fellowship recipients. ML Nogueira
   is supported by FAPESP (grant #13/21719-3). AFV was a CAPES Doctorate
   fellow and is currently a FAPESP fellow. Other than funding, sponsoring
   agencies had no role on the study design, collection and interpretation
   of the data, and writing of the manuscript. Two patents on the described
   results were filed: file BR 10 2013 033868 at the Instituto Nacional de
   Propriedade Intelectual (INPI, Brazil) and file 055498 at the World
   Intellectual Property Organization (WIPO-Geneva, Switzerland).
CR Acosta EG, 2014, ADV VIRUS RES, V88, P1, DOI 10.1016/B978-0-12-800098-4.00001-5
   Andrade LM, 2017, FUTURE VIROL, V12, P766, DOI 10.2217/fvl-2017-0086
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155
   Cabral-Castro MJ, 2016, J CLIN VIROL, V82, P108, DOI 10.1016/j.jcv.2016.07.017
   Cabral-Miranda G, 2018, BIOSENS BIOELECTRON, V113, P101, DOI 10.1016/j.bios.2018.04.058
   Carvalho F, 2018, J BIOMED NANOTECHNOL, V14, P829, DOI 10.1166/jbn.2018.2549
   CDC, 2019, DENG WHAT YOU NEED K
   Chang JY, 2005, CHEM COMMUN, P1092, DOI 10.1039/b414059a
   Chen HX, 2018, NANO LETT, V18, P4716, DOI 10.1021/acs.nanolett.8b01070
   Christian EA, 2013, P NATL ACAD SCI USA, V110, P18662, DOI 10.1073/pnas.1310962110
   Colombo TE, 2017, J CLIN VIROL, V96, P20, DOI 10.1016/j.jcv.2017.09.002
   Rocha ESD, 2013, J VIROL METHODS, V187, P114, DOI 10.1016/j.jviromet.2012.09.012
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Eberhardt K, 2015, EXPERT REV MOL DIAGN, V15, P773, DOI 10.1586/14737159.2015.1036744
   Estofolete CF, 2016, J CLIN VIROL, V81, P25, DOI 10.1016/j.jcv.2016.05.012
   Florkowski Christopher M, 2008, Clin Biochem Rev, V29 Suppl 1, pS83
   Guzmán María G., 2002, Rev Panam Salud Publica, V11, P223, DOI 10.1590/S1020-49892002000400003
   Guzman MG, 2010, EXPERT REV VACCINES, V9, P137, DOI [10.1586/erv.09.139, 10.1586/ERV.09.139]
   HALSTEAD SB, 1980, AM J TROP MED HYG, V29, P638, DOI 10.4269/ajtmh.1980.29.638
   Halstead SB, 2013, VACCINE, V31, P4501, DOI 10.1016/j.vaccine.2013.06.079
   Harrison SC, 2016, NAT IMMUNOL, V17, P1010, DOI 10.1038/ni.3539
   Jiang KY, 2004, J MATER CHEM, V14, P37, DOI 10.1039/b310359e
   Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17
   Khoshnevisan K, 2018, J DRUG TARGET, V26, P525, DOI 10.1080/1061186X.2017.1387790
   Koppolu V, 2018, J NEUROVIROL, V24, P255, DOI 10.1007/s13365-018-0614-8
   Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994
   Krishna VD, 2018, FOOD MICROBIOL, V75, P47, DOI 10.1016/j.fm.2018.01.025
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lee JH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072021
   Lin HE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001447
   Lindenbach B, 2007, FIELDS VIROLOGY, P1101, DOI DOI 10.1016/0038-092X(88)90131-4
   Lu YD, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8080629
   Malinowski PE, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17122867
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Mei Z, 2017, GOLD NANOROD ARRAY B, P129
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   Metz SW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0970-2
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Narvaez F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001397
   Nezami A, 2018, J PHARMACEUT BIOMED, V159, P425, DOI 10.1016/j.jpba.2018.07.031
   Panning M, 2017, EBIOMEDICINE, V16, P12, DOI 10.1016/j.ebiom.2017.01.045
   Truong PL, 2012, LAB CHIP, V12, P1102, DOI 10.1039/c2lc20588b
   Pissuwan D, 2008, BIOTECHNOL GENET ENG, V25, P93, DOI 10.5661/bger-25-93
   Quinan BR, 2014, VACCINE, V32, P2972, DOI 10.1016/j.vaccine.2014.03.093
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   da Silva ANMR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007425
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Roux S, 2005, LANGMUIR, V21, P2526, DOI 10.1021/la048082i
   Sharma V, 2009, MAT SCI ENG R, V65, P1, DOI 10.1016/j.mser.2009.02.002
   Shukla S, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01685
   Stiasny K, 2006, J GEN VIROL, V87, P2755, DOI 10.1099/vir.0.82210-0
   Stone J, 2011, WIRES NANOMED NANOBI, V3, P100, DOI 10.1002/wnan.120
   Stone J, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/29/295102
   Tang L, 2014, BIOSENS BIOELECTRON, V61, P70, DOI 10.1016/j.bios.2014.04.043
   Tsai WY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01372
   van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001
   Versiani A.F., 2016, FUTURE VIROL, V11, P1
   Versiani AF, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0259-4
   Vikesland PJ, 2018, NAT NANOTECHNOL, V13, P651, DOI 10.1038/s41565-018-0209-9
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Wang A., 2014, J NANOMATER, V2014, P1, DOI DOI 10.1016/J.CARB0N.2014.01.066
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   World Health Organization, 2019, DENG SEV DENG
   Yang CT, 2016, ANAL CHEM, V88, P11924, DOI 10.1021/acs.analchem.6b03798
   Yu C, 2007, BIOPHYS J, V93, P3684, DOI 10.1529/biophysj.107.110064
   Zhang H, 2013, TALANTA, V115, P857, DOI 10.1016/j.talanta.2013.06.059
NR 71
TC 1
Z9 1
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 9
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-68357-9
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK1RX
UT WOS:000548564900016
PM 32647259
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Rodrigues-Alves, ML
   Melo, OAD
   Silveira, P
   Mariano, RMD
   Leite, JC
   Santos, TAP
   Soares, IS
   Lair, DF
   Melo, MM
   Resende, LA
   da Silveira-Lemos, D
   Dutra, WO
   Gontijo, ND
   Araujo, RN
   Sant'Anna, MRV
   Andrade, LAF
   da Fonseca, FG
   Moreira, LA
   Giunchetti, RC
AF Rodrigues-Alves, Marina Luiza
   Melo-Junior, Otoni Alves de Oliveira
   Silveira, Patricia
   Mariano, Reysla Maria da Silveira
   Leite, Jaqueline Costa
   Santos, Thaiza Aline Pereira
   Soares, Ingrid Santos
   Lair, Daniel Ferreira
   Melo, Marilia Martins
   Resende, Lucilene Aparecida
   da Silveira-Lemos, Denise
   Dutra, Walderez Ornelas
   Gontijo, Nelder de Figueiredo
   Araujo, Ricardo Nascimento
   Sant'Anna, Mauricio Roberto Viana
   Andrade, Luis Adan Flores
   da Fonseca, Flavio Guimaraes
   Moreira, Luciano Andrade
   Giunchetti, Rodolfo Cordeiro
TI Historical Perspective and Biotechnological Trends to Block Arboviruses
   Transmission by ControllingAedes aegyptiMosquitos Using Different
   Approaches
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE Aedes aegypti; arboviruses; vector control; Latin America; vaccines
ID AEDES-AEGYPTI DIPTERA; ZIKA VIRUS; CHIKUNGUNYA VIRUS; PLASMODIUM-VIVAX;
   DENGUE VACCINES; MAYARO VIRUS; 1ST REPORT; WOLBACHIA; VECTOR; INFECTION
AB Continuous climate changes associated with the disorderly occupation of urban areas have exposed Latin American populations to the emergence and reemergence of arboviruses transmitted byAedes aegypti. The magnitude of the financial and political problems these epidemics may bring to the future of developing countries is still ignored. Due to the lack of effective antiviral drugs and vaccines against arboviruses, the primary measure for preventing or reducing the transmission of diseases depends entirely on the control of vectors or the interruption of human-vector contact. In Brazil the first attempt to controlA. aegyptitook place in 1902 by eliminating artificial sites of eproduction. Other strategies, such as the use of oviposition traps and chemical control with dichlorodiphenyltrichlorethane and pyrethroids, were successful, but only for a limited time. More recently, biotechnical approaches, such as the release of transgenics or sterile mosquitoes and the, development of transmission blocking vaccines, are being applied to try to control theA. aegyptipopulation and/or arbovirus transmission. Endemic countries spend about twice as much to treat patients as they do on the prevention of mosquito-transmitted diseases. The result of this strategy is an explosive outbreak of arboviruses cases. This review summarizes the social impacts caused byA. aegypti-transmitted diseases, mainly from a biotechnological perspective in vector control aimed at protecting Latin American populations against arboviruses.
C1 [Rodrigues-Alves, Marina Luiza; Melo-Junior, Otoni Alves de Oliveira; Silveira, Patricia; Mariano, Reysla Maria da Silveira; Leite, Jaqueline Costa; Santos, Thaiza Aline Pereira; Soares, Ingrid Santos; Lair, Daniel Ferreira; Resende, Lucilene Aparecida; da Silveira-Lemos, Denise; Dutra, Walderez Ornelas; Giunchetti, Rodolfo Cordeiro] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Biol Interacoes Celulares, Belo Horizonte, MG, Brazil.
   [Melo, Marilia Martins] Univ Fed Minas Gerais, Dept Clin & Cirurg Vet, Escola Vet, Belo Horizonte, MG, Brazil.
   [da Silveira-Lemos, Denise] Univ Jose Rosario Vellano, Dept Med, UNIFENAS, Belo Horizonte, MG, Brazil.
   [Gontijo, Nelder de Figueiredo; Araujo, Ricardo Nascimento; Sant'Anna, Mauricio Roberto Viana] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, Lab Fisiol Insetos Hematofagos, Belo Horizonte, MG, Brazil.
   [Andrade, Luis Adan Flores; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil.
   [Moreira, Luciano Andrade] Fiocruz MS, Inst Rene Rachou, Lab Mosquitos Vetores Endossimbiontes & Interacao, Belo Horizonte, MG, Brazil.
RP Giunchetti, RC (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Biol Interacoes Celulares, Belo Horizonte, MG, Brazil.
EM giunchetti@icb.ufmg.br
OI Cordeiro Giunchetti, Rodolfo/0000-0003-4181-7546
FU Fundacao de Amparo a Pesquisa do Estado de Minas GeraisMinas Gerais
   State Research Foundation (FAPEMIG) [PPM-00637-17]; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq) [309327/2017-2]; Ministerio da
   Saude/DECIT; CAPESCAPES; Instituto Nacional de Ciencia e Tecnologia em
   Doencas Tropicais (INCT-DT)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Minas Gerais (grant PPM-00637-17 to RG), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (grant 309327/2017-2 to RG),
   Ministerio da Saude/DECIT, CAPES and Instituto Nacional de Ciencia e
   Tecnologia em Doencas Tropicais (INCT-DT).
CR Ali S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005135
   Alice FJ, 1951, REV BRAS BIOL, V11, P125
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004677
   Zumaya-Estrada FA, 2018, SALUD PUBLICA MEXICO, V60, P77, DOI 10.21149/8140
   Alphey L, 2002, INSECT BIOCHEM MOLEC, V32, P1243, DOI 10.1016/S0965-1748(02)00087-5
   Alphey L, 2002, MOL BIOCHEM PARASIT, V121, P173, DOI 10.1016/S0166-6851(02)00040-3
   Alphey L, 2010, VECTOR-BORNE ZOONOT, V10, P295, DOI 10.1089/vbz.2009.0014
   Andrade M, 2007, CANCER TREAT RES, P55
   Azevedo AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058357
   Azevedo AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020528
   Barbosa PBBM, 2014, PARASITOL RES, V113, P3565, DOI 10.1007/s00436-014-4022-6
   Barrera R, 2017, J MED ENTOMOL, V54, P387, DOI 10.1093/jme/tjw187
   Beaty B.J., 1996, BIOL DIS VECTORS
   Boyce R, 2013, TROP MED INT HEALTH, V18, P564, DOI 10.1111/tmi.12087
   Brownstin JS, 2003, J INVERTEBR PATHOL, V84, P24, DOI 10.1016/S0022-2011(03)00082-X
   Caglioti C, 2013, NEW MICROBIOL, V36, P211
   Nascimento KLC, 2020, ENVIRON HEALTH INSIG, V14, DOI 10.1177/1178630219886570
   Dutra HLC, 2016, CELL HOST MICROBE, V19, P771, DOI 10.1016/j.chom.2016.04.021
   Dutra HLC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003689
   Carvalho DO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003864
   Carvalho FD, 2017, NEOTROP ENTOMOL, V46, P243, DOI 10.1007/s13744-017-0520-4
   CAUSEY OR, 1957, AM J TROP MED HYG, V6, P1017, DOI 10.4269/ajtmh.1957.6.1017
   Chavez JH, 2013, AM J TROP MED HYG, V89, P1013, DOI 10.4269/ajtmh.12-0591
   Cleton N, 2012, J CLIN VIROL, V55, P191, DOI 10.1016/j.jcv.2012.07.004
   Conway MJ, 2014, ANNU REV VIROL, V1, P71, DOI 10.1146/annurev-virology-031413-085513
   Cook PE, 2008, ADV EXP MED BIOL, V627, P126, DOI 10.1007/978-0-387-78225-6_11
   da Costa VG, 2014, VACCINE, V32, P4885, DOI 10.1016/j.vaccine.2014.07.008
   da-Cunha MP, 2005, MEM I OSWALDO CRUZ, V100, P441, DOI 10.1590/S0074-02762005000400017
   de Omena MC, 2007, BIORESOURCE TECHNOL, V98, P2549, DOI 10.1016/j.biortech.2006.09.040
   DEARRUDA M, 1986, AM J TROP MED HYG, V35, P873, DOI 10.4269/ajtmh.1986.35.873
   DEOLIVEIRAFERREIRA J, 1990, AM J TROP MED HYG, V43, P6
   Diaz-Gonzalez EE, 2015, AM J TROP MED HYG, V93, P1325, DOI 10.4269/ajtmh.15-0450
   Durbin AP, 2011, VIRUSES-BASEL, V3, P1800, DOI 10.3390/v3101800
   Ekwudu O, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-3936-3
   Evans BR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49660-6
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Fitzpatrick C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005785
   Garcia GA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56766-4
   Gerhardt RR, 2001, EMERG INFECT DIS, V7, P807
   Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105
   Govindarajan M., 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P43, DOI 10.1016/S2221-1691(11)60066-X
   GROOT H, 1959, AM J TROP MED HYG, V8, P604, DOI 10.4269/ajtmh.1959.8.604
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Gubler J., 1998, HLTH ENV DIGEST, V12, P54
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Harris AF, 2012, NAT BIOTECHNOL, V30, P828, DOI 10.1038/nbt.2350
   Harris AF, 2011, NAT BIOTECHNOL, V29, P1034, DOI 10.1038/nbt.2019
   Hertig M, 1924, J MED RES, V44, P329
   Hoffmann AA, 2011, NATURE, V476, P454, DOI 10.1038/nature10356
   Huang CYH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002243
   Hubalek Z, 2008, PARASITOL RES, V103, pS29, DOI 10.1007/s00436-008-1064-7
   Jiang KY, 2004, J MATER CHEM, V14, P37, DOI 10.1039/b310359e
   JUPP PG, 1981, T ROY SOC TROP MED H, V75, P15, DOI 10.1016/0035-9203(81)90005-5
   Kantor IN, 2016, MEDICINA-BUENOS AIRE, V76, P93
   Kittayapong P, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007771
   Kittayapong P, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3214-9
   Komar N, 2006, REV PANAM SALUD PUBL, V19, P112, DOI 10.1590/S1020-49892006000200006
   Kraemer MUG, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.35
   La Corte R, 2018, REV SOC BRAS MED TRO, V51, P284, DOI 10.1590/0037-8682-0449-2017
   Londono-Renteria B, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1802-0
   Long KC, 2011, AM J TROP MED HYG, V85, P750, DOI 10.4269/ajtmh.2011.11-0359
   Soares ENL, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0341-2018
   Lourenco de Oliveira R, 2015, DENGUE TEORIAS PRATI, P75
   Luna JD, 2005, J ETHNOPHARMACOL, V97, P199, DOI 10.1016/j.jep.2004.10.004
   Mackay AJ, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-225
   Macoris MD, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006390
   del Angel RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003551
   Martens P, 1999, AM SCI, V87, P534, DOI 10.1511/1999.42.839
   Mathias DK, 2012, INFECT IMMUN, V80, P1606, DOI 10.1128/IAI.06212-11
   McAllister JC, 2012, J VECTOR ECOL, V37, P325, DOI 10.1111/j.1948-7134.2012.00234.x
   McArthur MA, 2013, EXPERT REV VACCINES, V12, P933, DOI 10.1586/14760584.2013.815412
   McMeniman CJ, 2009, SCIENCE, V323, P141, DOI 10.1126/science.1165326
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Michael E, 1996, PARASITOLOGY, V112, P409, DOI 10.1017/S0031182000066646
   Miyata T, 2011, VACCINE, V29, P2720, DOI 10.1016/j.vaccine.2011.01.083
   MONATH TP, 1985, AM J TROP MED HYG, V34, P966, DOI 10.4269/ajtmh.1985.34.966
   Moreira LA, 2009, CELL, V139, P1268, DOI 10.1016/j.cell.2009.11.042
   Moulin E, 2016, New Microbes New Infect, V11, P6, DOI 10.1016/j.nmni.2016.02.003
   Moyes CL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005625
   O'Neill Scott L, 2018, Gates Open Res, V2, P36, DOI 10.12688/gatesopenres.12844.3
   Palchick S, 1996, BIOL DIS VECTORS, P816
   Pan American Health Organization, 2017, NEGL TROP VECT BORN
   Patil CD, 2011, PARASITOL RES, V108, P1253, DOI 10.1007/s00436-010-2174-6
   PINHEIRO FP, 1976, TROPENMED PARASITOL, V27, P213
   Piovezan R, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3794-z
   Ponlawat A, 2005, J MED ENTOMOL, V42, P821, DOI 10.1603/0022-2585(2005)042[0821:ISOAAA]2.0.CO;2
   Pontual EV, 2012, ARCH INSECT BIOCHEM, V79, P135, DOI 10.1002/arch.21012
   Powell JR, 2013, MEM I OSWALDO CRUZ, V108, P11, DOI 10.1590/0074-0276130395
   Qiu Y, 2020, VACCINE, V38, P2841, DOI 10.1016/j.vaccine.2020.02.011
   Rasgon JL, 2003, J MED ENTOMOL, V40, P125, DOI 10.1603/0022-2585-40.2.125
   Ross PA, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007958
   Ryan Peter A, 2019, Gates Open Res, V3, P1547, DOI 10.12688/gatesopenres.13061.2
   Santacoloma Veron L, 2012, REV PANAM SALUD PUBL, V27, P66, DOI [10.1590/S1020-49892010000100010, DOI 10.1590/S1020-49892010000100010]
   Santos da Silva Antonia, 2014, Rev Cubana Med Trop, V66, P174
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Seccacini E, 2014, PARASITOL RES, V113, P3355, DOI 10.1007/s00436-014-3998-2
   Sharp TM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007538
   Sinkins SP, 2000, INSECT TRANSGENESIS, P271
   Sutherst RW, 2004, CLIN MICROBIOL REV, V17, P136, DOI 10.1128/CMR.17.1.136-173.2004
   Tatem AJ, 2006, ADV PARASIT, V62, P293, DOI 10.1016/S0065-308X(05)62009-X
   Thomas SJ, 2013, AM J TROP MED HYG, V88, P73, DOI 10.4269/ajtmh.2012.12-0361
   Torresi J, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002261
   United Nation, 2014, WORLD URB PROGR
   Valle D, 2015, DENGUE TEORIAS PRATI, P93
   Valle Denise, 2019, Mem. Inst. Oswaldo Cruz, V114, pe180544, DOI 10.1590/0074-02760180544
   Walker T, 2011, NATURE, V476, P450, DOI 10.1038/nature10355
   Wermelinger ED, 2015, REV SOC BRAS MED TRO, V48, P770, DOI 10.1590/0037-8682-0087-2015
   Womack M., 1993, WING BEATS, V5, P4
   World Health Organization, 2017, WKLY EPIDEMIOL REC, V90, P609
   Yenkoidiok-Douti L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53208-z
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
   Zhao H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086573
   Zheng XY, 2019, NATURE, V572, P56, DOI 10.1038/s41586-019-1407-9
   Zust R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003521
NR 115
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 23
PY 2020
VL 7
AR 275
DI 10.3389/fmed.2020.00275
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML2GJ
UT WOS:000549290700001
PM 32656216
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Slhessarenko, RD
   dos Santos, MAM
   Lunardi, M
   Carneiro, BM
   Chavez-Pavoni, JH
   de Aguiar, DM
   Trettel, ACPT
   Andrighetti, CR
   da Fonseca, FG
   Araujo, JP
   Campos, FS
   de Arruda, LB
   Abrahao, JS
   Spilki, FR
AF Slhessarenko, Renata Dezengrini
   Mendes dos Santos, Marcelo Adriano
   Lunardi, Michele
   Carneiro, Bruno Moreira
   Chavez-Pavoni, Juliana Helena
   de Aguiar, Daniel Moura
   Pereira Tercas Trettel, Ana Claudia
   Andrighetti, Carla Regina
   da Fonseca, Flavio Guimaraes
   Araujo Junior, Joao Pessoa
   Campos, Fabricio Souza
   de Arruda, Luciana Barros
   Abrahao, Jonatas Santos
   Spilki, Fernando Rosado
TI 30th Brazilian Society for Virology 2019 Annual Meeting-Cuiaba, Mato
   Grosso, Brazil
SO VIRUSES-BASEL
LA English
DT Article
DE molecular virology; viral pathogenesis; antivirals; viral epidemiology;
   viral diseases
AB The 30th meeting of the Brazilian Society for Virology (SBV) was held, for the first time in its 30 years of existence, in Cuiaba, the capital of Mato Grosso State, Central Western Brazil, a tropical region between the three richest biomes in the world: Amazon Florest, Cerrado and Pantanal. In recent years, the field of virology has been built in the State. The aim of this report is to support participants and virologists to receive the most up-to-date information about the meeting, which occurred from 16 to 19 October 2019. National and international speakers gave SBV the opportunity to learn about their experience on their virology fields, sharing recent scientific findings, compiling conferences, round table presentations and work presentations in oral and poster sessions. The meeting held over 300 attendants, who were also involved on oral and poster presentations, showing a great variety of recent unpublished studies on environmental, basic, animal, human, plant and invertebrate virology. In addition, SBV offered the Helio Gelli Pereira award for the best research studies in each field presented during the meeting. The 30th meeting of SBV was very productive and has also encouraged scientific partnership and collaboration among virologists worldwide.
C1 [Slhessarenko, Renata Dezengrini] Univ Fed Mato Grosso UFMT, Fac Med, Lab Virol, BR-78060900 Cuiaba, MT, Brazil.
   [Mendes dos Santos, Marcelo Adriano] Univ Estado Mato Grosso UNEMAT, Fac Ciencias Saude, BR-78200000 Caceres, MT, Brazil.
   [Lunardi, Michele] Univ Cuiaba UNIC, Lab Vet Microbiol, BR-78065900 Cuiaba, MT, Brazil.
   [Carneiro, Bruno Moreira; Chavez-Pavoni, Juliana Helena] Univ Fed Rondonopolis UFR, Inst Ciencias Exatas & Nat, BR-78735090 Rondonopolis, MT, Brazil.
   [de Aguiar, Daniel Moura] Univ Fed Mato Grosso UFMT, Fac Med Vet, Lab Virol & Rickettiososes, BR-78060900 Cuiaba, MT, Brazil.
   [Pereira Tercas Trettel, Ana Claudia] Univ Estado Mato Grosso UNEMAT, Nursing Dept, BR-78300000 Tangara Da Serra, MT, Brazil.
   [Pereira Tercas Trettel, Ana Claudia] Univ Fed Mato Grosso UFMT, Collect Hlth Inst, BR-78060900 Cuiaba, MT, Brazil.
   [Andrighetti, Carla Regina] Univ Fed Mato Grosso UFMT, Inst Ciencias Saude, BR-78550728 Sinop, MT, Brazil.
   [da Fonseca, Flavio Guimaraes; Abrahao, Jonatas Santos] Univ Fed Minas Gerais UFMG, Dept Microbiol, BR-31270901 Belo Horizonte, MT, Brazil.
   [Araujo Junior, Joao Pessoa] Univ Estadual Paulista UNESP, Inst Biotechnol, BR-18607440 Botucatu, SP, Brazil.
   [Campos, Fabricio Souza] Univ Fed Tocantins UFT, Bioinformat & Biotechnol Lab, Campus Gurupi, BR-77410570 Gurupi, TO, Brazil.
   [de Arruda, Luciana Barros] Univ Fed Rio de Janeiro UFRJ, Inst Microbiol Paulo de Goes, Dept Virol, Lab Genet & Imunol Infeccoes Virais, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Spilki, Fernando Rosado] Federacao Estabelecimentos Ensino Super Novo Hamb, One Hlth Lab, BR-93525075 Novo Hamburgo, RS, Brazil.
RP Slhessarenko, RD (corresponding author), Univ Fed Mato Grosso UFMT, Fac Med, Lab Virol, BR-78060900 Cuiaba, MT, Brazil.; Spilki, FR (corresponding author), Federacao Estabelecimentos Ensino Super Novo Hamb, One Hlth Lab, BR-93525075 Novo Hamburgo, RS, Brazil.
EM renatadezengrini@yahoo.com.br; mardriano@gmail.com;
   michelelunardi@gmail.com; bruno@ufr.edu.br; juliana.helena@ufr.edu.br;
   danmoura@ufmt.br; ana.claudia@unemat.br; crandrei20@yahoo.com.br;
   fdafonseca@icb.ufmg.br; joao.pessoa@unesp.br; camposvet@gmail.com;
   arruda@micro.ufrj.br; jonatas.abrahao@gmail.com; fernandors@feevale.br
RI Spilki, Fernando/E-3736-2010; Campos, Fabricio Souza/ABA-6693-2020;
   Moura de Aguiar, Daniel/F-1268-2013
OI Spilki, Fernando/0000-0001-5804-7045; Campos, Fabricio
   Souza/0000-0002-5948-472X; ANDRIGHETTI, CARLA/0000-0001-6307-8399; Moura
   de Aguiar, Daniel/0000-0001-8631-522X; Tercas Trettel, Ana Claudia
   Pereira/0000-0001-8761-3325; Arruda, Luciana/0000-0002-7011-7197;
   Carneiro, Bruno/0000-0002-2355-7907; Slhessarenko,
   Renata/0000-0002-3246-899X
FU Brazilian Ministry of Health DECIT unit, Unimed Cuiaba, Feevale
   University; Altona Diagnostics Brazil; Zoetis Brazil Animal health;
   Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Ltd;
   Sigma-Aldrich Brazil; PEPperPRINT; Eco Diagnostica; CNPqNational Council
   for Scientific and Technological Development (CNPq) [401625/2019-2]
FX This meeting was funded by the Brazilian Ministry of Health DECIT unit,
   Unimed Cuiaba, Feevale University, Altona Diagnostics Brazil, Zoetis
   Brazil Animal health, Takeda Pharmaceutical Company, Sigma-Aldrich
   Brazil, PEPperPRINT, Eco Diagnostica and a CNPq grant number
   401625/2019-2.
CR Bertti K.M.L.B., 2018, THESIS
   Cahu R.C., 2019, P 30 BRAZ VIR C CUIA, P235
   Cestari L., 2019, P 30 BRAZ VIR C CUIA, P115
   Da Costa C.S., 2019, P 30 BRAZ VIR C CUIA, P159
   De Jesus B.L.S., 2019, P 30 BRAZ VIR C CUIA, P293
   De Jesus M.J.R., 2019, P 30 BRAZ VIR C CUIA, P246
   De Oliveira M.H.G.P., 2020, THESIS
   Fumagalli M.J., 2019, P 30 BRAZ VIR C CUIA, P220
   Hennigen A.F., 2019, P 30 BRAZ VIR C CUIA, P264
   Leal L.L., 2019, P 30 BRAZ VIR C CUIA
   Morgado F.S., 2019, P 30 BRAZ VIR C CUIA
   da Silva SJR, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010019
   Souza D.S.M., 2019, P 30 BRAZ VIR C CUIA, P147
   Toledo-Teixeira D.A., 2019, THESIS
NR 14
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2020
VL 12
IS 5
AR 494
DI 10.3390/v12050494
PG 9
WC Virology
SC Virology
GA NJ2FF
UT WOS:000565860200011
PM 32365597
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silva, DSDDE
   Barbosa-Stancioli, EF
   Coelho-Dos-Reis, JGA
   Da Fonseca, FG
AF Silva, Danielle Soares de Oliveira Daian e
   Barbosa-Stancioli, Edel Figueiredo
   Coelho-Dos-Reis, Jordana Graziela Alves
   Da Fonseca, Flavio Guimaraes
TI Short communication: a modified Vaccinia virus Ankara-based Porcine
   circovirus 2 vaccine elicits strong antibody response upon prime-boost
   homologous immunization in a preclinical model
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Porcine circovirus 2; Capsid protein; Modified Vaccinia virus Ankara
   (MVA); Recombinant vaccine; Homologous vaccination regimen
ID MULTISYSTEMIC WASTING SYNDROME; CAPSID PROTEIN; TYPE-2 PCV2; PIGS;
   INFECTION; PATHOGENESIS; COMBINATION; PROTECTION; EFFICACY; IMMUNITY
AB Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species.
C1 [Silva, Danielle Soares de Oliveira Daian e; Barbosa-Stancioli, Edel Figueiredo; Coelho-Dos-Reis, Jordana Graziela Alves; Da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Presidente Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
RP Da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Presidente Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Daian+e+Silva, Danielle/AAF-8852-2020
OI Barbosa-Stancioli, Edel/0000-0001-6584-4333
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Hertape Saude Animal Ltda - Hertape Saude Animal Ltda;
   CEVA Saude Animal Ltda
FX This study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) and by Hertape Saude Animal Ltda. The work was
   partially funded by Hertape Saude Animal Ltda. The company has been
   acquired by CEVA Saude Animal Ltda.
CR Aravindaram K, 2009, J GENE MED, V11, P288, DOI 10.1002/jgm.1300
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Calvo-Pinilla E, 2009, VACCINE, V28, P437, DOI 10.1016/j.vaccine.2009.10.027
   Carson C, 2009, VACCINE, V27, P1080, DOI 10.1016/j.vaccine.2008.11.094
   Castillo-Olivares J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016503
   Chandran D, 2010, INDIAN J MICROBIOL, V50, P266, DOI 10.1007/s12088-010-0026-9
   Chiam R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005997
   Silva DSODE, 2019, BRAZ J MICROBIOL, V50, P347, DOI 10.1007/s42770-019-00067-5
   Davies PR, 2012, TRANSBOUND EMERG DIS, V59, P18, DOI 10.1111/j.1865-1682.2012.01312.x
   Firth C, 2009, J VIROL, V83, P12813, DOI 10.1128/JVI.01719-09
   Ferrer MF, 2011, VIRAL IMMUNOL, V24, P331, DOI 10.1089/vim.2011.0018
   Grau-Roma L, 2009, VET MICROBIOL, V135, P272, DOI 10.1016/j.vetmic.2008.10.007
   Kamstrup S, 2004, VACCINE, V22, P1358, DOI 10.1016/j.vaccine.2004.01.032
   Lin WL, 2009, BIOCHEM BIOPH RES CO, V379, P1066, DOI 10.1016/j.bbrc.2009.01.001
   Martelli P, 2011, VET MICROBIOL, V149, P339, DOI 10.1016/j.vetmic.2010.12.008
   Meerts Peter, 2006, BMC Vet Res, V2, P6, DOI 10.1186/1746-6148-2-6
   Meng XJ, 2013, ANNU REV ANIM BIOSCI, V1, P43, DOI 10.1146/annurev-animal-031412-103720
   Opriessnig T, 2009, VACCINE, V27, P1002, DOI 10.1016/j.vaccine.2008.11.105
   Opriessnig T, 2007, J VET DIAGN INVEST, V19, P591, DOI 10.1177/104063870701900601
   Perez-Jimenez E, 2006, MICROBES INFECT, V8, P810, DOI 10.1016/j.micinf.2005.10.004
   Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006
   Quinan BR, 2016, VACCINE, V34, P6120, DOI 10.1016/j.vaccine.2016.10.058
   Quinan BR, 2014, FUTURE VIROL, V9, P173, DOI 10.2217/fvl.13.129
   Ramos I, 2008, VACCINE, V26, P333, DOI 10.1016/j.vaccine.2007.11.021
   Rodriguez-Arrioja GM, 2000, VET REC, V146, P762, DOI 10.1136/vr.146.26.762
   Roth JA, 2011, PROCEDIA VACCINOL, V5, P127, DOI 10.1016/j.provac.2011.10.009
   Segales Joaquim, 2005, Animal Health Research Reviews, V6, P119, DOI 10.1079/AHR2005106
   Sibila M, 2004, AM J VET RES, V65, P88, DOI 10.2460/ajvr.2004.65.88
   Wang K, 2008, J VIROL METHODS, V150, P1, DOI 10.1016/j.jviromet.2008.02.014
   Wang XW, 2007, VET MICROBIOL, V121, P215, DOI 10.1016/j.vetmic.2006.11.027
   Wang YP, 2015, APPL MICROBIOL BIOT, V99, P1155, DOI 10.1007/s00253-014-6167-8
   Weyer J, 2009, VACCINE, V27, P7198, DOI 10.1016/j.vaccine.2009.09.033
   White LA, 2017, PREV VET MED, V138, P55, DOI 10.1016/j.prevetmed.2016.12.013
   Zhang HW, 2014, VIRUSES-BASEL, V6, P4839, DOI 10.3390/v6124839
   Zheng LL, 2015, VIRUS RES, V201, P8, DOI 10.1016/j.virusres.2015.02.010
NR 35
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD SEP
PY 2020
VL 51
IS 3
BP 1439
EP 1445
DI 10.1007/s42770-020-00247-8
EA MAR 2020
PG 7
WC Microbiology
SC Microbiology
GA NF8EM
UT WOS:000532897100001
PM 32144692
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Andrade, LM
   Martins, EMN
   Versiani, AF
   Reis, DS
   da Fonseca, FG
   de Souza, IP
   Paniago, RM
   Pereira-Maia, E
   Ladeira, LO
AF Andrade, Lidia M.
   Martins, Estefania M. N.
   Versiani, Alice F.
   Reis, Daniela S.
   da Fonseca, Flavio G.
   de Souza, Ivina P.
   Paniago, Roberto M.
   Pereira-Maia, Elene
   Ladeira, Luiz O.
TI The physicochemical and biological characterization of a 24-month-stored
   nanocomplex based on gold nanoparticles conjugated with cetuximab
   demonstrated long-term stability, EGFR affinity and cancer cell death
   due to apoptosis
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Long-term stability; Gold nanoparticles; Cetuximab; Apoptosis; Cancer
ID DRUG-DELIVERY SYSTEM; ANTIBODY; IMMOBILIZATION; OPPORTUNITIES;
   TRAFFICKING; MECHANISMS; RESISTANCE; THERAPY; MODEL; SIZE
AB Nanotechnology is one of the most promising tools for future diagnosis and therapy. Thus, we have produced gold nanoparticles coated with cetuximab at a dose-range from 5 mu g up to 200 mu g, and prolonged stable nanocomplexes were obtained. The nanocomplexes were characterized by UV-Vis, zeta potential, TEM, fluorometry, infrared regions, XPS and atomic absorption spectrometry. For biological characterization the A431 cell line was used. Cellular uptake, target affinity and cell death were assessed using ICP-OES, immunocytochemistry and flow cytometry, respectively. The immobilization of cetuximab on the AuNPs surfaces was confirmed. The nanocomplex with 24 months of manufacturing promoted efficient EGFR binding and induced tumour cell death due to apoptosis. Significant (p < 0.05) cell death was achieved using relatively low cetuximab concentration for AuNPs coating compared to the antibody alone. Therefore, our results provided robust physicochemical and biological characterization data corroborating the cetuximab-bioconjugate AuNPs as a feasible nanocomplex for biomedical applications.
C1 [Andrade, Lidia M.; Martins, Estefania M. N.; Versiani, Alice F.; Paniago, Roberto M.; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, Nanobiomed Res Grp, Belo Horizonte, MG, Brazil.
   [Martins, Estefania M. N.] Ctr Desenvolvimento Tecnol Nucl, Belo Horizonte, MG, Brazil.
   [Versiani, Alice F.] Fac Med Sao Jose do Rio Preto, Dept Doencas Dermatol Infecciosas & Parasitarias, Sao Jose Do Rio Preto, SP, Brazil.
   [Reis, Daniela S.] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio G.] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [de Souza, Ivina P.; Pereira-Maia, Elene] Univ Fed Minas Gerais, Dept Quim, Belo Horizonte, MG, Brazil.
   [de Souza, Ivina P.] Ctr Fed Educ Tecnol Minas Gerais, Dept Quim, Belo Horizonte, MG, Brazil.
RP Andrade, LM (corresponding author), Univ Fed Minas Gerais, Dept Fis, ICEx, Av Antonio Carlos,6627 Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM lidia.nanobmrg@gmail.com
RI Paniago, Roberto M./N-1854-2014; Maia, Elene Pereira/A-6837-2008; de
   Andrade, Lidia Maria/O-7835-2019; Versiani, Alice/M-9782-2018
OI Maia, Elene Pereira/0000-0003-2699-6232; de Andrade, Lidia
   Maria/0000-0003-2594-4617; Versiani, Alice/0000-0003-1378-5380
FU Brazilian agency CNPqNational Council for Scientific and Technological
   Development (CNPq) [40261012013-0, 305445/2015-4, 437298/2018-03];
   Brazilian agency Pesquisador Mineiro FAPEMIG [00646-16, 2428660/2018];
   Brazilian agency Rede Mineira de Pesquisa e Inovacao para Bioengenharia
   de Nanossistemas-FAPEMIG [TEC - RED-00282-16]; Brazilian agency
   INCTCatalise; Brazilian agency CAPES-PNPD scholarship
FX This research was supported by the Brazilian agencies CNPq (grants
   40261012013-0, 305445/2015-4 and 437298/2018-03), Pesquisador Mineiro
   FAPEMIG (grants 00646-16 and 2428660/2018), Rede Mineira de Pesquisa e
   Inovacao para Bioengenharia de Nanossistemas-FAPEMIG TEC - RED-00282-16,
   INCTCatalise and CAPES-PNPD scholarship.
CR Ahmed M, 2015, BIOCONJUGATE CHEM, V26, P812, DOI 10.1021/acs.bioconjchem.5b00139
   Andrade L. M., 2012, J CANC SCI THER, V4, P131, DOI DOI 10.4172/1948-5956.1000127
   Andrade LM, 2017, FUTURE VIROL, V12, P766, DOI 10.2217/fvl-2017-0086
   Balasubramanian SK, 2010, BIOMATERIALS, V31, P9023, DOI 10.1016/j.biomaterials.2010.08.012
   Barbosa MB, 2019, COLLOID SURFACE B, V175, P175, DOI 10.1016/j.colsurfb.2018.11.064
   Barman J, 2018, CURR PHARM BIOTECHNO, V19, P644, DOI 10.2174/1389201019666180821093239
   Barrow SJ, 2014, NANO LETT, V14, P3799, DOI 10.1021/nl5009053
   Bastus NG, 2011, LANGMUIR, V27, P11098, DOI 10.1021/la201938u
   Bhattacharyya S, 2011, CHEM COMMUN, V47, P8530, DOI 10.1039/c1cc12902c
   Bhattacharyya S, 2010, P NATL ACAD SCI USA, V107, P14541, DOI 10.1073/pnas.1006507107
   Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Feofanova N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/461687
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0
   Gao J, 2012, LANGMUIR, V28, P4464, DOI 10.1021/la204289k
   Garcia-Fernandez L, 2017, NANOSCALE, V9, P6111, DOI 10.1039/c7nr00947j
   Geraldo JM, 2017, INT J RADIAT BIOL, V93, P958, DOI 10.1080/09553002.2017.1341661
   Groysbeck N, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361-6528/aaff0a
   Hartshorn C.M., 2015, CANC NANOTECHNOLOGY
   Humbert C, 2013, GOLD BULL, V46, P299, DOI 10.1007/s13404-013-0126-5
   Jain S, 2012, BRIT J RADIOL, V85, P101, DOI 10.1259/bjr/59448833
   Jazayeri Mir Hadi, 2016, Sensing and Bio-Sensing Research, V9, P17, DOI 10.1016/j.sbsr.2016.04.002
   Kao HW, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/29/295102
   Karmani L, 2013, CONTRAST MEDIA MOL I, V8, P402, DOI 10.1002/cmmi.1539
   Karyakin AA, 2000, ANAL CHEM, V72, P3805, DOI 10.1021/ac9907890
   Kim JS, 2017, J CANCER, V8, P2713, DOI 10.7150/jca.19458
   Kim YP, 2015, MASS SPECTROM REV, V34, P237, DOI 10.1002/mas.21437
   Li DD, 2017, J BIOPHOTONICS, V10, P1636, DOI 10.1002/jbio.201700011
   Li S, 2019, NANOMEDICINE-UK, V14, P317, DOI 10.2217/nnm-2018-0161
   Liu MF, 2014, J BIOMED NANOTECHNOL, V10, P2038, DOI 10.1166/jbn.2014.1894
   Liu WQ, 2015, INT J CLIN EXP MED, V8, P2182
   Maya S, 2013, CARBOHYD POLYM, V93, P661, DOI 10.1016/j.carbpol.2012.12.032
   Patra CR, 2008, CANCER RES, V68, P1970, DOI 10.1158/0008-5472.CAN-07-6102
   Pelaz B, 2012, LANGMUIR, V28, P8965, DOI 10.1021/la204712u
   Philip D, 2008, SPECTROCHIM ACTA A, V71, P80, DOI 10.1016/j.saa.2007.11.012
   Pinilla-Macua I, 2015, METHOD CELL BIOL, V130, P347, DOI 10.1016/bs.mcb.2015.05.008
   Puvanakrishnan P., 2012, NANORODS, V317, P310, DOI [10.1002/lsm.22019, DOI 10.1002/LSM.22019]
   Qian YC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07490
   Rebucci M, 2011, INT J ONCOL, V38, P189, DOI 10.3892/ijo_00000838
   Ribeiro H., 2018, ACAD J POLYM SCI, V1, P1
   Rodriguez-Quijada C, 2018, J PHYS CHEM B, V122, P2827, DOI 10.1021/acs.jpcb.8b00168
   Stern ST, 2010, J CONTROL RELEASE, V146, P164, DOI 10.1016/j.jconrel.2010.04.008
   Tan G., 2015, CONJUGATION POLYM CO, P1297, DOI [10.3390/nano5031297, DOI 10.3390/NANO5031297]
   Tripathi K, 2018, ACS OMEGA, V3, P8253, DOI 10.1021/acsomega.8b00591
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   Venditto VJ, 2013, ADV DRUG DELIVER REV, V65, P80, DOI 10.1016/j.addr.2012.09.038
   Verma HN, 2014, VET WORLD, V7, P72, DOI 10.14202/vetworld.2014.72-77
   Versiani AF, 2016, FUTURE VIROL, V11, P293, DOI 10.2217/fvl-2015-0010
   Wang AL, 2014, J PHYS CHEM C, V118, P8134, DOI 10.1021/jp411543y
   Wang YT, 2016, SCI REP-UK, V6, DOI 10.1038/srep25468
   Wen H, 2015, AAPS J, V17, P1327, DOI 10.1208/s12248-015-9814-9
   Wicki A, 2015, J CONTROL RELEASE, V200, P138, DOI 10.1016/j.jconrel.2014.12.030
   Wofram J., 2015, CURR DRUG TARGETS, V16, P1671, DOI [10.1038/ki.2012.40, DOI 10.1038/KI.2012.40]
NR 53
TC 2
Z9 2
U1 3
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD FEB
PY 2020
VL 107
AR 110203
DI 10.1016/j.msec.2019.110203
PG 12
WC Materials Science, Biomaterials
SC Materials Science
GA JU0RI
UT WOS:000501386500078
PM 31761220
DA 2020-12-08
ER

PT J
AU Versiani, AF
   Rocha, RP
   Mendes, TAO
   Pereira, GC
   dos Reis, JGAC
   Bartholomeu, DC
   da Fonseca, FG
AF Versiani, Alice F.
   Rocha, Raissa Prado
   Mendes, Tiago A. O.
   Pereira, Glauco C.
   Coelho dos Reis, Jordana Graziella A.
   Bartholomeu, Daniella C.
   da Fonseca, Flavio G.
TI Identification of B-Cell Epitopes with Potential to Serologicaly
   Discrimnate Dengue from Zika Infections
SO VIRUSES-BASEL
LA English
DT Article
DE dengue diagnose; Zika; peptides; epitopes; pepELISA
ID COMPLETE NUCLEOTIDE-SEQUENCE; VIRUS; PROTEIN; TYPE-3; GENES; ELISA
AB Dengue is currently one of the most important arbovirus infections worldwide. Early diagnosis is important for disease outcome, particularly for those afflicted with the severe forms of infection. The goal of this work was to identify conserved and polymorphic linear B-cell Dengue virus (DENV) epitopes that could be used for diagnostic purposes. To this end, we aligned the predicted viral proteome of the four DENV serotype and performed in silico B-cell epitope mapping. We developed a script in Perl integrating alignment and prediction information to identify potential serotype-specific epitopes. We excluded epitopes that were similarly present in the yellow fever and zika viruses' proteomes. A total of 15 polymorphic and nine conserved peptides among DENV serotypes were selected. Peptides were spotted on cellulose membranes and tested against sera from rabbits that were monoinfected with each DENV serotype. Although serotype-specific peptides failed to recognize any sera, three conserved peptides were recognized by all anti-dengue sera and were included on an ELISA test employing a well-characterized human sera bank. Of the three peptides, one was able to efficiently identify sera from all four DENV serotypes and to discriminate them from Zika virus positive sera.
C1 [Versiani, Alice F.; Rocha, Raissa Prado; Coelho dos Reis, Jordana Graziella A.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Dept Microbiol, Lab Virol Bas & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
   [Versiani, Alice F.] Fac Med Sao Jose do Rio Preto, Dept Doencas Infecciosas & Parasitarias, Lab Pesquisa Virol, BR-15090000 Sao Jose Do Rio Preto, Brazil.
   [Mendes, Tiago A. O.; Bartholomeu, Daniella C.] Univ Fed Minas Gerais, Dept Parasitol, Lab Imunol & Genom Parasitos, BR-31270901 Belo Horizonte, MG, Brazil.
   [Pereira, Glauco C.] FUNED, Fundacao Ezequiel Dias, BR-30510010 Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Lab Virol Bas & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
EM afversiani@gmail.com; raissa.biotec@gmail.com;
   tiagomgmendes@yahoo.com.br; glaiconep@gmail.com; reisjordana@gmail.com;
   daniellaufmg@gmail.com; fdafonseca@icb.ufmg.br
RI Rocha, Raissa/ABF-1480-2020; Versiani, Alice/M-9782-2018
OI Versiani, Alice/0000-0003-1378-5380; Mendes, Tiago Antonio de
   Oliveira/0000-0002-5569-4893
FU CAPESCAPES; FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-04295-17]; FINEPCiencia Tecnologia e Inovacao (FINEP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); C.A.P.E.S. studentshipCAPES
FX This work was supported by CAPES, FAPEMIG, FINEP and CNPq. The grant
   from FAPEMIG was CBB-APQ-04295-17 (EDITAL 007/2017-PROGRAMA DE PESQUISA
   PARA O SUS/PPSUS). A FINEP-ZIKA institutional grant was used in the
   development of this work. F.G. da Fonseca, T.A.O. Mendes and D.C.
   Bartholomeu are CNPq fellowship recipients. A.F. Versiani and RP Rocha
   were/are C.A.P.E.S. studentship recipients. A.F. Versiani is currently a
   FAPESP fellow.
CR Abdelgawad A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138370
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   AnandaRao R, 2005, PROTEIN EXPRES PURIF, V41, P136, DOI 10.1016/j.pep.2005.01.009
   Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   BLOK J, 1992, VIROLOGY, V187, P573, DOI 10.1016/0042-6822(92)90460-7
   Brady OJ, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-351
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Chan HB, 2017, SINGAP MED J, V58, P632, DOI 10.11622/smedj.2017100
   Chang HH, 2017, B WORLD HEALTH ORGAN, V95, P517, DOI 10.2471/BLT.16.182105
   CHU MC, 1989, J GEN VIROL, V70, P1701, DOI 10.1099/0022-1317-70-7-1701
   Mendes TAD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002524
   DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0
   Dubois ME, 2012, VECTOR-BORNE ZOONOT, V12, P400, DOI 10.1089/vbz.2011.0779
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0
   FU JL, 1992, VIROLOGY, V188, P953, DOI 10.1016/0042-6822(92)90560-C
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0
   Halstead SB, 2019, LANCET CHILD ADOLESC, V3, P734, DOI 10.1016/S2352-4642(19)30205-6
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Klungthong C, 2004, VIROLOGY, V329, P168, DOI 10.1016/j.virol.2004.08.003
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Lin RJ, 2017, EXPERT REV ANTI-INFE, V15, P729, DOI 10.1080/14787210.2017.1358610
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   del Angel RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003551
   Narayan R, 2016, INDIAN J MED RES, V143, P128, DOI 10.4103/0971-5916.193300
   OSATOMI K, 1990, VIROLOGY, V176, P643, DOI 10.1016/0042-6822(90)90037-R
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Peyrefitte CN, 2003, J CLIN MICROBIOL, V41, P5195, DOI 10.1128/JCM.41.11.5195-5198.2003
   Puri B, 1998, VIRUS GENES, V17, P85, DOI 10.1023/A:1008009202695
   Rathakrishnan Anusyah, 2013, Expert Opin Med Diagn, V7, P99, DOI 10.1517/17530059.2012.718759
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Roehrig JT, 2003, ADV VIRUS RES, V59, P141, DOI 10.1016/S0065-3527(03)59005-4
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Sahili A. E, 2017, VIRUSES, V9, P1
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Tatusova T, 2014, NUCLEIC ACIDS RES, V42, pD553, DOI 10.1093/nar/gkt1274
   Tian H, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-245
   Valadon P, 1996, J IMMUNOL METHODS, V197, P171, DOI 10.1016/0022-1759(96)00133-0
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Yoong L.F., DENGUE VIRUS TYPE 4
   Yuan X., DENGUE VIRUS TYPE 3
   ZHAO B, 1986, VIROLOGY, V155, P77, DOI 10.1016/0042-6822(86)90169-8
NR 46
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2019
VL 11
IS 11
AR 1079
DI 10.3390/v11111079
PG 16
WC Virology
SC Virology
GA JV3UX
UT WOS:000502292300107
PM 31752352
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Giannattasio-Ferraz, S
   Laguardia-Nascimento, M
   Gasparini, MR
   Leite, LR
   Araujo, FMG
   Salim, ACD
   de Oliveira, AP
   Nicolil, JR
   de Oliveira, GC
   da Fonseca, FG
   Barbosa-Stancioli, EF
AF Giannattasio-Ferraz, Silvia
   Laguardia-Nascimento, Mateus
   Gasparini, Marcela Ribeiro
   Leite, Laura Rabelo
   Gomes Araujo, Flavio Marcos
   de Matos Salim, Anna Christina
   de Oliveira, Andre Penido
   Nicolil, Jacques Robert
   de Oliveira, Guilherme Correa
   da Fonseca, Flavio Guimaraes
   Barbosa-Stancioli, Edel Figueiredo
TI A common vaginal microbiota composition among breeds of Bos taurus
   indicus (Gyr and Nellore)
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Microbiota; Metagenomics; Bovine; Gyr; Vaginal tract
ID ESCHERICHIA-COLI; GUT MICROBIOTA; DAIRY-COWS; IDENTIFICATION; FUNGI;
   PREVALENCE; DIVERSITY; BACTERIA; ARCHAEA; WOMEN
AB Describing the bovine vaginal microbiota is essential to better understand its physiology and its impact on health maintenance. Despite the economic importance of reproduction of these animals, bovine vaginal microbial community is still poorly described in comparison with rumen microbiome. Previous studies of our group described the vaginal microbiota of Nellore, an important Bos taurus indicus breed, using metagenomics. In order to better understand this microbiota, the present work aims to investigate another important breed, Gyr. Results have shown bacterial dominance over Archaea and Fungi was observed, with the most abundant bacterial phylum (Firmicutes) representing 40-50% of bacterial population, followed by Bacteroidetes, Proteobacteria, and Actinobacteria. The Fungi kingdom had the Mycosphaerella genus as its main representative, followed by Cladosporium. Archaea were observed at a very low abundance in all animals, with a high relative abundance of Methanobrevibacter genus. These results demonstrate a high microbial diversity on vaginal tract of Gyr, as demonstrated for Nellore and different from the previously described for other species. Our results indicate a great similarity between vaginal microbiota of Nellore and Gyr despite the differences in animal handling and genetic improvement. As observed for both breeds, individual variation is the largest source of microbial diversity between animals.
C1 [Giannattasio-Ferraz, Silvia; Laguardia-Nascimento, Mateus; Gasparini, Marcela Ribeiro; Nicolil, Jacques Robert; da Fonseca, Flavio Guimaraes; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Leite, Laura Rabelo; Gomes Araujo, Flavio Marcos; de Matos Salim, Anna Christina; de Oliveira, Guilherme Correa] Fiocruz MS, Ctr Pesquisa Rene Rachou, Belo Horizonte, MG, Brazil.
   [de Oliveira, Andre Penido] Empresa Pesquisa Agr Minas Gerais EPAMIG, Uberaba, MG, Brazil.
   [de Oliveira, Guilherme Correa] Inst Tecnol Vale, Belem, Para, Brazil.
RP Barbosa-Stancioli, EF (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Belo Horizonte, MG, Brazil.
EM edelfb@icb.ufmg.br
RI Barbosa-Stancioli, Edel F/J-7230-2012
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Nicoli, Jacques
   Robert/0000-0003-2390-2608
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [473879/2013-1]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (Grant ID 473879/2013-1).
CR Amin J. D., 1996, Bulletin of Animal Health and Production in Africa, V44, P15
   Andersson AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002836
   Antonio MAD, 1999, J INFECT DIS, V180, P1950, DOI 10.1086/315109
   BELAY N, 1990, J CLIN MICROBIOL, V28, P1666, DOI 10.1128/JCM.28.7.1666-1668.1990
   Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107
   Bicalho MLS, 2017, J DAIRY SCI, V100, P3043, DOI 10.3168/jds.2016-11623
   Branco KMGR, 2010, BRAZ J MED BIOL RES, V43, P338, DOI [10.1590/S0100-879X2010007500013, 10.1590/S0100-879X2010000400003]
   Carberry CA, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-41
   Dias J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01553
   Dridi B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007063
   Dumonceaux Tim J, 2009, J Clin Microbiol, V47, P4067, DOI 10.1128/JCM.00112-09
   Faveri M, 2011, J PERIODONTAL RES, V46, P338, DOI 10.1111/j.1600-0765.2011.01347.x
   Garoussi MT, 2016, J MYCOL MED, V26, P22, DOI 10.1016/j.mycmed.2015.10.013
   Moreno CG, 2016, J APPL MICROBIOL, V121, P1232, DOI 10.1111/jam.13239
   Guatimosim E, 2016, PERSOONIA, V37, P106, DOI 10.3767/003158516X690934
   HERTHELIUS M, 1989, INFECT IMMUN, V57, P2447, DOI 10.1128/IAI.57.8.2447-2451.1989
   Keller L A M, 2012, ISRN Vet Sci, V2012, P396590, DOI 10.5402/2012/396590
   Kwiatkowski NP, 2012, J MOL DIAGN, V14, P393, DOI 10.1016/j.jmoldx.2012.02.004
   Laguardia-Nascimento M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143294
   Larsen A, 2013, FEMS MICROBIOL ECOL, V85, P483, DOI 10.1111/1574-6941.12136
   Lepp PW, 2004, P NATL ACAD SCI USA, V101, P6176, DOI 10.1073/pnas.0308766101
   Loaces I, 2015, APPL MICROBIOL BIOT, V99, P9049, DOI 10.1007/s00253-015-6801-0
   Matkovic K, 2009, ARH HIG RADA TOKSIKO, V60, P395, DOI 10.2478/10004-1254-60-2009-1970
   Meyer F, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-386
   Miller EA, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01936
   Minana-Galbis D, 2010, INT J SYST EVOL MICR, V60, P1600, DOI 10.1099/ijs.0.003699-0
   Oikonomou G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085904
   Otero C, 1999, ANAEROBE, V5, P305, DOI 10.1006/anae.1999.0245
   Otero C, 2000, LETT APPL MICROBIOL, V31, P251, DOI 10.1046/j.1365-2672.2000.00809.x
   Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494
   Pereira CB, 2016, MICROB PATHOGENESIS, V100, P205, DOI 10.1016/j.micpath.2016.09.022
   Randhawa IAS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153013
   REID G, 1985, INFECT IMMUN, V49, P320, DOI 10.1128/IAI.49.2.320-324.1985
   Roehe R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005846
   Sevim E, 2011, J BACTERIOL, V193, P575, DOI 10.1128/JB.01193-10
   SHARDA R, 1991, INDIAN VET J, V68, P197
   Spear GT, 2012, AIDS RES HUM RETROV, V28, P1244, DOI 10.1089/aid.2011.0382
   Swartz Jeffrey D, 2014, Front Vet Sci, V1, P19, DOI 10.3389/fvets.2014.00019
   Verkley GJM, 2004, MYCOL RES, V108, P1271, DOI 10.1017/S0953756204001054
   Wallace RJ, 2017, GENET SEL EVOL, V49, DOI 10.1186/s12711-017-0285-6
   Wang Y, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-19
   Yildirim S, 2014, ISME J, V8, P2431, DOI 10.1038/ismej.2014.90
   Zinicola M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120504
NR 43
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD OCT
PY 2019
VL 50
IS 4
BP 1115
EP 1124
DI 10.1007/s42770-019-00120-3
PG 10
WC Microbiology
SC Microbiology
GA KI8ME
UT WOS:000511611200027
PM 31468349
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bagno, FF
   Godoi, LC
   Salazar, N
   Pereira, GD
   Figueiredo, MM
   da Fonseca, FG
AF Bagno, Flavia Fonseca
   Godoi, Lara Carvalho
   Salazar, Natalia
   Pereira, Glauco de Carvalho
   Figueiredo, Maria Marta
   da Fonseca, Flavio Guimaraes
TI Development of an enzyme-linked immunosorbent assay using recombinant
   protein antigen for the diagnosis of Chikungunya virus
SO DATA IN BRIEF
LA English
DT Article; Data Paper
DE Chikungunya virus; Diagnostics; ELISA; E2 Envelope protein; Recombinant
   protein
ID PREDICTION
AB We describe here the development of an in-house enzyme linked immunosorbent assay (ELISA) for the diagnostic of Chikungunya virus (CHIKV) infections using a recombinant protein from CHIKV. The recombinant protein gene was designed based on 154 sequences and we used computational methods to predict its structure and antigenic potential. To confirm predictions, the gene coding for the recombinant CHIKV protein (rCHIKVp) was synthetized and expressed in prokaryotic system. Subsequently, the protein was purified by affinity chromatography and used as antigen in an indirect ELISA. We present data regarding the optimization of the recombinant antigen production and preparation of the ELISA to detect IgG against CHIKV in human sera. (C) 2019 The Author(s). Published by Elsevier Inc.
C1 [Bagno, Flavia Fonseca; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Bagno, Flavia Fonseca; Godoi, Lara Carvalho; Salazar, Natalia; Figueiredo, Maria Marta; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Ctr Tecnol Vacinas, Belo Horizonte, MG, Brazil.
   [Godoi, Lara Carvalho] Univ Fed Minas Gerais, Colegio Tecn, Belo Horizonte, MG, Brazil.
   [Pereira, Glauco de Carvalho] Fundacao Ezequiel Dias FUNED, Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI /J-6626-2017
OI /0000-0002-2093-9942; Bagno, Flavia/0000-0003-1578-6678
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-03081-17 (EDITAL 001/2017), CBB-APQ-04295-17 (EDITAL
   007/2017)]; ZIKA grant [MCTI/FINEP/FNDCT 01/2016]
FX We thank Marcos Vinicius F. Silva and Talita Emile R. Adelino (Fundacao
   Ezequiel Dias, Brazil) for helping with the sera samples. We also thank
   the Centro de Tecnologia em Vacinas' team (CTVacinas, Brazil) for
   discussions. This work was supported by FAPEMIG - grants
   #CBB-APQ-03081-17 (EDITAL 001/2017) and #CBB-APQ-04295-17 (EDITAL
   007/2017). It was also supported by a MCTI/FINEP/FNDCT 01/2016 ZIKA
   grant.
CR Bagno FF, 2019, J CLIN VIROL, V113, P27, DOI 10.1016/j.jcv.2019.02.006
   Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
NR 7
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3409
J9 DATA BRIEF
JI Data Brief
PD AUG
PY 2019
VL 25
AR 104015
DI 10.1016/j.dib.2019.104015
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JK8QJ
UT WOS:000495104500048
PM 31194157
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silva, DSODE
   Pinho, TMG
   Rachid, MA
   Barbosa-Stancioli, DF
   Da Fonseca, FG
AF Daian e Silva, D. S. O.
   Pinho, T. M. G.
   Rachid, M. A.
   Barbosa-Stancioli, D. F.
   Da Fonseca, F. G.
TI The Perennial Use of the Green Fluorescent Protein Marker in a Live
   Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse
   Effects in Mice
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE MVA-based vaccine; Green fluorescent protein; GFP; Acute responses
ID MYELOPEROXIDASE; MECHANISMS; ABSENCE; MVA
AB Recombinant virus vectors represent a promising strategy for vaccine research. Among available viral vectors, members of the Poxviridae familyespecially the modified Vaccinia virus Ankara (MVA)stand out as immunogenic and safe vaccine platforms. Because MVA usually does not produce plaques in cell culture, visible selection markers such as the green fluorescent protein (GFP) are frequently incorporated into the constructions in order to facilitate the recognition of recombinants. However, these genetic markers have to be removed before any clinical trial. Here, we evaluated the acute responses generated in mice immunized with a MVA vector in which the GFP marker was not removed. We observed no differences in neutrophil, monocyte, or total leucocyte recruitment among animals inoculated with MVA or MVA-GFP. Likewise, there were no differences in neutrophil activation between mice groups. Hepatic functions were not altered in either MVA or MVA-GFP-inoculated mice, and we observed no histopathological alterations in different tissues from virus-inoculated animals. In conclusion, the presence of GFP is innocuous to immunized animals and do not alter acute physiopathological responses to the MVA vector. We suggest that keeping the GFP marker may be a good strategy for vaccine development, production, and evaluation.
C1 [Daian e Silva, D. S. O.; Pinho, T. M. G.; Barbosa-Stancioli, D. F.; Da Fonseca, F. G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
   [Rachid, M. A.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Patol, Belo Horizonte, MG, Brazil.
RP Da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Rachid, Milene Alvarenga/C-3530-2017; Daian+e+Silva,
   Danielle/AAF-8852-2020
OI Rachid, Milene Alvarenga/0000-0002-3142-6552; 
FU CAPESCAPES; Post-Graduation program in Microbiology from the
   Universidade Federal de Minas Gerais; FAPEMIGMinas Gerais State Research
   Foundation (FAPEMIG); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This research was supported by CAPES and the Post-Graduation program in
   Microbiology from the Universidade Federal de Minas Gerais. Financial
   resources came also from grants by FAPEMIG and CNPq.
CR Andrade LM, 2017, FUTURE VIROL, V12, P766, DOI 10.2217/fvl-2017-0086
   Barcelos LS, 2004, INFLAMM RES, V53, P576, DOI 10.1007/s00011-004-1299-4
   Bekheet I. W., 2009, Open Tropical Medicine Journal, V2, P1, DOI 10.2174/1874315300902010001
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Buckland BC, 2005, NAT MED, V11, pS16, DOI 10.1038/nm1218
   Campos F, 2011, CLIN SCI, V121, P11, DOI 10.1042/CS20100427
   Dowall SD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156637
   Drexler I, 2004, CURR OPIN BIOTECH, V15, P506, DOI 10.1016/j.copbio.2004.09.001
   Earl PL, 2017, J VIROL, V91, DOI 10.1128/JVI.01042-17
   Edwards L, 2013, BEST PRACT RES CL GA, V27, P471, DOI 10.1016/j.bpg.2013.08.002
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Kothari N, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.09.001
   Langenmayer MC, 2018, BIOLOGICALS, V54, P58, DOI 10.1016/j.biologicals.2018.05.004
   Luyten J, 2016, HEALTH AFFAIR, V35, P212, DOI 10.1377/hlthaff.2015.1088
   Moss B, 2007, FIELDS VIROLOGY, V2, P2637
   Moss B, 2013, VACCINE, V31, P4220, DOI 10.1016/j.vaccine.2013.03.042
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899
   Ozer J, 2008, TOXICOLOGY, V245, P194, DOI 10.1016/j.tox.2007.11.021
   Plotkin SA, 2015, NEW ENGL J MED, V373, P297, DOI 10.1056/NEJMp1506820
   Price PJR, 2015, J IMMUNOL, V194, P1164, DOI 10.4049/jimmunol.1301410
   Price PJR, 2014, J VIROL, V88, P10840, DOI 10.1128/JVI.01524-14
   Prokopowicz Z, 2012, ARCH IMMUNOL THER EX, V60, P43, DOI 10.1007/s00005-011-0156-8
   Quinan BR, 2014, FUTURE VIROL, V9, P173, DOI 10.2217/fvl.13.129
   Ramirez JC, 2003, ARCH VIROL, V148, P827, DOI 10.1007/s00705-003-0006-z
   Souza DG, 2000, BRIT J PHARMACOL, V131, P1800, DOI 10.1038/sj.bjp.0703756
   van der Veen BS, 2009, ANTIOXID REDOX SIGN, V11, P2899, DOI [10.1089/ars.2009.2538, 10.1089/ARS.2009.2538]
   Zuverink M, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv097
NR 28
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD APR
PY 2019
VL 50
IS 2
BP 347
EP 355
DI 10.1007/s42770-019-00067-5
PG 9
WC Microbiology
SC Microbiology
GA HW9TN
UT WOS:000467033700002
PM 30877662
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bagno, FF
   Figueiredo, MM
   Villarrea, J
   Pereira, GD
   Godoi, LC
   da Fonseca, FG
AF Bagno, Flavia Fonseca
   Figueiredo, Maria Marta
   Villarrea, Jannely
   Pereira, Glauco de Carvalho
   Godoi, Lara Carvalho
   da Fonseca, Flavio Guimaraes
TI Undetected Chikungunya virus co-infections in a Brazilian region
   presenting hyper-endemic circulation of Dengue and Zika
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Chikungunya; Arboviruses; Diagnosis; Dengue; Zika; Co-infection
AB Background: Chikungunya virus (CHIKV) causes a disease characterized by acute onset of fever accompanied by arthralgia. Clinical similarities and co-circulation of other arboviruses such as Dengue virus (DENV) and Zika virus (ZIKV), have complicated their differentiation, making their diagnoses a challenge for the health authorities. Misdiagnosis is a serious issue to the management of patients and development of public health measures.
   Objectives: We carried out further screening of CHIKV, DENV and ZIKV cases in Minas Gerais, Brazil, after diagnostics were already issued by a state laboratory and according to the Brazilian Ministry of Health (BMH) policy. Our aim was to look for possible co-infections or previous arboviruses' exposure.
   Study design: Sera from 193 patients with symptoms of arboviral infections were tested for DEV, ZKV and/or CHIKV by the State laboratory, according to clinical suspicion and following standard BMH guidelines. After an official diagnosis was issued for each patient, we retested samples applying a broader panel of ELISA-based serological tests.
   Results: We identified 13 patients with concurrent or consecutive infections (IgM positive for more than one arbovirus), including 11 individuals that were positive for CHIKV and other previously confirmed arbovirus infection.
   Discussion: Guidelines established in many arbovirus-endemic countries prioritizes the diagnosis of Zika and Dengue and no further analyzes are done when samples are positive for those viruses. As a result, possible cases of co-infections with chikungunya are neglected, which affects the epidemiological assessments of virus circulation, patient management, and the development of public health policies.
C1 [Bagno, Flavia Fonseca; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Bagno, Flavia Fonseca; Figueiredo, Maria Marta; Godoi, Lara Carvalho; da Fonseca, Flavio Guimaraes] Ctr Tecnol Vacinas, Belo Horizonte, MG, Brazil.
   [Villarrea, Jannely] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
   [Pereira, Glauco de Carvalho] Fundacao Ezequiel Dias FUNED, Belo Horizonte, MG, Brazil.
   [Godoi, Lara Carvalho] Univ Fed Minas Gerais, Colegio Tecn, Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Av Pres Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
EM flavia.bagno@gmail.com; mariamartafigueiredo@gmail.com;
   jvillarreal@college.harvard.edu; glaicone@gmail.com;
   lcarvalhogodoi@gmail.com; fdafonseca@icb.ufmg.br
OI Bagno, Flavia/0000-0003-1578-6678
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-03081-17 (EDITAL 001/2017), CBB-APQ-04295-17 (EDITAL 007/2017)]
FX We thank Marcos Vinicius F. Silva and Talita Emile R. Adelino (Fundacao
   Ezequiel Dias, Brazil) for helping with the sera samples. We thank Edel
   F Barbosa-Stancioli and the Centro de Tecnologia em Vacinas' team
   (CTVacinas, Brazil) for discussions. This work was supported by FAPEMIG
   -grants #CBB-APQ-03081-17 (EDITAL 001/2017) and #CBB-APQ-04295-17
   (EDITAL 007/2017).
CR Brazil Ministry of Health, 2018, DENG CHIK ZIK VIR EP
   Brazil Ministry of Health, 2017, CHIK CLIN MAN PORT, P5
   Donalisio MR, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006889, 10.1590/s1518-8787.2017051006889]
   Edwards T, 2016, EMERG INFECT DIS, V22, P2003, DOI 10.3201/eid2211.161017
   Hisamuddini M, 2018, EPIDEMIOL INFECT, V146, P1642, DOI [10.1017/S0950268818001590, 10.1017/s0950268818001590]
   Mardekian SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/834371
   Mehta R, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1978
   Ministry of Health of Brazil, 2017, HLTH BRAZ 2015 2016
   Neto N., 2018, OPEN FORUM INFECT S1, V5, pS167, DOI [10.1093/ofid/ofy210.454, DOI 10.1093/OFID/OFY210.454]
   Norman FF, 2016, AM J TROP MED HYG, V95, P1166, DOI 10.4269/ajtmh.16-0426
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Salles TS, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2830-8
   Sardi SI, 2016, J CLIN MICROBIOL, V54, P2348, DOI 10.1128/JCM.00877-16
   Taraphdar D, 2012, AM J TROP MED HYG, V86, P720, DOI 10.4269/ajtmh.2012.11-0704
   Watanabe S, 2019, J INFECT DIS, V219, P223, DOI 10.1093/infdis/jiy482
   Carrillo-Hernandez MY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2976-1
   Zambrano H, 2016, AM J TROP MED HYG, V95, P894, DOI 10.4269/ajtmh.16-0323
NR 17
TC 9
Z9 9
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD APR
PY 2019
VL 113
BP 27
EP 30
DI 10.1016/j.jcv.2019.02.006
PG 4
WC Virology
SC Virology
GA HP1ZM
UT WOS:000461467700006
PM 30836281
DA 2020-12-08
ER

PT J
AU de Freitas, LFD
   Oliveira, RP
   Miranda, MCG
   Rocha, RP
   Barbosa-Stancioli, EF
   Faria, AMC
   da Fonseca, FG
AF de Freitas, Lorena F. D.
   Oliveira, Rafael P.
   Miranda, Mariana C. G.
   Rocha, Raissa P.
   Barbosa-Stancioli, Edel F.
   Faria, Ana Maria C.
   da Fonseca, Flavio G.
TI The Virulence of Different Vaccinia Virus Strains Is Directly
   Proportional to Their Ability To Downmodulate Specific Cell Mediated
   Immune Compartments In Vivo
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE Lister strain; MVA; vaccinia virus; Western Reserve strain; mouse model;
   modulation of the host immune response
ID THERAPEUTIC VACCINATION; CLINICAL-TRIAL; ANKARA STRAIN; T-CELLS; MVA E2;
   INFECTION; IMMUNOGENICITY; CD4(+); MICE; RESPONSES
AB Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses in vivo, and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4' T cells. CD41 T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-u), gamma interferon (IFN-y), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses.
   IMPORTANCE Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
C1 [de Freitas, Lorena F. D.; Rocha, Raissa P.; Barbosa-Stancioli, Edel F.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil.
   [Oliveira, Rafael P.] Inst Fed Parana, Palmas, PR, Brazil.
   [Miranda, Mariana C. G.; Faria, Ana Maria C.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Barbosa-Stancioli, Edel F/J-7230-2012; Rocha, Raissa/ABF-1480-2020; de
   Oliveira, Rafael Pires/B-9161-2015
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; de Oliveira, Rafael
   Pires/0000-0002-5941-7009; Faria, Ana Maria/0000-0002-0604-8510
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG); CNPqNational
   Council for Scientific and Technological Development (CNPq); Instituto
   Nacional de Ciencia e Tecnologia de Vacinas (INCTV) (National Institute
   of Science and Technology of Vaccines); Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)CAPES; CAPESCAPES
FX The work was supported by FAPEMIG and CNPq grants and by the Instituto
   Nacional de Ciencia e Tecnologia de Vacinas (INCTV) (National Institute
   of Science and Technology of Vaccines). F.G. da Fonseca was a CNPq
   fellowship recipient during the development of this work. The
   Post-Graduation programs at UFMG are supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). L.F.D. de Freitas
   and R. P. Rocha were/are CAPES fellowship recipients.
CR Abboud G, 2016, J VIROL, V90, P129, DOI 10.1128/JVI.01894-15
   Abdalrhman I, 2006, VACCINE, V24, P4152, DOI 10.1016/j.vaccine.2006.02.012
   Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Altenburg AF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08719-y
   Amato RJ, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S7654
   Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123
   Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159
   Chahroudi A, 2005, J VIROL, V79, P10397, DOI 10.1128/JVI.79.16.10397-10407.2005
   Earl PL, 2017, J VIROL, V91, DOI 10.1128/JVI.01042-17
   Fazekas de St Groth B, 2004, IMMUNOL CELL BIOL, V82, P260, DOI 10.1111/j.0818-9641.2004.01243.x
   Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   Garcia F, 2011, VACCINE, V29, P8309, DOI 10.1016/j.vaccine.2011.08.098
   Garcia-Hernandez E, 2006, CANCER GENE THER, V13, P592, DOI 10.1038/sj.cgt.7700937
   Guimaraes-Walker A, 2008, VACCINE, V26, P6671, DOI 10.1016/j.vaccine.2008.09.016
   Gutierrez CMC, 2004, HUM GENE THER, V15, P421, DOI 10.1089/10430340460745757
   Hernandez Raquel, 2010, Curr Protoc Microbiol, VAppendix 4, p4I, DOI 10.1002/9780471729259.mca04is17
   Hu ZT, 2016, CELL MOL IMMUNOL, V13, P82, DOI 10.1038/cmi.2014.128
   Jacobs BL, 2009, ANTIVIR RES, V84, P1, DOI 10.1016/j.antiviral.2009.06.006
   JELINKOV.A, 1973, ACTA VIROL, V17, P124
   Karupiah G, 1996, J VIROL, V70, P8301, DOI 10.1128/JVI.70.12.8301-8309.1996
   Kaur S, 2008, PARASITOL RES, V103, P1413, DOI 10.1007/s00436-008-1150-x
   Knitlova J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114374
   Kreijtz JHCM, 2013, VACCINE, V31, P4217, DOI 10.1016/j.vaccine.2013.06.073
   KURILLA MG, 1993, J VIROL, V67, P7623, DOI 10.1128/JVI.67.12.7623-7628.1993
   Lehmann MH, 2016, J LEUKOCYTE BIOL, V99, P1057, DOI 10.1189/jlb.4MA0815-376RR
   LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.immunol.11.1.191
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Meisinger-Henschel C, 2010, J VIROL, V84, P9907, DOI 10.1128/JVI.00756-10
   Meseda CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149364
   MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031
   Nicol MP, 2010, CURR OPIN MOL THER, V12, P124
   Qin L, 2015, J VIROL, V89, P1809, DOI 10.1128/JVI.02797-14
   Qin L, 2011, J VIROL, V85, P13049, DOI 10.1128/JVI.05779-11
   Rajasagi NK, 2009, J VIROL, V83, P5256, DOI 10.1128/JVI.01997-08
   Ramirez JC, 2000, J VIROL, V74, P7651, DOI 10.1128/JVI.74.16.7651-7655.2000
   Ramirez JC, 2003, ARCH VIROL, V148, P827, DOI 10.1007/s00705-003-0006-z
   Ramirez JC, 2000, J VIROL, V74, P923, DOI 10.1128/JVI.74.2.923-933.2000
   Reading PC, 2003, J GEN VIROL, V84, P1973, DOI 10.1099/vir.0.19285-0
   Rosenthal SR, 2001, EMERG INFECT DIS, V7, P920, DOI 10.3201/eid0706.010602
   Russell TA, 2014, IMMUNOL CELL BIOL, V92, P466, DOI 10.1038/icb.2014.10
   Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507
   Gomes JAS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/974067
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Smee DF, 2001, ANTIVIR CHEM CHEMOTH, V12, P71, DOI 10.1177/095632020101200105
   Smith GL, 2013, J GEN VIROL, V94, P2367, DOI 10.1099/vir.0.055921-0
   Stevceva L, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-9
   STICKL H, 1974, DEUT MED WOCHENSCHR, V99, P2386, DOI 10.1055/s-0028-1108143
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   Tapia MD, 2016, LANCET INFECT DIS, V16, P31, DOI 10.1016/S1473-3099(15)00362-X
   Tulman ER, 2006, J VIROL, V80, P9244, DOI 10.1128/JVI.00945-06
   Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
NR 54
TC 2
Z9 2
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAR
PY 2019
VL 93
IS 6
AR e02191-18
DI 10.1128/JVI.02191-18
PG 16
WC Virology
SC Virology
GA HN6JN
UT WOS:000460292400050
PM 30567985
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Oliveira, G
   Silva, L
   Leao, T
   Mougari, S
   da Fonseca, FG
   Kroon, EG
   La Scola, B
   Abrahao, JS
AF Oliveira, Graziele
   Silva, Lorena
   Leao, Thiago
   Mougari, Said
   da Fonseca, Flavio Guimaraes
   Kroon, Erna Geessien
   La Scola, Bernard
   Abrahao, Jonatas Santos
TI Tupanvirus-infected amoebas are induced to aggregate with uninfected
   cells promoting viral dissemination
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MANNOSE-BINDING PROTEIN; GIANT VIRUS; ACANTHAMOEBA; PATHOGENESIS;
   PHAGOCYTOSIS
AB The discovery of giant viruses in the last years has fascinated the scientific community due to virus particles size and genome complexity. Among such fantastic discoveries, we have recently described tupanviruses, which particles present a long tail, and has a genome that contains the most complete set of translation-related genes ever reported in the known virosphere. Here we describe a new kind of virus-host interaction involving tupanvirus. We observed that tupanvirus-infected amoebas were induced to aggregate with uninfected cells, promoting viral dissemination and forming giant host cell bunches. Even after mechanical breakdown of bunches, amoebas reaggregated within a few minutes. This remarkable interaction between infected and uninfected cells seems to be promoted by the expression of a mannose receptor gene. Our investigations demonstrate that the pre-treatment of amoebas with free mannose inhibits the formation of bunches, in a concentration-dependent manner, suggesting that amoebal-bunch formation correlates with mannose receptor gene expression. Finally, our data suggest that bunch-forming cells are able to interact with uninfected cells promoting the dissemination and increase of tupanvirus progeny.
C1 [Oliveira, Graziele; Silva, Lorena; Leao, Thiago; da Fonseca, Flavio Guimaraes; Kroon, Erna Geessien; Abrahao, Jonatas Santos] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Mougari, Said; La Scola, Bernard] Aix Marseille Univ, IHU Mediterranee Infect, AP HM, URMITE,UM63,CNRS 7278,IRD 198,INSERM 1095, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
RP Abrahao, JS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
EM jonatas.abrahao@gmail.com
RI Kroon, Erna/V-5444-2019
OI Oliveira, Graziele/0000-0002-8521-0351; Mougari,
   Said/0000-0002-9319-5454
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); CAPES (Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior)CAPES; FAPEMIG (Fundacao de Amparo a Pesquisa do estado
   de Minas Gerais)Minas Gerais State Research Foundation (FAPEMIG);
   PRPq-UFMG (Pro-Reitoria de Pesquisa of UFMG); Microscopy Center of UFMG
FX We are grateful to our colleagues from Laboratorio de Virus of
   Universidade Federal de Minas Gerais. In addition, we thank CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), CAPES
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), FAPEMIG
   (Fundacao de Amparo a Pesquisa do estado de Minas Gerais), PRPq-UFMG
   (Pro-Reitoria de Pesquisa of UFMG) and the Microscopy Center of UFMG.
   F.G.F; E.G.K and J.S.A are CNPq researchers. E.G.K.; B.L.S. and J.S.A.
   are members of a CAPES-COFECUB project.
CR Abrahao J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03168-1
   Abrahao Jonatas Santos, 2016, Curr Protoc Microbiol, V41, DOI 10.1002/cpmc.2
   Aherfi S, 2014, VIROLOGY, V466, P27, DOI 10.1016/j.virol.2014.07.014
   ALLEN PG, 1990, J CELL PHYSIOL, V145, P508, DOI 10.1002/jcp.1041450317
   Andreani J, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110300
   Bajrai LH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110278
   Barre A, 1997, PLANT MOL BIOL, V33, P691, DOI 10.1023/A:1005704616565
   Boyer M, 2009, P NATL ACAD SCI USA, V106, P21848, DOI 10.1073/pnas.0911354106
   Cao ZY, 1998, J BIOL CHEM, V273, P15838, DOI 10.1074/jbc.273.25.15838
   Andrade ACDP, 2017, J VIROL, V91, DOI 10.1128/JVI.01335-17
   Garate M, 2006, INVEST OPHTH VIS SCI, V47, P1056, DOI 10.1167/iovs.05-0477
   Garate M, 2005, INFECT IMMUN, V73, P5775, DOI 10.1128/IAI.73.9.5775-5781.2005
   Garate M, 2004, J BIOL CHEM, V279, P29849, DOI 10.1074/jbc.M402334200
   Khan NA, 2006, FEMS MICROBIOL REV, V30, P564, DOI 10.1111/j.1574-6976.2006.00023.x
   Kim JH, 2012, EXP PARASITOL, V132, P287, DOI 10.1016/j.exppara.2012.08.007
   La Scola B, 2003, SCIENCE, V299, P2033
   Legendre M, 2015, P NATL ACAD SCI USA, V112, pE5327, DOI 10.1073/pnas.1510795112
   Legendre M, 2014, P NATL ACAD SCI USA, V111, P4274, DOI 10.1073/pnas.1320670111
   Rodrigues RAL, 2015, J VIROL, V89, P11812, DOI 10.1128/JVI.01976-15
   Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003
   Niederkorn JY, 1999, MICROBES INFECT, V1, P437, DOI 10.1016/S1286-4579(99)80047-1
   Philippe N, 2013, SCIENCE, V341, P281, DOI 10.1126/science.1239181
   Reed L. J., 1938, AM J EPIDEMIOL, V128, P192
   Reteno DG, 2015, J VIROL, V89, P6585, DOI 10.1128/JVI.00115-15
   Sergeev V. N., 2002, Mikrobiologiya, V71, P725
   Siddiqui R, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-6
   Sorokin DY, 2014, EXTREMOPHILES, V18, P791, DOI 10.1007/s00792-014-0670-9
   Yang ZT, 1997, INFECT IMMUN, V65, P439, DOI 10.1128/IAI.65.2.439-445.1997
   Yoo KT, 2012, KOREAN J PARASITOL, V50, P365, DOI 10.3347/kjp.2012.50.4.365
NR 29
TC 8
Z9 8
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 17
PY 2019
VL 9
AR 183
DI 10.1038/s41598-018-36552-4
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HH7ZS
UT WOS:000455951300031
PM 30655573
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Andrade, LM
   Cox, L
   Versiani, AF
   da Fonseca, FG
AF Andrade, Lidia M.
   Cox, Laura
   Versiani, Alice F.
   da Fonseca, Flavio G.
TI A growing world of small things: a brief review on the nanostructured
   vaccines
SO FUTURE VIROLOGY
LA English
DT Review
DE carbon nanotubes; gold nanorods; nanoparticle vaccines; nanostructured
   vaccines
ID WALLED CARBON NANOTUBES; FUNCTIONALIZED GOLD NANOPARTICLES;
   COST-EFFECTIVENESS; IMMUNE-RESPONSE; DENDRITIC CELLS; RECOMBINANT
   FRAGMENT; DELIVERY; INFLUENZA; ADJUVANT; VACCINATION
AB Vaccines are the most cost-effective intervention in the management of infectious disease. Much of what we perceive as quality of life is related to a good health status and disease absence, for which vaccines are substantially responsible. Nonetheless, there are many infectious diseases for which no vaccine solution is available. That could be due to limitations of the classic approaches to vaccine development, including inactivated, subunit and attenuated vaccines. Nanostructured immunogens belong to a class of nonclassic vaccines in which nanostructures are loaded with antigen-related molecules. Here, we briefly review important features of the nanostructured vaccines - mainly those based in carbon nanotubes and gold nanorods - and discuss their use to prevent infectious diseases, especially those caused by viruses.
C1 [Andrade, Lidia M.] Univ Fed Minas Gerais, Dept Fis, Lab Nanomat, Belo Horizonte, MG, Brazil.
   [Andrade, Lidia M.; Cox, Laura; Versiani, Alice F.] Univ Fed Minas Gerais, Dept Fis, NanoBioMed Res Grp, Belo Horizonte, MG, Brazil.
   [Cox, Laura; Versiani, Alice F.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM dafonseca@icb.ufmg.br
RI de Andrade, Lidia Maria/O-7835-2019; Versiani, Alice/M-9782-2018
OI de Andrade, Lidia Maria/0000-0003-2594-4617; Versiani,
   Alice/0000-0003-1378-5380
CR Alustiza F, 2016, VACCINE, V34, P3291, DOI 10.1016/j.vaccine.2016.05.004
   Barhate G, 2014, J PHARM SCI-US, V103, P3448, DOI 10.1002/jps.24161
   Barhate G, 2013, INT J PHARMACEUT, V441, P636, DOI 10.1016/j.ijpharm.2012.10.033
   Bernasconi V, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5482087
   Calderon-Gonzalez R, 2015, HUM VACC IMMUNOTHER, V11, P2501, DOI 10.1080/21645515.2015.1063756
   Calegari LP, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0196-7
   Carabineiro SAC, 2017, MOLECULES, V22
   Chen YS, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/19/195101
   Chiodo F, 2015, CARBOHYD RES, V405, P102, DOI 10.1016/j.carres.2014.07.012
   Coester CJ, 2000, J MICROENCAPSUL, V17, P187
   Coller BAG, 2011, CURR OPIN IMMUNOL, V23, P391, DOI 10.1016/j.coi.2011.03.005
   Dakterzada F, 2016, VACCINE, V34, P1472, DOI 10.1016/j.vaccine.2016.01.041
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   de Boer PT, 2014, HUM VACC IMMUNOTHER, V10, P2048, DOI 10.4161/hv.28670
   De Filette M, 2008, VACCINE, V26, P6503, DOI 10.1016/j.vaccine.2008.09.038
   De la Hoz-Restrepo F, 2013, VACCINE, V31, pC80, DOI 10.1016/j.vaccine.2013.05.064
   Delogu LG, 2012, NANOMEDICINE-UK, V7, P231, DOI [10.2217/nnm.11.101, 10.2217/NNM.11.101]
   DeRussy BM, 2014, SCI REP-UK, V4, DOI 10.1038/srep05550
   Di Gianvincenzo P, 2015, BIOCONJUGATE CHEM, V26, P755, DOI 10.1021/acs.bioconjchem.5b00077
   Di Gianvincenzo P, 2012, METHOD ENZYMOL, V509, P21, DOI 10.1016/B978-0-12-391858-1.00002-2
   Foldvari M, 2008, NANOMED-NANOTECHNOL, V4, P183, DOI 10.1016/j.nano.2008.04.003
   Gong YX, 2015, FISH SHELLFISH IMMUN, V42, P213, DOI 10.1016/j.fsi.2014.11.004
   Gregory AE, 2012, VACCINE, V30, P6777, DOI 10.1016/j.vaccine.2012.09.021
   Gregory AE, 2015, NANOMED-NANOTECHNOL, V11, P447, DOI 10.1016/j.nano.2014.08.005
   Guzman MG, 2010, EXPERT REV VACCINES, V9, P137, DOI [10.1586/erv.09.139, 10.1586/ERV.09.139]
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Hartwig DD, 2015, MEM I OSWALDO CRUZ, V110, P134, DOI 10.1590/0074-02760140276
   Kang S, 2017, J CONTROL RELEASE, V256, P56, DOI 10.1016/j.jconrel.2017.04.024
   Kreuter J, 2007, INT J PHARMACEUT, V331, P1, DOI 10.1016/j.ijpharm.2006.10.021
   Kumar R, 2015, VACCINE, V33, P5064, DOI 10.1016/j.vaccine.2015.08.025
   Lacerda L, 2012, BIOMATERIALS, V33, P3334, DOI 10.1016/j.biomaterials.2012.01.024
   Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021
   Li WA, 2013, CURR OPIN IMMUNOL, V25, P238, DOI 10.1016/j.coi.2012.12.008
   Muennig PA, 2001, CLIN INFECT DIS, V33, P1879, DOI 10.1086/324491
   Nakayama M., 2014, FRONT IMMUNOL, V5, P1
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   O'Hagan DT, 2015, VACCINE, V33, pB14, DOI 10.1016/j.vaccine.2015.01.088
   Oliveira TL, 2016, MEM I OSWALDO CRUZ, V111, P712, DOI 10.1590/0074-02760160214
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Paul AM, 2014, J GEN VIROL, V95, P1712, DOI 10.1099/vir.0.066084-0
   Pissuwan D, 2008, BIOTECHNOL GENET ENG, V25, P93, DOI 10.5661/bger-25-93
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668
   Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09
   Rodriguez-Del Rio E, 2015, VACCINE, V33, P1465, DOI 10.1016/j.vaccine.2015.01.062
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Sadat TMF, 2014, ASIAN PAC J CANCER P, V15, P517, DOI DOI 10.7314/APJCP.2014.15.2.517
   Safari D, 2012, INT J INFECT DIS, V16, pE313, DOI 10.1016/j.ijid.2012.05.1011
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Saluja SS, 2014, INT J NANOMED, V9, P5231, DOI 10.2147/IJN.S66639
   Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906
   Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108
   Schmidt ST, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010007
   Schwartzman LM, 2015, MBIO, V6, DOI 10.1128/mBio.01044-15
   Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440
   Silvestre BT, 2014, VACCINE, V32, P2160, DOI 10.1016/j.vaccine.2014.02.062
   Simon A, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-396
   Sridhar S, 2015, VACCINES, V3, P373, DOI 10.3390/vaccines3020373
   Stone J, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/29/295102
   Tao WQ, 2017, ANTIVIR RES, V141, P62, DOI 10.1016/j.antiviral.2017.01.021
   Tao WQ, 2015, VACCINE, V33, P2307, DOI 10.1016/j.vaccine.2015.03.063
   Tao WQ, 2014, NANOMEDICINE-UK, V9, P237, DOI 10.2217/nnm.13.58
   Taylor U, 2010, CYTOM PART A, V77A, P439, DOI 10.1002/cyto.a.20846
   Thiele F, 2015, J VIROL, V89, P2698, DOI 10.1128/JVI.03244-14
   Torres AG, 2015, VACCINE, V33, P686, DOI 10.1016/j.vaccine.2014.11.057
   van Hateren A, 2010, TISSUE ANTIGENS, V76, P259, DOI 10.1111/j.1399-0039.2010.01550.x
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Versiani AF, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0259-4
   Versiani AF, 2016, FUTURE VIROL, V11, P293, DOI 10.2217/fvl-2015-0010
   Vetro M, 2017, NANOMEDICINE-UK, V12, P13, DOI 10.2217/nnm-2016-0306
   Xie XP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04229-z
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yaron PN, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-45
   Zepp F, 2010, VACCINE, V28, pC14, DOI 10.1016/j.vaccine.2010.07.020
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zhou QQ, 2016, ACS NANO, V10, P2678, DOI 10.1021/acsnano.5b07716
   Zhu B, 2014, FISH SHELLFISH IMMUN, V41, P279, DOI 10.1016/j.fsi.2014.09.014
NR 78
TC 5
Z9 5
U1 0
U2 18
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD DEC
PY 2017
VL 12
IS 12
BP 766
EP 778
DI 10.2217/fvl-2017-0086
PG 13
WC Virology
SC Virology
GA FO6LW
UT WOS:000416975700008
DA 2020-12-08
ER

PT J
AU Oliveira, GP
   Lima, MT
   Arantes, TS
   Assis, FL
   Rodrigues, RAL
   da Fonseca, FG
   Bonjardim, CA
   Kroon, EG
   Colson, P
   La Scola, B
   Abrahao, JS
AF Oliveira, Graziele Pereira
   Lima, Mauricio Teixeira
   Arantes, Thalita Souza
   Assis, Felipe Lopes
   Lima Rodrigues, Rodrigo Araujo
   da Fonseca, Flavio Guimaraes
   Bonjardim, Claudio Antonio
   Kroon, Erna Geessien
   Colson, Philippe
   La Scola, Bernard
   Abrahao, Jonatas Santos
TI The Investigation of Promoter Sequences of Marseilleviruses Highlights a
   Remarkable Abundance of the AAATATTT Motif in Intergenic Regions
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE lateral gene transfer; Marseilleviridae; gene expression; promoter
ID COMPLETE GENOME SEQUENCE; GIANT VIRUS; GENE; MEMBER; AMEBAS
AB Viruses display a wide range of genomic profiles and, consequently, a variety of gene expression strategies. Specific sequences associated with transcriptional processes have been described in viruses, and putative promoter motifs have been elucidated for some nucleocytoplasmic large DNA viruses (NCLDV). Among NCLDV, the Marseilleviridae is a well-recognized family because of its genomic mosaicism. The marseilleviruses have an ability to incorporate foreign genes, especially from sympatric organisms inhabiting Acanthamoeba, its main known host. Here, we identified for the first time an eight-nucleotide A/T-rich promoter sequence (AAATATTT) associated with 55% of marseillevirus genes that is conserved in all marseilleviruses lineages, a higher level of conservation than that of any giant virus described to date. We instigated our prediction about the promoter motif by biological assays and by evaluating how single mutations in this octamer can impact gene expression. The investigation of sequences that regulate the expression of genes relative to lateral transfer revealed that the promoter motifs do not appear to be incorporated by marseilleviruses from donor organisms. Indeed, analyses of the intergenic regions that regulate lateral gene transfer-related genes have revealed an independent origin of the marseillevirus intergenic regions that does not match gene-donor organisms. About 50% of AAATATTT motifs spread throughout intergenic regions of the marseilleviruses are present as multiple copies. We believe that such multiple motifs are associated with increased expression of a given gene or are related to incorporation of foreign genes into the mosaic genome of marseilleviruses.
   IMPORTANCE The marseilleviruses draw attention because of the peculiar features of their genomes; however, little is known about their gene expression patterns or the factors that regulate those expression patterns. The limited published research on the expression patterns of the marseilleviruses and their unique genomes has led us to study the promoter motif sequences in the intergenic regions of the marseilleviruses. This work is the first to analyze promoter sequences in the genomes of the marseilleviruses. We also suggest a strong capacity to acquire foreign genes and to express those genes mediated by multiple copies of the promoter motifs available in intergenic regions. These findings contribute to an understanding of genomic expansion and plasticity observed in these giant viruses.
C1 [Oliveira, Graziele Pereira; Lima, Mauricio Teixeira; Arantes, Thalita Souza; Assis, Felipe Lopes; Lima Rodrigues, Rodrigo Araujo; da Fonseca, Flavio Guimaraes; Bonjardim, Claudio Antonio; Kroon, Erna Geessien; Abrahao, Jonatas Santos] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Belo Horizonte, MG, Brazil.
   [Colson, Philippe; La Scola, Bernard] Aix Marseille Univ, AP HM, IHU Mediterranee Infect, URMITE,UM63,CNRS 7278,IRD 198,INSERM 1095, Marseille, France.
RP Abrahao, JS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Belo Horizonte, MG, Brazil.
EM jonatas.abrahao@gmail.com
RI Kroon, Erna/V-5444-2019
OI Teixeira Lima, Mauricio/0000-0002-0830-3909; Araujo Lima Rodrigues,
   Rodrigo/0000-0001-7148-4012
CR Aherfi S, 2016, EMERG INFECT DIS, V22, P2008, DOI 10.3201/eid2211.160189
   Aherfi S, 2016, LANCET INFECT DIS, V16, pE225, DOI 10.1016/S1473-3099(16)30051-2
   Aherfi S, 2014, ARCH VIROL, V159, P2349, DOI 10.1007/s00705-014-2023-5
   Aherfi S, 2013, VIRUS GENES, V47, P550, DOI 10.1007/s11262-013-0965-4
   Andersson JO, 2009, ANNU REV MICROBIOL, V63, P177, DOI 10.1146/annurev.micro.091208.073203
   BAILEY TL, 1994, P 2 INT C INT SYST M, P28
   Boughalmi M, 2013, INTERVIROLOGY, V56, P386, DOI 10.1159/000354560
   Boyer M, 2009, P NATL ACAD SCI USA, V106, P21848, DOI 10.1073/pnas.0911354106
   Browning DF, 2004, NAT REV MICROBIOL, V2, P57, DOI 10.1038/nrmicro787
   Clarke M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-2-r11
   DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1
   Dornas FP, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030076
   Doutre G, 2014, J VIROL, V88, P14340, DOI 10.1128/JVI.02414-14
   Fabre E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15087
   Fischer MG, 2010, P NATL ACAD SCI USA, V107, P19508, DOI 10.1073/pnas.1007615107
   Fitzgerald LA, 2008, VIROLOGY, V380, P388, DOI 10.1016/j.virol.2008.07.025
   Garcia-Escudero R, 2000, J VIROL, V74, P8176, DOI 10.1128/JVI.74.17.8176-8182.2000
   Haberle V, 2016, SEMIN CELL DEV BIOL, V57, P11, DOI 10.1016/j.semcdb.2016.01.014
   Jakob NJ, 2001, VIROLOGY, V286, P182, DOI 10.1006/viro.2001.0963
   La Scola B, 2003, SCIENCE, V299, P2033
   Legendre M, 2010, GENOME RES, V20, P664, DOI 10.1101/gr.102582.109
   Nalcacioglu R, 2007, J GEN VIROL, V88, P2488, DOI 10.1099/vir.0.82947-0
   Oliveira GP, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9010016
   Popgeorgiev N, 2013, J CLIN MICROBIOL, V51, P4102, DOI 10.1128/JCM.01918-13
   Popgeorgiev N, 2013, J INFECT DIS, V208, P1042, DOI 10.1093/infdis/jit292
   Raoult D, 2010, INTERVIROLOGY, V53, P321, DOI 10.1159/000312917
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944
   Salem TZ, 2008, ARCH VIROL, V153, P149, DOI 10.1007/s00705-007-1081-3
   Suhre K, 2005, P NATL ACAD SCI USA, V102, P14689, DOI 10.1073/pnas.0506465102
   Takemura M, 2016, MICROBES ENVIRON, V31, P442, DOI 10.1264/jsme2.ME16107
   Thomas V, 2011, ENVIRON MICROBIOL, V13, P1454, DOI 10.1111/j.1462-2920.2011.02446.x
   Van Etten JL, 2002, ARCH VIROL, V147, P1479, DOI 10.1007/s00705-002-0822-6
   Yang ZL, 2011, J VIROL, V85, P9899, DOI 10.1128/JVI.05446-11
   YATES PR, 1995, BIOCHEM SOC T, V23, pS139, DOI 10.1042/bst023139s
NR 35
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2017
VL 91
IS 21
AR e01088-17
DI 10.1128/JVI.01088-17
PG 10
WC Virology
SC Virology
GA FK0UI
UT WOS:000413195400030
PM 28794030
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU de Oliveira, JS
   Figueiredo, PD
   Costa, GB
   de Assis, FL
   Drumond, BP
   da Fonseca, FG
   Nogueira, ML
   Kroon, EG
   Trindade, GD
AF de Oliveira, Jaqueline Silva
   Figueiredo, Poliana de Oliveira
   Costa, Galileu Barbosa
   de Assis, Felipe Lopes
   Drumond, Betania Paiva
   da Fonseca, Flavio Guimaraes
   Nogueira, Mauricio Lacerda
   Kroon, Erna Geessien
   Trindade, Giliane de Souza
TI Vaccinia Virus Natural Infections in Brazil: The Good, the Bad, and the
   Ugly
SO VIRUSES-BASEL
LA English
DT Review
DE orthopoxvirus; smallpox vaccine; vaccinia virus; zoonosis; public
   health; ecology; host range; natural infections
ID SAO-PAULO STATE; BOVINE VACCINIA; HYDROCHOERUS-HYDROCHAERIS; MOLECULAR
   CHARACTERIZATION; CLINICAL DESCRIPTION; ECZEMA VACCINATUM; MAHARASHTRA
   STATE; SMALLPOX VACCINE; VARIOLA MINOR; OUTBREAK
AB The orthopoxviruses (OPV) comprise several emerging viruses with great importance to human and veterinary medicine, including vaccinia virus (VACV), which causes outbreaks of bovine vaccinia (BV) in South America. Historically, VACV is the most comprehensively studied virus, however, its origin and natural hosts remain unknown. VACV was the primary component of the smallpox vaccine, largely used during the smallpox eradication campaign. After smallpox was declared eradicated, the vaccination that conferred immunity to OPV was discontinued, favoring a new contingent of susceptible individuals to OPV. VACV infections occur naturally after direct contact with infected dairy cattle, in recently vaccinated individuals, or through alternative routes of exposure. In Brazil, VACV outbreaks are frequently reported in rural areas, affecting mainly farm animals and humans. Recent studies have shown the role of wildlife in the VACV transmission chain, exploring the role of wild rodents as reservoirs that facilitate VACV spread throughout rural areas. Furthermore, VACV circulation in urban environments and the significance of this with respect to public health, have also been explored. In this review, we discuss the history, epidemiological, ecological and clinical aspects of natural VACV infections in Brazil, also highlighting alternative routes of VACV transmission, the factors involved in susceptibility to infection, and the natural history of the disease in humans and animals, and the potential for dissemination to urban environments.
C1 [de Oliveira, Jaqueline Silva; Figueiredo, Poliana de Oliveira; Costa, Galileu Barbosa; Drumond, Betania Paiva; Kroon, Erna Geessien; Trindade, Giliane de Souza] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, BR-31270901 Belo Horizonte, MG, Brazil.
   [de Assis, Felipe Lopes] US FDA, Silver Spring, MD 20993 USA.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Virol Basica & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Lab Pesquisas Virol, Dept Doencas Infecciosas Parasitarias, BR-15090000 Sao Paulo, Brazil.
RP Costa, GB; Trindade, GD (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, BR-31270901 Belo Horizonte, MG, Brazil.
EM jaquelinebmedica@hotmail.com; polianaofigueiredo@yahoo.com.br;
   galileuk1@gmail.com; felipelopesassis@gmail.com;
   betaniadrumond@gmail.com; fdafonseca@icb.ufmg.br; mnogueira@famerp.br;
   ernagkroon@gmail.com; giliane@icb.ufmg.br
RI Nogueira, Mauricio L/B-7599-2012; Kroon, Erna/V-5444-2019; Costa,
   Galileu Barbosa/M-5768-2019
OI Nogueira, Mauricio L/0000-0003-1102-2419; Barbosa Costa,
   Galileu/0000-0001-7360-6722
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Pro-Reitoria
   de Pesquisa/UFMG (PRPq)
FX We are thankful colleagues from the Laboratorio de Virus (ICB-UFMG) for
   their excellent technical support. We are also grateful to Joel Barratt
   for English reviewing process and for appropriate and constructive
   suggestions on the manuscript. Financial support was provided by the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), and
   Pro-Reitoria de Pesquisa/UFMG (PRPq). F.G. da Fonseca, M.L. Nogueira,
   E.G. Kroon, and G.S. Trindade are researchers from CNPq.
CR Abrahao JS, 2017, EQUINE VET J, V49, P221, DOI 10.1111/evj.12571
   Abrahao JS, 2010, EMERG INFECT DIS, V16, P976, DOI 10.3201/eid1606.091187
   Abrahao JS, 2010, J CLIN VIROL, V48, P69, DOI 10.1016/j.jcv.2010.02.001
   Abrahao JS, 2009, FOODBORNE PATHOG DIS, V6, P1141, DOI 10.1089/fpd.2009.0324
   Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Abrahao JS, 2009, ARCH VIROL, V154, P1551, DOI 10.1007/s00705-009-0470-1
   Abrahao JS, 2015, EMERG INFECT DIS, V21, P695, DOI 10.3201/eid2104.140351
   Abrahao JS, 2010, J MED VIROL, V82, P692, DOI 10.1002/jmv.21617
   Alves PA, 2016, COMP IMMUNOL MICROB, V49, P70, DOI 10.1016/j.cimid.2016.09.005
   Assis FL, 2013, EMERG INFECT DIS, V19, P2045, DOI 10.3201/eid1912.120937
   Assis FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050413
   Barbosa AV, 2014, J INFECT DEV COUNTR, V8, P1646, DOI 10.3855/jidc.5216
   Batista V. H., 2009, VIRUS REV RES, DOI 10.17525/vrr.v14i1.27
   BAXBY D, 1971, ARCH GES VIRUSFORSCH, V35, P70, DOI 10.1007/BF01249754
   Baxby D, 1981, JENNERS SMALLPOX VAC
   BEHBEHANI AM, 1983, MICROBIOL REV, V47, P455, DOI 10.1128/MMBR.47.4.455-509.1983
   Bhanuprakash V, 2010, TRANSBOUND EMERG DIS, V57, P375, DOI 10.1111/j.1865-1682.2010.01158.x
   Campos RK, 2011, ARCH VIROL, V156, P275, DOI 10.1007/s00705-010-0857-z
   CHANDRA R, 1986, ACTA VIROL, V30, P390
   Costa GB, 2015, EMERG INFECT DIS, V21, P2244, DOI 10.3201/eid2112.141249
   Costa GB, 2017, EMERG INFECT DIS, V23, P360, DOI 10.3201/eid2302.161341
   Costa GB, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0575-6
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   da Fonseca FG, 2011, FUTURE VIROL, V6, P697, DOI 10.2217/FVL.11.46
   Damaso CR, 2018, LANCET INFECT DIS, V18, pE55, DOI 10.1016/S1473-3099(17)30445-0
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Damon I., 2013, POXVIRUSES, p[2160, 2184]
   de Oliveira JS, 2017, VACCINE, V35, P3281, DOI 10.1016/j.vaccine.2017.04.048
   DEQUADRO.CC, 1972, B WORLD HEALTH ORGAN, V46, P165
   DiGiacomo R. F., 1994, BIOL LAB RABBIT
   Downie A. W., 1939, IMMUNOLOGICAL RELATI
   Downie A. W., 1939, STUDY LESIONS PRODUC
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Duggan AT, 2016, CURR BIOL, V26, P3407, DOI 10.1016/j.cub.2016.10.061
   DUMBELL K, 1993, ARCH VIROL, V128, P257, DOI 10.1007/BF01309438
   Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114
   Essbauer S, 2007, ZOONOSES PUBLIC HLTH, V54, P118, DOI 10.1111/j.1863-2378.2007.01035.x
   Fassbender P, 2016, EMERG INFECT DIS, V22, P553, DOI 10.3201/eid2203.151158
   FENNER F, 1958, VIROLOGY, V5, P502, DOI 10.1016/0042-6822(58)90042-4
   Fenner F, 1988, SMALLPOX ITS ERADICA
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Geessien Kroon Erna, 2016, Curr Protoc Microbiol, V42, DOI 10.1002/cpmc.13
   Goyal T, 2013, J DERMATOL, V52, P1224, DOI [10.1111/ijd.12120, DOI 10.1111/IJD.12120]
   Guedes MIMC, 2013, TRANSBOUND EMERG DIS, V60, P552, DOI 10.1111/j.1865-1682.2012.01372.x
   Gurav YK, 2011, PREV VET MED, V100, P242, DOI 10.1016/j.prevetmed.2011.03.008
   Henderson DA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0113
   Henderson DA, 2009, SMALLPOX DEATH DIS I
   Hughes CM, 2011, EMERG INFECT DIS, V17, P730, DOI 10.3201/eid1704.101010
   Kolhapure RM, 1997, INDIAN J MED RES, V106, P441
   Kroon EG, 2011, ANTIVIR RES, V92, P150, DOI 10.1016/j.antiviral.2011.08.018
   Kugelman JR, 2014, EMERG INFECT DIS, V20, P232, DOI 10.3201/eid2002.130118
   Laguardia-Nascimento M, 2017, ARCH VIROL, V162, P2797, DOI 10.1007/s00705-017-3407-0
   Laguardia-Nascimento M, 2016, J VET DIAGN INVEST, V28, P377, DOI 10.1177/1040638716645836
   Dutra LAL, 2017, ARCH VIROL, V162, P439, DOI 10.1007/s00705-016-3121-3
   Lederman E, 2009, VACCINE, V27, P375, DOI 10.1016/j.vaccine.2008.11.019
   Lederman ER, 2012, J INFECT DIS, V206, P1372, DOI 10.1093/infdis/jis510
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Leite JA, 2007, VIRUS GENES, V35, P531, DOI 10.1007/s11262-007-0133-9
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   de Oliveira TML, 2015, FOODBORNE PATHOG DIS, V12, P898, DOI 10.1089/fpd.2015.1974
   de Oliveira TML, 2010, FOODBORNE PATHOG DIS, V7, P1491, DOI 10.1089/fpd.2010.0597
   Marques JT, 2001, VIRUS GENES, V23, P291, DOI 10.1023/A:1012521322845
   Medaglia MLG, 2015, J VIROL, V89, P11909, DOI 10.1128/JVI.01833-15
   Megid J, 2008, AM J TROP MED HYG, V79, P647, DOI 10.4269/ajtmh.2008.79.647
   Megid J, 2012, EMERG INFECT DIS, V18, P189, DOI 10.3201/eid1801.110692
   Ferraz KMPMD, 2010, POPUL ECOL, V52, P263, DOI 10.1007/s10144-009-0181-1
   Ministerio da Agricultura Pecuaria e Abastecimento (MAPA), 2015, DAD REB BOV BAB BRAS
   Miranda JB, 2017, EMERG INFECT DIS, V23, P931, DOI 10.3201/eid2306.161643
   Moojen V., 1996, VIROSES CONFUNDIVEIS
   Franco-Luiz APM, 2016, EMERG INFECT DIS, V22, P2174, DOI 10.3201/eid2212.160447
   Franco-Luiz APM, 2016, COMP IMMUNOL MICROB, V46, P16, DOI 10.1016/j.cimid.2016.03.003
   Franco-Luiz APM, 2014, EMERG INFECT DIS, V20, P1576, DOI 10.3201/eid2009.140154
   Mota BEF, 2010, ARCH VIROL, V155, P1139, DOI 10.1007/s00705-010-0675-3
   Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Nalca A, 2010, DRUG DES DEV THER, V4, P71
   Nedunchelliyan S, 1992, Indian J Public Health, V36, P57
   Oliveira DB, 2013, AM J TROP MED HYG, V89, P1142, DOI 10.4269/ajtmh.13-0369
   Oliveira GP, 2014, AM J TROP MED HYG, V90, P1021, DOI 10.4269/ajtmh.13-0621
   Olson VA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090242
   Peres MG, 2016, EMERG INFECT DIS, V22, P271, DOI 10.3201/eid2202.140747
   Peres MG, 2013, ARCH VIROL, V158, P2433, DOI 10.1007/s00705-013-1740-5
   Quenelle DC, 2007, ANTIMICROB AGENTS CH, V51, P4118, DOI 10.1128/AAC.00762-07
   Quiner CA, 2017, INT J HEALTH GEOGR, V16, DOI 10.1186/s12942-017-0100-1
   Quixabeira-Santos JC, 2011, EMERG INFECT DIS, V17, P726, DOI 10.3201/eid1704.101581
   Rehfeld IS, 2017, J DAIRY SCI, V100, P7051, DOI 10.3168/jds.2017-12560
   Rehfeld IS, 2013, RES VET SCI, V95, P752, DOI 10.1016/j.rvsc.2013.05.005
   Rehfeld IS, 2017, RES VET SCI, V114, P233, DOI 10.1016/j.rvsc.2017.03.022
   Rehfeld IS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127350
   Rivetti AV, 2013, VET MICROBIOL, V162, P103, DOI 10.1016/j.vetmic.2012.09.005
   RODRIGUESDASILVA G, 1963, PUBLIC HEALTH REP, V78, P165, DOI 10.2307/4591745
   Sanchez-Sampedro L, 2015, VIRUSES-BASEL, V7, P1726, DOI 10.3390/v7041726
   Sant'ana F. F, 2013, PESQUI VET BRASIL, P860, DOI [10.1590/S0100-736X2013000700006, DOI 10.1590/S0100-736X2013000700006]
   Schatzmayr G. H, 2005, VIRUS REV RES, V10, DOI 10.17525/vrrjournal.v10i2.249
   Schatzmayr HG, 2009, REV SOC BRAS MED TRO, V42, P672, DOI 10.1590/S0037-86822009000600012
   Shchelkunov SN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003756
   Shchelkunov SN, 2011, VACCINE, V29, pD49, DOI 10.1016/j.vaccine.2011.05.037
   Gomes JAS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/974067
   Silva L., 2008, VIROSES EMERGENTES B, P132
   Silva P, 1985, BRAS MED VET ZOOTEC, V38, P323
   Silva-Fernandes AT, 2009, J CLIN VIROL, V44, P308, DOI 10.1016/j.jcv.2009.01.007
   Singh RK, 2012, INDIAN J VIROL, V23, P1, DOI 10.1007/s13337-012-0068-1
   Singh R. K, 2006, INDIA REV SCI TECH, V25, P981, DOI 10.20506/rst.25.3.1708
   Theves C, 2014, CLIN MICROBIOL INFEC, V20, P210, DOI 10.1111/1469-0691.12536
   THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19
   Trindade G, 2014, J VACCINES VACCIN, V5, DOI [10.4172/2157-7560.1000i101, DOI 10.4172/2157-7560.1000I101]
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GD, 2008, J VIROL METHODS, V152, P63, DOI 10.1016/j.jviromet.2008.05.028
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GD, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120328
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Usme-Ciro JA, 2017, EMERG INFECT DIS, V23, P649, DOI 10.3201/eid2304.161041
   Venkatesan G, 2010, VET ITAL, V46, P439
   Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668
   Wertheimer ER, 2012, VACCINE, V30, P985, DOI 10.1016/j.vaccine.2011.12.049
   Young GE, 2011, EMERG INFECT DIS, V17, P718, DOI 10.3201/eid1704.101316
   Zafar A, 2007, EMERG INFECT DIS, V13, P902, DOI 10.3201/eid1306.061068
NR 119
TC 15
Z9 15
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2017
VL 9
IS 11
AR 340
DI 10.3390/v9110340
PG 21
WC Virology
SC Virology
GA FO4KB
UT WOS:000416810300030
PM 29140260
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ferreira, CS
   Ladeira, LO
   Leite, CF
   da Fonseca, FG
   Ribeiro, EMD
   Versiani, AF
   Silva, JFD
   Magalhaes, CLD
   Silva, BD
AF Ferreira, Cyntia Silva
   Ladeira, Luiz Orlando
   Leite, Cristiano Fantini
   da Fonseca, Flavio Guimaraes
   de Castro Ribeiro, Erica Milena
   Versiani, Alice Freitas
   de Souza Silva, Jorge Fernando
   de Brito Magalhaes, Cintia Lopes
   Silva, Breno de Mello
TI USE OF GOLD NANORODS FOR THE DEVELOPMENT OF PRACTICAL CLASSES IN
   NANOTECHNOLOGY
SO QUIMICA NOVA
LA Portuguese
DT Article
DE gold nanorods; surface plasmon resonance; nanotechnology experiment
ID IN-VIVO; NANOPARTICLES; PROTEIN; IMMUNOSENSOR; PROSPECTS; DELIVERY;
   BIOLOGY; GROWTH
AB A gold nanoparticles functionalization experiment was conducted in a biotechnology summer course at UFOP as a model for the introduction of the laboratory practice in nanotechnology for postgraduate courses in the areas of chemistry and biotechnology. The gold nanorods were synthesized by the seed method and then, functionalized with anti-IL-6 antibodies using the reagents EDAC/NHS and polyethyleneimine (PEI). This nanocompound was tested against the binding with the specific antigen (IL-6) and changes in the longitudinal plasmon absorption spectrum showed the coupling efficiency, which was also verified by the decrease in zeta potential. The experiment was satisfactory, with a positive feedback from participants, and could be implemented in nanotechnology practical classes from postgraduate courses, as a way for improve education in the emergent area of nanobiotechnology.
C1 [Ferreira, Cyntia Silva; de Castro Ribeiro, Erica Milena; de Souza Silva, Jorge Fernando; de Brito Magalhaes, Cintia Lopes; Silva, Breno de Mello] Univ Fed Ouro Preto, Dept Ciencias Biol, BR-35400000 Ouro Preto, MG, Brazil.
   [Ladeira, Luiz Orlando; Leite, Cristiano Fantini] Univ Fed Minas Gerais, Dept Fis, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes; Versiani, Alice Freitas] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Ferreira, CS (corresponding author), Univ Fed Ouro Preto, Dept Ciencias Biol, BR-35400000 Ouro Preto, MG, Brazil.
EM csf.ferreira@gmail.com
RI silva, breno/W-5122-2018
OI silva, breno/0000-0003-2472-8111
CR Abbas A. K., 2014, CELLULAR MOL IMMUNOL
   Adabo AH, 2016, J COLLOID INTERF SCI, V467, P271, DOI 10.1016/j.jcis.2016.01.030
   Alkilany AM, 2012, ADV DRUG DELIVER REV, V64, P190, DOI 10.1016/j.addr.2011.03.005
   Boulos SP, 2013, LANGMUIR, V29, P14984, DOI 10.1021/la402920f
   Chen SN, 2015, SENSOR ACTUAT B-CHEM, V221, P1391, DOI 10.1016/j.snb.2015.08.023
   Chumakova OV, 2008, CANCER LETT, V261, P215, DOI 10.1016/j.canlet.2007.11.023
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Fangueiro JF, 2015, EUR J PHARM BIOPHARM, V95, P307, DOI 10.1016/j.ejpb.2014.12.023
   Faraday M, 1857, PHILOS T ROY SOC LON, V147, P145, DOI DOI 10.1098/RSTL.1857.0011
   Hirano T, 1998, Int Rev Immunol, V16, P249
   Hu CM, 2014, ELECTROCHIM ACTA, V117, P239, DOI 10.1016/j.electacta.2013.11.132
   Huang XH, 2010, J ADV RES, V1, P13, DOI 10.1016/j.jare.2010.02.002
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Hullmann A, 2007, SCIENTOMETRICS, V70, P739, DOI 10.1007/s11192-007-0310-6
   Hunter R., 1981, ZETA POTENTIAL COLLO
   Hussein AK, 2015, RENEW SUST ENERG REV, V42, P460, DOI 10.1016/j.rser.2014.10.027
   Hwang SY, 2011, PURE APPL CHEM, V83, P233, DOI 10.1351/PAC-CON-10-09-35
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Jensen TR, 2000, J PHYS CHEM B, V104, P10549, DOI 10.1021/jp002435e
   Junior M. A. M., 2012, QUIM NOVA, V35, P1872
   Santos JFL, 2016, QUIM NOVA, V39, P1098, DOI 10.21577/0100-4042.20160126
   Link S, 1999, J PHYS CHEM B, V103, P8410, DOI 10.1021/jp9917648
   Liopo A., 2012, J NANOMED NANOTECHNO, V2, P1
   Ma YJ, 2013, ANALYST, V138, P5338, DOI 10.1039/c3an00690e
   Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y
   Murphy CJ, 2005, J PHYS CHEM B, V109, P13857, DOI 10.1021/jp0516846
   Nietzold C, 2012, ANALYST, V137, P2821, DOI 10.1039/c2an35054h
   Nikoobakht B, 2003, CHEM MATER, V15, P1957, DOI [10.1021/cm020732l, 10.1021/cm0207321]
   Perez-Juste J, 2004, ADV FUNCT MATER, V14, P571, DOI 10.1002/adfm.200305068
   Perret G, 2016, SOLID STATE ELECTRON, V115, P66, DOI 10.1016/j.sse.2015.08.019
   Pissuwan D, 2008, BIOTECHNOL GENET ENG, V25, P93, DOI 10.5661/bger-25-93
   Pyshnaya IA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/908175
   Quadros C. C., 2016, QUIM NOVA, V39, P1015
   Rincon M, 2012, TRENDS IMMUNOL, V33, P571, DOI 10.1016/j.it.2012.07.003
   Silva A. G. M. da, 2014, QUIM NOVA, V37, P1716
   Tiwari PM, 2011, NANOMATERIALS-BASEL, V1, P31, DOI 10.3390/nano1010031
   Turkevich J., 1951, ANAL CHEM, V55, P475
   Vaz R, 2015, QUIM NOVA, V38, P1366, DOI 10.5935/0100-4042.20150150
   Vigderman L, 2012, ADV MATER, V24, P4811, DOI 10.1002/adma.201201690
   Vonnemann J, 2014, THERANOSTICS, V4, P629, DOI 10.7150/thno.8518
   Wang W, 2013, J COLLOID INTERF SCI, V404, P223, DOI 10.1016/j.jcis.2013.04.020
   Wangoo N, 2008, J COLLOID INTERF SCI, V323, P247, DOI 10.1016/j.jcis.2008.04.043
   Wilson R, 2008, CHEM SOC REV, V37, P2028, DOI 10.1039/b712179m
   Xu XL, 2014, J MATER CHEM A, V2, P3528, DOI [10.1039/c3ta13905k, 10.1039/c3ta13905]
   Yang DP, 2008, CHEM-ASIAN J, V3, P2010, DOI 10.1002/asia.200800195
   Yu YY, 1997, J PHYS CHEM B, V101, P6661
   Zapp E, 2014, BIOSENS BIOELECTRON, V59, P127, DOI 10.1016/j.bios.2014.03.026
   Zhu H, 2017, ACTA BIOMATER, V50, P534, DOI 10.1016/j.actbio.2016.12.050
NR 48
TC 0
Z9 0
U1 1
U2 6
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD JUN
PY 2017
VL 40
IS 5
BP 594
EP 601
DI 10.21577/0100-4042.20170021
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA FA4KU
UT WOS:000405413000015
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Versiani, AF
   Astigarraga, RG
   Rocha, ESO
   Barboza, APM
   Kroon, EG
   Rachid, MA
   Souza, DG
   Ladeira, LO
   Barbosa-Stancioli, EF
   Jorio, A
   Da Fonseca, FG
AF Versiani, Alice F.
   Astigarraga, Ruiz G.
   Rocha, Eliseu S. O.
   Barboza, Ana Paula M.
   Kroon, Erna G.
   Rachid, Milene A.
   Souza, Daniele G.
   Ladeira, Luiz O.
   Barbosa-Stancioli, Edel F.
   Jorio, Ado
   Da Fonseca, Flavio G.
TI Multi-walled carbon nanotubes functionalized with recombinant Dengue
   virus 3 envelope proteins induce significant and specific immune
   responses in mice
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Dengue vaccine; Carbon nanotubes; Subunit vaccine; Nanoconjugate
ID DENGUE VIRUS; T-CELLS; IMMUNIZATION; VACCINES; ENHANCE; ANTIGEN
AB Background: Dengue is the most prevalent arthropod-borne viral disease in the world. In this article we present results on the development, characterization and immunogenic evaluation of an alternative vaccine candidate against Dengue.
   Methods: The MWNT-DENV3E nanoconjugate was developed by covalent functionalization of carboxylated multi-walled carbon nanotubes (MWNT) with recombinant dengue envelope (DENV3E) proteins. The recombinant antigens were bound to the MWNT using a diimide-activated amidation process and the immunogen was characterized by TEM, AFM and Raman Spectroscopy. Furthermore, the immunogenicity of this vaccine candidate was evaluated in a murine model.
   Results: Immunization with MWNT-DENV3E induced comparable IgG responses in relation to the immunization with non-conjugated proteins; however, the inoculation of the nanoconjugate into mice generated higher titers of neutralizing antibodies. Cell-mediated responses were also evaluated, and higher dengue-specific splenocyte proliferation was observed in cell cultures derived from mice immunized with MWNT-DENV3E when compared to animals immunized with the non-conjugated DENV3E.
   Conclusions: Despite the recent licensure of the CYD-TDV dengue vaccine in some countries, results from the vaccine's phase III trial have cast doubts about its overall efficacy and global applicability. While questions about the effectiveness of the CYD-TDV vaccine still lingers, it is wise to keep at hand an array of vaccine candidates, including alternative non-classical approaches like the one presented here.
C1 [Versiani, Alice F.; Astigarraga, Ruiz G.; Barbosa-Stancioli, Edel F.; Da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
   [Rocha, Eliseu S. O.; Kroon, Erna G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Belo Horizonte, MG, Brazil.
   [Rachid, Milene A.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Patol, Belo Horizonte, MG, Brazil.
   [Ladeira, Luiz O.] Univ Fed Minas Gerais, Inst Ciencias Exatas, Dept Fis, Belo Horizonte, MG, Brazil.
   [Jorio, Ado] Univ Fed Minas Gerais, Dept Fis, Lab Nanoscopia, Belo Horizonte, MG, Brazil.
   [Souza, Daniele G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Microorganism Host Interact, Belo Horizonte, MG, Brazil.
RP Da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Rachid, Milene Alvarenga/C-3530-2017; Kroon,
   Erna Geessien/B-3631-2015; Jorio, Ado/F-2141-2010; Barbosa-Stancioli,
   Edel F/J-7230-2012; Versiani, Alice/M-9782-2018
OI Rachid, Milene Alvarenga/0000-0002-3142-6552; Kroon, Erna
   Geessien/0000-0003-2721-3826; Jorio, Ado/0000-0002-5978-2735;
   Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Versiani,
   Alice/0000-0003-1378-5380; Ladeira, Luiz Orlando/0000-0002-4935-6070
FU FAPEMIG (Pronex Bio-NC); CAPESCAPES; CNPq (Universal Grant)
   [470914/2012-2]; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by FAPEMIG (Pronex Bio-NC), CAPES and CNPq
   (Universal Grant # 470914/2012-2). EG Kroon, DG Souza, LO Ladeira, A
   Jorio, EFB Stancioli and FG da Fonseca are CNPq fellowship recipients.
   Other than funding, sponsoring agencies had no role on the study design,
   collection and interpretation of the data, and writing of the
   manuscript. No writing assistance was utilized.
CR Acosta EG, 2014, ADV VIRUS RES, V88, P1, DOI 10.1016/B978-0-12-800098-4.00001-5
   Andersen CAS, 2009, J IMMUNOL, V183, P2294, DOI 10.4049/jimmunol.0804091
   Babu JP, 2008, VACCINE, V26, P4655, DOI 10.1016/j.vaccine.2008.07.006
   de Faria PCB, 2014, NANO LETT, V14, P5458, DOI 10.1021/nl502911a
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bianco A, 2011, CHEM COMMUN, V47, P10182, DOI 10.1039/c1cc13011k
   Calegari LP, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0196-7
   Clements DE, 2010, VACCINE, V28, P2705, DOI 10.1016/j.vaccine.2010.01.022
   Coller BAG, 2011, VACCINE, V29, P7267, DOI 10.1016/j.vaccine.2011.07.021
   Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011
   Rocha ESD, 2013, J VIROL METHODS, V187, P114, DOI 10.1016/j.jviromet.2012.09.012
   Delogu LG, 2012, NANOMEDICINE-UK, V7, P231, DOI [10.2217/nnm.11.101, 10.2217/NNM.11.101]
   Dresselhaus MS, 2010, PHILOS T R SOC A, V368, P5355, DOI 10.1098/rsta.2010.0213
   Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590
   Ferlauto AS, 2006, APPL PHYS A-MATER, V84, P271, DOI 10.1007/s00339-006-3617-x
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2013, VACCINE, V31, P4501, DOI 10.1016/j.vaccine.2013.06.079
   Hansen J, 2008, J INFECT DIS, V198, P758, DOI 10.1086/590670
   Hu PQ, 2004, J IMMUNOL, V172, P1595, DOI 10.4049/jimmunol.172.3.1595
   Hunsawong T, 2015, VACCINE, V33, P1702, DOI 10.1016/j.vaccine.2015.02.016
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Jain KK, 2012, EXPERT OPIN DRUG DIS, V7, P1029, DOI 10.1517/17460441.2012.722078
   Jiang KY, 2004, J MATER CHEM, V14, P37, DOI 10.1039/b310359e
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209
   Kraszewski S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040703
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Mathew A, 2014, FUTURE MICROBIOL, V9, P411, DOI 10.2217/fmb.13.171
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   Meng J, 2008, SMALL, V4, P1364, DOI 10.1002/smll.200701059
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Narvaez F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001397
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r
   Pescatori M, 2013, BIOMATERIALS, V34, P4395, DOI 10.1016/j.biomaterials.2013.02.052
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Scheinberg DA, 2013, ADV DRUG DELIVER REV, V65, P2016, DOI 10.1016/j.addr.2013.07.013
   Silvestre BT, 2014, VACCINE, V32, P2160, DOI 10.1016/j.vaccine.2014.02.062
   Simon A, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-396
   Stayton PS, 2003, TRENDS BIOTECHNOL, V21, P465, DOI 10.1016/j.tibtech.2003.09.004
   Tregoning JS, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.PLAS-0028-2014
   Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003
   Villa CH, 2011, ACS NANO, V5, P5300, DOI 10.1021/nn200182x
   WHO, 2016, WEEKL EP REC DENG VA, V30
   WHO, 2007, GUID PLAQ RED NEUTR
   Yandara N, 2008, VACCINE, V26, P5864, DOI 10.1016/j.vaccine.2008.08.014
NR 49
TC 22
Z9 22
U1 0
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 4
PY 2017
VL 15
AR 26
DI 10.1186/s12951-017-0259-4
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA ER0ZB
UT WOS:000398517000001
PM 28376812
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gazzinelli-Guimaraes, PH
   de Freitas, LFD
   Gazzinelli-Guimaraes, AC
   Coelho, F
   Barbosa, FS
   Nogueira, D
   Amorim, C
   Dhom-Lemos, LD
   Oliveira, LM
   da Silveira, AB
   da Fonseca, FG
   Bueno, LL
   Fujiwara, RT
AF Gazzinelli-Guimaraes, Pedro Henrique
   Daher de Freitas, Lorena Falabella
   Gazzinelli-Guimaraes, Ana Clara
   Coelho, Fabiana
   Barbosa, Fernando Sergio
   Nogueira, Denise
   Amorim, Chiara
   Dhom-Lemos, Lucas de Carvalho
   Oliveira, Luciana Maria
   da Silveira, Alexandre Barcelos
   da Fonseca, Flavio Guimaraes
   Bueno, Lilian Lacerda
   Fujiwara, Ricardo Toshio
TI Concomitant helminth infection downmodulates the Vaccinia virus-specific
   immune response and potentiates virus-associated pathology
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Larval ascariasis; Vaccinia virus, co-infection; Immunomodulation; Lung
   inflammation; Helminth immunology
ID ASCARIS-LUMBRICOIDES; PARASITIC INFECTIONS; INTESTINAL PARASITES;
   NORTHWEST ETHIOPIA; SOUTHERN ETHIOPIA; RISK-FACTORS; RURAL AREA; T-CELL;
   PREVALENCE; COINFECTION
AB The aim of this work was to elucidate the immunopathological mechanisms of how helminths may influence the course of a viral infection, using a murine model. Severe virulence, a relevant increase in the virus titres in the lung and a higher mortality rate were observed in Ascaris and Vaccinia virus (VACV) co-infected mice, compared with VACV mono-infected mice. Immunopathological analysis suggested that the ablation of CD8(+) T cells, the marked reduction of circulating CD4(+) T cells producing IFN-gamma, and the robust pulmonary inflammation were associated with the increase of morbidity/mortality in co-infection and subsequently with the negative impact of concomitant pulmonary ascariasis and respiratory VACV infection for the host. On the other hand, when evaluating the impact of the co-infection on the parasitic burden, co-infected mice presented a marked decrease in the total number of migrating Ascaris lung-stage larvae in comparison with Ascaris mono-infettion. Taken together, our major findings suggest that Ascaris and VACV co-infection may potentiate the virus-associated pathology by the down modulation of the VACV-specific immune response. Moreover, this study provides new evidence of how helminth parasites may influence the course of a coincident viral infection. (C) 2016 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.
C1 [Gazzinelli-Guimaraes, Pedro Henrique; Gazzinelli-Guimaraes, Ana Clara; Barbosa, Fernando Sergio; Nogueira, Denise; Amorim, Chiara; Dhom-Lemos, Lucas de Carvalho; Oliveira, Luciana Maria; Bueno, Lilian Lacerda; Fujiwara, Ricardo Toshio] Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, Belo Horizonte, MG, Brazil.
   [Daher de Freitas, Lorena Falabella; Coelho, Fabiana; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Biol Sci, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [da Silveira, Alexandre Barcelos] Univ Fed Uberlandia, Inst Biomed Sci, Dept Morphol, Uberlandia, MG, Brazil.
RP Fujiwara, RT (corresponding author), Univ Fed Minas Gerais, Dept Parasitol, Inst Ciencias Biol, Lab Immunol & Genom Parasites, Bloco E4,Sala 167, Belo Horizonte, MG, Brazil.
EM fujiwara@icb.ufmg.br
RI Fujiwara, Ricardo Toshio/J-7579-2012; de Oliveira, Luciana/I-8842-2012;
   Gazzinelli-Guimaraes, Pedro Henrique/E-7693-2013; NOGUEIRA, DENISE
   S/O-7137-2018; Bueno, Lilian/AAQ-1939-2020; NOGUEIRA,
   DENISE/N-7139-2019; Coelho, Fabiana Magalhaes/K-6001-2013
OI Fujiwara, Ricardo Toshio/0000-0002-4713-575X; Gazzinelli-Guimaraes,
   Pedro Henrique/0000-0003-4932-2206; NOGUEIRA, DENISE
   S/0000-0003-4091-8783; Bueno, Lilian/0000-0003-3510-4590; NOGUEIRA,
   DENISE/0000-0003-4091-8783; 
FU Fundacao de Amparo a Pesquisa do Estado de Mina Gerais/FAPEMIG, Brazil
   [CBB APQ-01202-09, CBB - PPM-00296-11]; Brazilian National Research
   Council (CNPq)National Council for Scientific and Technological
   Development (CNPq) [478729/2011-1, 470613/2012-5]; Pro-Reitoria de
   Pesquisa of Universidade Federal de Minas Gerais; CAPES (Programa
   Nacional de Incentivo a Parasitologia Basica); CNPq fellowshipNational
   Council for Scientific and Technological Development (CNPq)
FX This work was financially supported by the Fundacao de Amparo a Pesquisa
   do Estado de Mina Gerais/FAPEMIG, Brazil (Grant# CBB APQ-01202-09 and
   Grant# CBB - PPM-00296-11), the Brazilian National Research Council
   (CNPq) (Grant# 478729/2011-1 and Grant# 470613/2012-5), Pro-Reitoria de
   Pesquisa of Universidade Federal de Minas Gerais and CAPES (Programa
   Nacional de Incentivo a Parasitologia Basica). PHGG was supported by a
   CNPq fellowship.
CR Abanyie FA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-1
   ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948
   Boes J, 1998, VET PARASITOL, V75, P181, DOI 10.1016/S0304-4017(97)00197-0
   Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727
   Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944
   Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830
   Cooper PJ, 2001, INFECT IMMUN, V69, P1574, DOI 10.1128/IAI.69.3.1574-1580.2001
   Degarege A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-291
   Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x
   Fekadu S, 2013, J INFECT DEV COUNTR, V7, P868, DOI 10.3855/jidc.2906
   Gazzinelli-Guimaraes PH, 2013, INT J PARASITOL, V43, P697, DOI 10.1016/j.ijpara.2013.02.009
   Gelaw A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-304
   Hagel I, 2011, ACTA TROP, V117, P189, DOI 10.1016/j.actatropica.2010.12.001
   Hayasaka D, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-22
   Hotez PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002865
   LEE MS, 1992, J VIROL, V66, P2617, DOI 10.1128/JVI.66.5.2617-2630.1992
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Li XX, 2014, AM J TROP MED HYG, V90, P106, DOI 10.4269/ajtmh.13-0426
   Megid J, 2012, EMERG INFECT DIS, V18, P189, DOI 10.3201/eid1801.110692
   Mengesha Bewketu, 2014, BMC Res Notes, V7, P75, DOI 10.1186/1756-0500-7-75
   Mulu A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-227
   Nogueira DS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004382
   Phongluxa K, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-328
   Reading PC, 2003, J GEN VIROL, V84, P1973, DOI 10.1099/vir.0.19285-0
   Reese TA, 2014, SCIENCE, V345, P573, DOI 10.1126/science.1254517
   ROBINSON RD, 1991, J TROP MED HYG, V94, P411
   Roka M, 2013, T ROY SOC TROP MED H, V107, P502, DOI 10.1093/trstmh/trt049
   Saha DR, 2008, EPIDEMIOL INFECT, V136, P661, DOI 10.1017/S0950268807008886
   Sanchez AL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002378
   Smith GL, 2013, J GEN VIROL, V94, P2367, DOI 10.1099/vir.0.055921-0
   Tian LG, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-36
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
NR 34
TC 7
Z9 7
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2017
VL 47
IS 1
BP 1
EP 10
DI 10.1016/j.ijpara.2016.08.007
PG 10
WC Parasitology
SC Parasitology
GA EK4ZP
UT WOS:000393937000001
PM 28003150
DA 2020-12-08
ER

PT J
AU Quinan, BR
   Versiani, AF
   da Fonseca, FG
AF Quinan, Barbara R.
   Versiani, Alice Freitas
   da Fonseca, Flavio G.
TI A MVA construct expressing a secretable form of the Dengue virus 3
   envelope protein protects immunized mice from dengue-induced
   encephalitis
SO VACCINE
LA English
DT Article
DE Dengue vaccine; MVA; Recombinant MVA; Neutralizing antibodies;
   Encephalitis model
ID CD8(+) T-CELLS; VACCINE; RECOMBINANT; ANKARA; EFFICACY; MODEL
AB Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Quinan, Barbara R.; Versiani, Alice Freitas; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Versiani, Alice/M-9782-2018
OI Versiani, Alice/0000-0003-1378-5380
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG); CNPqNational
   Council for Scientific and Technological Development (CNPq); Institute
   Nacional de Ciencia e Tecnologia de Vacinas - INCTV (National Institute
   of Science and Technology of Vaccines)
FX We thank Dr. EG Kroon for the DENV3 viral strain used in the challenge.
   We also thank TMG Pinho and FM Coelho for technical help. The work was
   supported by FAPEMIG and CNPq grants and by the Institute Nacional de
   Ciencia e Tecnologia de Vacinas - INCTV (National Institute of Science
   and Technology of Vaccines). FG da Fonseca is a CNPq fellowship
   recipient. Funding sources had no role in the experiments' design,
   interpretation of results, writing or submission of the article.
CR Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Cottingham MG, 2013, VACCINE, V31, P4247, DOI 10.1016/j.vaccine.2013.03.021
   Dai PH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003989
   Flipse J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003749
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Mathew A, 2014, FUTURE MICROBIOL, V9, P411, DOI 10.2217/fmb.13.171
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   PAHO, 2014, 5 FOLD INCR DENG CAS
   Quinan BR, 2014, VACCINE, V32, P2972, DOI 10.1016/j.vaccine.2014.03.093
   de Souza KPR, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-267
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Verheust C, 2012, VACCINE, V30, P2623, DOI 10.1016/j.vaccine.2012.02.016
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   WHO, 2007, GUID PLAQ RED NEUTR
   Yauch LE, 2014, ADV VIRUS RES, V88, P315, DOI 10.1016/B978-0-12-800098-4.00007-6
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
NR 21
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 7
PY 2016
VL 34
IS 50
BP 6120
EP 6122
DI 10.1016/j.vaccine.2016.10.058
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA EF9AH
UT WOS:000390622600006
PM 27817963
OA Bronze
DA 2020-12-08
ER

PT J
AU Trindade, GD
   Emerson, GL
   Sammons, S
   Frace, M
   Govil, D
   Mota, BEF
   Abrahao, JS
   de Assis, FL
   Olsen-Rasmussen, M
   Goldsmith, CS
   Li, Y
   Carroll, D
   da Fonseca, FG
   Kroon, E
   Damon, IK
AF Trindade, Giliane de Souza
   Emerson, Ginny L.
   Sammons, Scott
   Frace, Michael
   Govil, Dhwani
   Fernandes Mota, Bruno Eduardo
   Abrahao, Jonatas Santos
   de Assis, Felipe Lopes
   Olsen-Rasmussen, Melissa
   Goldsmith, Cynthia S.
   Li, Yu
   Carroll, Darin
   da Fonseca, Flavio Guimaraes
   Kroon, Erna
   Damon, Inger K.
TI Serro 2 Virus Highlights the Fundamental Genomic and Biological Features
   of a Natural Vaccinia Virus Infecting Humans
SO VIRUSES-BASEL
LA English
DT Article
DE vaccinia virus; genome; virulence; outbreak; poxvirus; public health
ID MONOCLONAL-ANTIBODIES; SMALLPOX VACCINE; DRUG-RESISTANCE; CANTAGALO
   VIRUS; PROTECTS MICE; IN-VITRO; POXVIRUS; SEQUENCE; STRAINS; GENE
AB Vaccinia virus (VACV) has been implicated in infections of dairy cattle and humans, and outbreaks have substantially impacted local economies and public health in Brazil. During a 2005 outbreak, a VACV strain designated Serro 2 virus (S2V) was collected from a 30-year old male milker. Our aim was to phenotypically and genetically characterize this VACV Brazilian isolate. S2V produced small round plaques without associated comets when grown in BSC40 cells. Furthermore, S2V was less virulent than the prototype strain VACV-Western Reserve (WR) in a murine model of intradermal infection, producing a tiny lesion with virtually no surrounding inflammation. The genome of S2V was sequenced by primer walking. The coding region spans 184,572 bp and contains 211 predicted genes. Mutations in envelope genes specifically associated with small plaque phenotypes were not found in S2V; however, other alterations in amino acid sequences within these genes were identified. In addition, some immunomodulatory genes were truncated in S2V. Phylogenetic analysis using immune regulatory-related genes, besides the hemagglutinin gene, segregated the Brazilian viruses into two clusters, grouping the S2V into Brazilian VACV group 1. S2V is the first naturally-circulating human-associated VACV, with a low passage history, to be extensively genetically and phenotypically characterized.
C1 [Trindade, Giliane de Souza; Emerson, Ginny L.; Sammons, Scott; Frace, Michael; Govil, Dhwani; Olsen-Rasmussen, Melissa; Goldsmith, Cynthia S.; Li, Yu; Carroll, Darin; Damon, Inger K.] Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, CCID CDC, Atlanta, GA 30329 USA.
   [Trindade, Giliane de Souza; Fernandes Mota, Bruno Eduardo; Abrahao, Jonatas Santos; de Assis, Felipe Lopes; da Fonseca, Flavio Guimaraes; Kroon, Erna] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Trindade, GD; Damon, IK (corresponding author), Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, CCID CDC, Atlanta, GA 30329 USA.; Trindade, GD (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
EM gitrindade@yahoo.com.br; dtt4@cdc.gov; ssammons@cdc.gov; mfrace@cdc.gov;
   dgovil@cdc.gov; brunofmota@gmail.com; jonatas.abrahao@gmail.com;
   felipelopesassis@gmail.com; mOlsen-Rasmussen@cdc.gov;
   cgoldsmith@cdc.gov; lay4@cdc.gov; dcarroll@cdc.gov;
   fdafonseca@icb.ufmg.br; kroone@icb.ufmg.br; IDamon@cdc.gov
RI Kroon, Erna/V-5444-2019; Kroon, Erna/B-3631-2015
OI Mota, Bruno/0000-0003-0348-4875; Kroon, Erna/0000-0003-2721-3826
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Ministerio da
   Agricultura, Pecuaria e Abastecimento (MAPA)
FX We thank Joao Rodrigues dos Santos, Angela Sana Lopes, Ilda Gamma, and
   colleagues from Laboratorio de Virus (ICB-UFMG/Escola de Veterinaria)
   for their excellent technical support. We also thank the Instituto
   Mineiro de Agropecuaria (IMA) for technical support during the field
   expeditions. G.d.S.T., F.G.d.F., J.S.A. and E.K. are CNPq researchers.
   Financial support was provided by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo
   a Pesquisa do Estado de Minas Gerais (FAPEMIG), Ministerio da
   Agricultura, Pecuaria e Abastecimento (MAPA). G.d.S.T., J.S.A., F.G.d.F.
   and E.K. are researchers from CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The findings and conclusions in this
   manuscript are those of the author(s) and do not necessarily represent
   the official position of the Centers for Disease Control and Prevention.
CR Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Aldaz-Carroll L, 2005, J VIROL, V79, P6260, DOI 10.1128/JVI.79.10.6260-6271.2005
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Andrei G, 2010, VIRUSES-BASEL, V2, P2803, DOI 10.3390/v2122803
   Assis FL, 2012, EMERG INFECT DIS, V18, P2035, DOI 10.3201/eid1812.120145
   Becker MN, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-58
   Bell E, 2004, VIROLOGY, V325, P425, DOI 10.1016/j.virol.2004.05.004
   Benhnia MREI, 2009, J VIROL, V83, P1201, DOI 10.1128/JVI.01797-08
   Berhanu A, 2008, J VIROL, V82, P3517, DOI 10.1128/JVI.01854-07
   Besemer J, 2001, NUCLEIC ACIDS RES, V29, P2607, DOI 10.1093/nar/29.12.2607
   Bhattacharjee A. B., 1966, MED J, V60, P209
   BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991
   Bugert JJ, 1998, VIROLOGY, V242, P51, DOI 10.1006/viro.1997.9001
   Chen ZC, 2007, J VIROL, V81, P8989, DOI 10.1128/JVI.00906-07
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Damon I., 2007, POXVIRUSES, P2049
   Damon IK, 2009, J GEN VIROL, V90, P1962, DOI 10.1099/vir.0.010553-0
   Davies DH, 2005, J VIROL, V79, P11724, DOI 10.1128/JVI.79.18.11724-11733.2005
   Domi A, 2008, J VIROL, V82, P4215, DOI 10.1128/JVI.00037-08
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114
   Ehlers A, 2002, BIOINFORMATICS, V18, P1544, DOI 10.1093/bioinformatics/18.11.1544
   Fenner F., 1988, SMALLPOX ITS ERADICA, V49
   Fernandes T., 1999, SAUDE MANGUINHOS, V6, P51
   Gammon DB, 2008, J VIROL, V82, P12520, DOI 10.1128/JVI.01528-08
   Grosenbach D. W., 2009, P NATL ACAD SCI USA, V2, P838, DOI [10.1073/pnas.091213410720080762, DOI 10.1073/PNAS.091213410720080762]
   Hansen AK, 2011, EUR J IMMUNOL, V41, P1948, DOI 10.1002/eji.201141413
   Henderson DA, 1998, EMERG INFECT DIS, V4, P488, DOI 10.3201/eid0403.980340
   Heraud JM, 2006, J IMMUNOL, V177, P2552, DOI 10.4049/jimmunol.177.4.2552
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Huemer HP, 2012, RES VET SCI, V92, P333, DOI 10.1016/j.rvsc.2011.03.011
   ISAACS SN, 1992, P NATL ACAD SCI USA, V89, P628, DOI 10.1073/pnas.89.2.628
   Jackson SS, 2005, J VIROL, V79, P6554, DOI 10.1128/JVI.79.10.6554-6559.2005
   JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1
   Katz E, 2003, J VIROL, V77, P12266, DOI 10.1128/JVI.77.22.12266-12275.2003
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kinnunen PM, 2011, VECTOR-BORNE ZOONOT, V11, P1133, DOI 10.1089/vbz.2010.0170
   Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545
   Kornbluth RS, 2006, ANTIMICROB AGENTS CH, V50, P4038, DOI 10.1128/AAC.00380-06
   Kotwal Girish J., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P135
   Law M, 2002, J GEN VIROL, V83, P209, DOI 10.1099/0022-1317-83-1-209
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Leite JA, 2007, VIRUS GENES, V35, P531, DOI 10.1007/s11262-007-0133-9
   Leite JA, 2011, ARCH VIROL, V156, P617, DOI 10.1007/s00705-010-0900-0
   Lopes de S., 1965, AM J TROP MED HYG, V14, P156
   LUM GS, 1967, AM J TROP MED HYG, V16, P332, DOI 10.4269/ajtmh.1967.16.332
   Martinez J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000811
   McCausland MM, 2010, ANTIVIR THER, V15, P661, DOI 10.3851/IMP1573
   Medaglia MLG, 2015, J VIROL, V89, P11909, DOI 10.1128/JVI.01833-15
   Medaglia MLG, 2009, EMERG INFECT DIS, V15, P1142, DOI 10.3201/eid1507.081702
   Megid J, 2008, AM J TROP MED HYG, V79, P647, DOI 10.4269/ajtmh.2008.79.647
   Morikawa S, 2005, J VIROL, V79, P11873, DOI 10.1128/JVI.79.18.11873-11891.2005
   Moss B, 2006, VIROLOGY, V344, P48, DOI 10.1016/j.virol.2005.09.037
   Moss B., 2007, POXVIRIDAE THEIR REP, P2906
   Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258
   Myskiw C, 2009, J VIROL, V83, P6757, DOI 10.1128/JVI.02570-08
   OGUIURA N, 1993, J GEN VIROL, V74, P1409, DOI 10.1099/0022-1317-74-7-1409
   Puehler F, 1998, VIROLOGY, V248, P231, DOI 10.1006/viro.1998.9278
   Quixabeira-Santos JC, 2011, EMERG INFECT DIS, V17, P726, DOI 10.3201/eid1704.101581
   Rudraraju R, 2010, VACCINE, V28, P4997, DOI 10.1016/j.vaccine.2010.05.023
   Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544
   Shchelkunov SN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003756
   SHCHELKUNOV SN, 1993, FEBS LETT, V319, P163, DOI 10.1016/0014-5793(93)80059-4
   Silva P. L., 1986, BRAS MED VET ZOOTEC, V3, P323
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Smee Donald F., 2005, Antiviral Chemistry & Chemotherapy, V16, P203
   Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730
   SMITH GL, 1984, BIOTECHNOL GENET ENG, V2, P383, DOI 10.1080/02648725.1984.10647806
   SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333
   Smith VP, 2002, J VIROL, V76, P1124, DOI 10.1128/JVI.76.3.1124-1134.2002
   Symons JA, 2002, J GEN VIROL, V83, P2833, DOI 10.1099/0022-1317-83-11-2833
   TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Tscharke DC, 2002, J GEN VIROL, V83, P1977, DOI 10.1099/0022-1317-83-8-1977
   Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916
   Yang G, 2005, J VIROL, V79, P13139, DOI 10.1128/JVI.79.20.13139-13149.2005
NR 81
TC 9
Z9 9
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD DEC
PY 2016
VL 8
IS 12
AR 328
DI 10.3390/v8120328
PG 21
WC Virology
SC Virology
GA EI4SW
UT WOS:000392484600008
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Barbosa, AAS
   Versiani, AF
   Sousa, LFD
   de Miranda, AS
   Gasparini, MR
   Brant, F
   Silva, DG
   Quintino-de-Carvalho, IL
   Soriani, FM
   da Fonseca, FG
   Vasconcelos, AC
   Barcelos, LD
   Teixeira, MM
   Teixeira, AL
   Machado, FS
   Barbosa-Stancioli, EF
   Rachid, MA
AF Silva Barbosa, Aline Aparecida
   Versiani, Alice Freitas
   da Cunha Sousa, Larissa Fonseca
   de Miranda, Aline Silva
   Gasparini, Marcela Ribeiro
   Brant, Fatima
   Silva, Daniele Goncalves
   Quintino-de-Carvalho, Iracema Luisa
   Soriani, Frederico Marianetti
   da Fonseca, Flavio Guimaraes
   Vasconcelos, Anilton Cesar
   Barcelos, Luciola da Silva
   Teixeira, Mauro Martins
   Teixeira, Antonio Lucio
   Machado, Fabiana Simao
   Barbosa-Stancioli, Edel Figueiredo
   Rachid, Milene Alvarenga
TI Role of the suppressor of cytokine signaling 2 (SOCS2) during
   meningoencephalitis caused by Bovine herpesvirus 5 (BoHV-5)
SO COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
DE Bovine herpesvirus 5; Brain; Inflammation; SOCS2; Mice
ID IMMUNE-RESPONSE; INFECTION; DISEASE; PROTEIN; VIRUS; ENCEPHALITIS;
   CONTRIBUTES; INHIBITION; INDUCTION; PATHWAY
AB The role of suppressors of cytokine signaling( SOCS) in meningoencephalitis caused by Bovine herpesvirus 5 (BoHV-5) was evaluated by intracranial infection in C57BL/6 wild-type mice (WT) and SOCS2 deficient mice (SOCS2(-/-)). Both infected groups presented weight loss, ruffled fur and hunched posture. Additionally, infected SOCS2(-/-) mice showed swollen chamfer and progressive depression. Infected WT animals developed mild meningitis, characterized by infiltration of mononuclear cells. Moreover, viral DNA was detected in liver and lung from infected WT group. This group also showed elevated brain levels of IFN-gamma, IL-10, CXCL1 and CCL5, when compared with non-infected WT animals. Brain inflammation was exacerbated in infected SOCS2(-/-) mice with widespread distribution of the virus and increased brain levels of TNF-alpha, IFN-gamma, IL-10, IL-12, CXCL1 and CCL5, when compared with WT infected mice. Moreover, infected SOCS2 deficient mice exhibited reduced brain mRNA expression of IFN alpha. and IFN beta and increased expression of mRNA of SOCS1, compared with infected WT mice. Taken together, our study provides an insight into the role of SOCS2 in modulating the immune response to BoHV-5 infection. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Silva, Daniele Goncalves; Vasconcelos, Anilton Cesar; Rachid, Milene Alvarenga] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Patol Geral, Belo Horizonte, MG, Brazil.
   [Silva Barbosa, Aline Aparecida; Versiani, Alice Freitas; Gasparini, Marcela Ribeiro; Quintino-de-Carvalho, Iracema Luisa; da Fonseca, Flavio Guimaraes; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Inst Ciencias Biol, Microbiol, Belo Horizonte, MG, Brazil.
   [de Miranda, Aline Silva] Univ Fed Minas Gerais, Inst Ciencias Biol, Morfol, Belo Horizonte, MG, Brazil.
   [da Cunha Sousa, Larissa Fonseca; Brant, Fatima; Teixeira, Mauro Martins; Machado, Fabiana Simao] Univ Fed Minas Gerais, Inst Ciencias Biol, Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Soriani, Frederico Marianetti] Univ Fed Minas Gerais, Inst Ciencias Biol, Biol Geral, Belo Horizonte, MG, Brazil.
   [Barcelos, Luciola da Silva] Univ Fed Minas Gerais, Inst Ciencias Biol, Fisiol & Biofis, Belo Horizonte, MG, Brazil.
   [Teixeira, Antonio Lucio] Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Psychiat & Behav Sci, Translat Psychiat Program, Houston, TX 77030 USA.
RP Rachid, MA (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Apoptose, Campus Pampulha,Av Antonio Carlos 6-627, BR-31270901 Belo Horizonte, MG, Brazil.
EM alinesb.bio@gmail.com; alicefv_vet@yahoo.com.br;
   laris.fonseca@gmail.com; mirandas.aline@gmail.com;
   marcela.gasparini@pirbright.ac.uk; fatimacbrant@gmail.com;
   danivets@gmail.com; iracemaluisa@yahoo.com.br; fredsori@gmail.com;
   fdafonseca@cpqrr.fiocruz.br; anilton@icb.ufmg.br; aloicul@yahoo.com;
   mmtex.ufmg@gmail.com; altexr@gmail.com; machadofs@gmail.com;
   edelfb@icb.ufmg.br; milenerachid@gmail.com
RI Barbosa-Stancioli, Edel F/J-7230-2012; Rachid, Milene
   Alvarenga/C-3530-2017; Barcelos, Luciola S/A-1109-2013; Versiani,
   Alice/M-9782-2018
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Rachid, Milene
   Alvarenga/0000-0002-3142-6552; Barcelos, Luciola S/0000-0001-9133-4011;
   Versiani, Alice/0000-0003-1378-5380; Simao Machado,
   Fabiana/0000-0001-9272-5209
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FapemigMinas Gerais State Research Foundation (FAPEMIG)
   [APQ-04392-10]; PRPq-UFMG, Brazil
FX M.A. Rachid was supported by CNPq, Fapemig (APQ-04392-10) and PRPq-UFMG,
   Brazil. M.A. Rachid, A.C. Vasconcelos, L.S. Barcelos, F.G. Fonseca, M.M.
   Teixeira, A.L. Teixeira, F.S. Machado and E.F. Barbosa-Stancioli
   received fellowships from CNPq.
CR Abril C, 2004, J VIROL, V78, P3644, DOI 10.1128/JVI.78.7.3644-3653.2004
   Akhtar LN, 2011, J VIROL, V85, P1912, DOI 10.1128/JVI.01857-10
   Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1
   Amaral DCG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-23
   Cheng SM, 2009, BLOOD, V113, P5192, DOI 10.1182/blood-2008-10-183525
   da Silva LF, 2011, VIRUS RES, V160, P143, DOI 10.1016/j.virusres.2011.06.003
   Zajac MPD, 2010, VET J, V184, P138, DOI 10.1016/j.tvjl.2009.03.035
   Elias F, 2004, PESQUI VET BRASIL, V24, P123, DOI 10.1590/S0100-736X2004000300003
   Esper L, 2012, AM J PATHOL, V181, P130, DOI 10.1016/j.ajpath.2012.03.042
   Fenner JE, 2006, NAT IMMUNOL, V7, P33, DOI 10.1038/ni1287
   Frey KG, 2009, J IMMUNOL, V183, P1253, DOI 10.4049/jimmunol.0900570
   Lee HR, 2009, J INTERF CYTOK RES, V29, P621, DOI 10.1089/jir.2009.0067
   Machado FS, 2006, IMMUNOL RES, V35, P209, DOI 10.1385/IR:35:3:209
   Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355
   Machado GF, 2013, MICROB PATHOGENESIS, V57, P10, DOI 10.1016/j.micpath.2013.01.003
   Neto HMA, 2009, ARQ BRAS MED VET ZOO, V61, P1
   Piganis RAR, 2011, J BIOL CHEM, V286, P33811, DOI 10.1074/jbc.M111.270207
   Pothlichet J, 2008, J IMMUNOL, V180, P2034, DOI 10.4049/jimmunol.180.4.2034
   Rico-Bautista E, 2006, CYTOKINE GROWTH F R, V17, P431, DOI 10.1016/j.cytogfr.2006.09.008
   Rissi DR, 2008, J VET DIAGN INVEST, V20, P346, DOI 10.1177/104063870802000315
   Vilela M.C., 2008, NEUROSCI LETT
   Vilela MC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-19
   Vilela MC, 2010, NEUROSCI LETT, V479, P58, DOI 10.1016/j.neulet.2010.05.028
   Yokota S, 2004, J VIROL, V78, P6282, DOI 10.1128/JVI.78.12.6282-6286.2004
NR 24
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0147-9571
EI 1878-1667
J9 COMP IMMUNOL MICROB
JI Comp. Immunol. Microbiol. Infect. Dis.
PD AUG
PY 2016
VL 47
BP 26
EP 31
DI 10.1016/j.cimid.2016.05.003
PG 6
WC Immunology; Microbiology; Veterinary Sciences
SC Immunology; Microbiology; Veterinary Sciences
GA DT7CT
UT WOS:000381645400004
PM 27477504
DA 2020-12-08
ER

PT J
AU Arantes, TS
   Rodrigues, RAL
   Silva, LKD
   Oliveira, GP
   de Souza, HL
   Khalil, JYB
   de Oliveira, DB
   Torres, AA
   da Silva, LL
   Colson, P
   Kroon, EG
   da Fonseca, FG
   Bonjardim, CA
   La Scola, B
   Abrahao, JS
AF Arantes, Thalita Souza
   Lima Rodrigues, Rodrigo Araujo
   dos Santos Silva, Ludmila Karen
   Oliveira, Graziele Pereira
   de Souza, Helton Luis
   Khalil, Jacques Y. B.
   de Oliveira, Danilo Bretas
   Torres, Alice Abreu
   da Silva, Luis Lamberti
   Colson, Philippe
   Kroon, Erna Geessien
   da Fonseca, Flavio Guimaraes
   Bonjardim, Claudio Antonio
   La Scola, Bernard
   Abrahao, Jonatas Santos
TI The Large Marseillevirus Explores Different Entry Pathways by Forming
   Giant Infectious Vesicles
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRUS; ACANTHAMOEBA; AMEBAS; FAMILY
AB Triggering the amoebal phagocytosis process is a sine qua non condition for most giant viruses to initiate their replication cycle and consequently to promote their progeny formation. It is well known that the amoebal phagocytosis process requires the recognition of particles of >500 nm, and most amoebal giant viruses meet this requirement, such as mimivirus, pandoravirus, pithovirus, and mollivirus. However, in the context of the discovery of amoebal giant viruses in the last decade, Marseillevirus marseillevirus (MsV) has drawn our attention, because despite its ability to successfully replicate in Acanthamoeba, remarkably it does not fulfill the >500-nm condition, since it presents an similar to 250-nm icosahedrally shaped capsid. We deeply investigated the MsV cycle by using a set of methods, including virological, molecular, and microscopic (immunofluorescence, scanning electron microscopy, and transmission electron microscopy) assays. Our results revealed that MsV is able to form giant vesicles containing dozens to thousands of viral particles wrapped by membranes derived from amoebal endoplasmic reticulum. Remarkably, our results strongly suggested that these giant vesicles are able to stimulate amoebal phagocytosis and to trigger the MsV replication cycle by an acidification-independent process. Also, we observed that MsV entry may occur by the phagocytosis of grouped particles (without surrounding membranes) and by an endosome-stimulated pathway triggered by single particles. Taken together, not only do our data deeply describe the main features of MsV replication cycle, but this is the first time, to our knowledge, that the formation of giant infective vesicles related to a DNA virus has been described.
   IMPORTANCE
   Triggering the amoebal phagocytosis process is a sine qua non condition required by most giant viruses to initiate their replication cycle. This process requires the recognition of particles of >500 nm, and many giant viruses meet this requirement. However, MsV is unusual, as despite having particles of similar to 250 nm it is able to replicate in Acanthamoeba. Our results revealed that MsV is able to form giant vesicles, containing dozens to thousands of viral particles, wrapped in membranes derived from amoebal endoplasmic reticulum. Remarkably, our results strongly suggest that these giant vesicles are able to stimulate phagocytosis using an acidification-independent process. Our work not only describes the main features of the MsV replication cycle but also describes, for the first time to our knowledge, the formation of huge infective vesicles in a large DNA viruses.
C1 [Arantes, Thalita Souza; Lima Rodrigues, Rodrigo Araujo; dos Santos Silva, Ludmila Karen; Oliveira, Graziele Pereira; de Souza, Helton Luis; de Oliveira, Danilo Bretas; Torres, Alice Abreu; Kroon, Erna Geessien; da Fonseca, Flavio Guimaraes; Bonjardim, Claudio Antonio; Abrahao, Jonatas Santos] Univ Fed Minas Gerais, Inst Biol Sci, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [da Silva, Luis Lamberti] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell & Mol Biol, BR-14049 Ribeirao Preto, SP, Brazil.
   [Khalil, Jacques Y. B.; Colson, Philippe; La Scola, Bernard] Aix Marseille Univ, URMITE CNRS UMR 6236, IRD 3R198, Marseille, France.
RP Abrahao, JS (corresponding author), Univ Fed Minas Gerais, Inst Biol Sci, Dept Microbiol, Belo Horizonte, MG, Brazil.; La Scola, B (corresponding author), Aix Marseille Univ, URMITE CNRS UMR 6236, IRD 3R198, Marseille, France.
EM bernard.la-scola@univ-amu.fr; jonatas.abrahao@gmail.com
RI daSilva, Luis LP/A-9949-2010; Abreu Torres, Alice/B-1475-2018; Kroon,
   Erna Geessien/B-3631-2015; Colson, Philippe/P-6355-2014; daSilva, Luis
   LP/AAD-5657-2019; Kroon, Erna/V-5444-2019; LA SCOLA, Bernard/P-6477-2016
OI daSilva, Luis LP/0000-0003-3558-0087; Abreu Torres,
   Alice/0000-0003-2352-2584; Kroon, Erna Geessien/0000-0003-2721-3826;
   Colson, Philippe/0000-0001-6285-0308; daSilva, Luis
   LP/0000-0003-3558-0087; LA SCOLA, Bernard/0000-0001-8006-7704; Araujo
   Lima Rodrigues, Rodrigo/0000-0001-7148-4012
FU MCTI \ Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [470645/2011-3]
FX This work, including the efforts of Jonatas Santos Abrahao, was funded
   by MCTI vertical bar Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) (470645/2011-3).
CR Aherfi S, 2014, ARCH VIROL, V159, P2349, DOI 10.1007/s00705-014-2023-5
   Altan-Bonnet N, 2015, J VIROL, V89, P12242, DOI 10.1128/JVI.01452-15
   Boyer M, 2009, P NATL ACAD SCI USA, V106, P21848, DOI 10.1073/pnas.0911354106
   Dornas FP, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01086
   Doutre G, 2014, J VIROL, V88, P14340, DOI 10.1128/JVI.02414-14
   Feng ZD, 2013, NATURE, V496, P367, DOI 10.1038/nature12029
   Ghigo E, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000087
   Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278
   Kato S, 1959, BIKEN J, V2, P343
   Koch G, 1978, Front Biol, V46, P475
   La Scola B, 2003, SCIENCE, V299, P2033
   Lagier JC, 2012, CLIN MICROBIOL INFEC, V18, P1185, DOI 10.1111/1469-0691.12023
   Legendre M, 2015, P NATL ACAD SCI USA, V112, pE5327, DOI 10.1073/pnas.1510795112
   Legendre M, 2014, P NATL ACAD SCI USA, V111, P4274, DOI 10.1073/pnas.1320670111
   Rodrigues RAL, 2015, J VIROL, V89, P11812, DOI 10.1128/JVI.01976-15
   Milrot E, 2016, CELL MICROBIOL, V18, P3, DOI 10.1111/cmi.12486
   Philippe N, 2013, SCIENCE, V341, P281, DOI 10.1126/science.1239181
   Popgeorgiev N, 2013, J CLIN MICROBIOL, V51, P4102, DOI 10.1128/JCM.01918-13
   Popgeorgiev N, 2013, J INFECT DIS, V208, P1042, DOI 10.1093/infdis/jit292
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reteno DG, 2015, J VIROL, V89, P6585, DOI 10.1128/JVI.00115-15
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Senkevich TG, 2005, P NATL ACAD SCI USA, V102, P18572, DOI 10.1073/pnas.0509239102
   Thomas V, 2011, ENVIRON MICROBIOL, V13, P1454, DOI 10.1111/j.1462-2920.2011.02446.x
   Townsley AC, 2006, J VIROL, V80, P8899, DOI 10.1128/JVI.01053-06
   Visvesvara GS, 2007, FEMS IMMUNOL MED MIC, V50, P1, DOI 10.1111/j.1574-695X.2007.00232.x
   WEISMAN RA, 1967, BIOCHEMISTRY-US, V6, P485, DOI 10.1021/bi00854a017
NR 27
TC 36
Z9 38
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2016
VL 90
IS 11
BP 5246
EP 5255
DI 10.1128/JVI.00177-16
PG 10
WC Virology
SC Virology
GA DM2ES
UT WOS:000376160200005
PM 26984730
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Versiani, AF
   Andrade, LM
   Martins, EMN
   Scalzo, S
   Geraldo, JM
   Chaves, CR
   Ferreira, DC
   Ladeira, M
   Guatimosim, S
   Ladeira, LO
   da Fonseca, FG
AF Versiani, Alice F.
   Andrade, Lidia M.
   Martins, Estefania M. N.
   Scalzo, Sergio
   Geraldo, Jony M.
   Chaves, Claudilene R.
   Ferreira, Daniele C.
   Ladeira, Marina
   Guatimosim, Silvia
   Ladeira, Luiz O.
   da Fonseca, Flavio G.
TI Gold nanoparticles and their applications in biomedicine
SO FUTURE VIROLOGY
LA English
DT Review
DE biosensor; cancer therapy; functionalization; gold nanoparticles; gold
   nanorods; vaccine
ID SURFACE-PLASMON RESONANCE; PHOTOTHERMAL THERAPY; CELLULAR UPTAKE; SHAPE
   CONTROL; IN-VITRO; NANORODS; CANCER; ENHANCEMENT; BIOSENSOR; ENERGY
AB Although used in medical applications for centuries, the development of nanotechnology has shed new light in the plethora of possible medical and biological applications using gold-based nanostructures. Gold nanostructures are stable and relatively inert in biological systems, leading to low reatogenicity, biocompatibility and general lack of toxicity. Allied to that, gold nanoparticles present optical and electronic properties that have been exploited in a range of biomedical applications. In this review we discuss biologically relevant properties of gold nanoparticles and how they are used in some biomedicine fields, especially those involving biosensing of biological analytes - including viruses and antibodies against them, cancer therapies, and antigen delivery, including viral antigens - as part of nonclassic vaccine strategies.
C1 [Versiani, Alice F.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
   [Versiani, Alice F.; Andrade, Lidia M.; Martins, Estefania M. N.; Scalzo, Sergio; Geraldo, Jony M.; Ferreira, Daniele C.; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, NanoBioMed Res Grp, BR-30161 Belo Horizonte, MG, Brazil.
   [Andrade, Lidia M.; Geraldo, Jony M.; Chaves, Claudilene R.; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, Lab Nanomat, BR-30161 Belo Horizonte, MG, Brazil.
   [Martins, Estefania M. N.] Ctr Desenvolvimento Tecnol Nucl CDTN CNEN, Lab Quim Nanoestruturas Carbono, Belo Horizonte, MG, Brazil.
   [Scalzo, Sergio; Ladeira, Marina; Guatimosim, Silvia] Univ Fed Minas Gerais, Dept Fisiol & Biofis, Lab Sinalizacao Intracelular, Belo Horizonte, MG, Brazil.
   [Geraldo, Jony M.] Univ Fed Minas Gerais, Fac Med, Dept Anat Imagem, Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
RI Guatimosim, Silvia/ABB-2658-2020; de Andrade, Lidia Maria/O-7835-2019;
   Versiani, Alice/M-9782-2018
OI Guatimosim, Silvia/0000-0001-8386-3722; de Andrade, Lidia
   Maria/0000-0003-2594-4617; Versiani, Alice/0000-0003-1378-5380
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX Preparation of this article and part of the experimental data presented
   here were supported by CAPES, FAPEMIG (Pronex Bio-NC), INCTV and CNPq.
   FG Fonseca, S Guatimosim and LO Ladeira are CNPq fellowship recipients.
   Other than funding, sponsoring agencies had no role in the preparation
   of this manuscript. The authors thank FV Oliveira for the artwork
   contributions. They also appreciate the scientific support provided by
   CA Furtado and AP Santos. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Albanese A, 2011, ACS NANO, V5, P5478, DOI 10.1021/nn2007496
   Alkilany AM, 2008, LANGMUIR, V24, P10235, DOI 10.1021/la8018343
   Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051-010-9911-8
   Alkilany AM, 2009, SMALL, V5, P701, DOI 10.1002/smll.200801546
   Anijdan SHM, 2013, INT J MOL CELL MED, V2, P118
   Aubin-Tam ME, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/3/034001
   Barhate G, 2013, INT J PHARMACEUT, V441, P636, DOI 10.1016/j.ijpharm.2012.10.033
   Berbeco RI, INT J RAD ONCOL BIOL, V81, P270
   Cai WB, 2008, NANOTECHNOL SCI APPL, V1, P17, DOI 10.2147/NSA.S3788
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Chakraborty S, 2011, LANGMUIR, V27, P7722, DOI 10.1021/la200787t
   Chakravarty P, 2008, P NATL ACAD SCI USA, V105, P8697, DOI 10.1073/pnas.0803557105
   Chanda N, 2009, NANO LETT, V9, P1798, DOI 10.1021/nl8037147
   Chen W, 2001, MATER RES BULL, V36, P335, DOI 10.1016/S0025-5408(01)00497-4
   Chen YS, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/19/195101
   Chithrani DB, 2010, RADIAT RES, V173, P719, DOI 10.1667/RR1984.1
   Choi J, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.5.051203
   Choi J, 2012, SMALL, V8, P746, DOI 10.1002/smll.201101789
   Choi J, 2011, ANTI-CANCER AGENT ME, V11, P953, DOI 10.2174/187152011797927599
   Choi R, 2010, LANGMUIR, V26, P17520, DOI 10.1021/la1029728
   Dickerson EB, 2008, CANCER LETT, V269, P57, DOI 10.1016/j.canlet.2008.04.026
   Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Silva FDD, 2013, BIOSENS BIOELECTRON, V50, P202, DOI 10.1016/j.bios.2013.06.036
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Eustis S, 2006, CHEM SOC REV, V35, P209, DOI 10.1039/b514191e
   Fadeel B, 2010, ADV DRUG DELIVER REV, V62, P362, DOI 10.1016/j.addr.2009.11.008
   Fallarini S, 2013, NANOSCALE, V5, P390, DOI 10.1039/c2nr32338a
   Feofanova N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/461687
   FINKELSTEIN AE, 1976, ANN RHEUM DIS, V35, P251, DOI 10.1136/ard.35.3.251
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Goodrich GP, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3290817
   Gregory AE, 2012, VACCINE, V30, P6777, DOI 10.1016/j.vaccine.2012.09.021
   Grzelczak M, 2008, CHEM SOC REV, V37, P1783, DOI 10.1039/b711490g
   Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005
   Harper SL, 2011, ACS NANO, V5, P4688, DOI 10.1021/nn200546k
   Hong Y, 2012, J NANOMATER, V2012, P7
   Horimoto NN, 2008, CHEM PHYS LETT, V467, P105, DOI 10.1016/j.cplett.2008.10.067
   Huang HC, 2010, ACS NANO, V4, P2892, DOI 10.1021/nn901884d
   Huang HY, 2015, BIOSENS BIOELECTRON, V68, P442, DOI 10.1016/j.bios.2015.01.039
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Jain S, 2012, BRIT J RADIOL, V85, P101, DOI 10.1259/bjr/59448833
   Kabashin AV, 2009, NAT MATER, V8, P867, DOI [10.1038/NMAT2546, 10.1038/nmat2546]
   Kang B, 2010, J AM CHEM SOC, V132, P1517, DOI 10.1021/ja9102698
   Kreuter J, 2007, INT J PHARMACEUT, V331, P1, DOI 10.1016/j.ijpharm.2006.10.021
   Lai DY, 2012, WIRES NANOMED NANOBI, V4, P1, DOI 10.1002/wnan.162
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li R, 2015, TALANTA, V140, P143, DOI 10.1016/j.talanta.2015.03.041
   Liu X, 2015, TALANTA, V132, P150, DOI 10.1016/j.talanta.2014.08.072
   Lohse SE, 2013, CHEM MATER, V25, P1250, DOI 10.1021/cm303708p
   Lu XC, 2013, ANALYST, V138, P642, DOI 10.1039/c2an36099c
   MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328
   Manson J, 2011, GOLD BULL, V44, P195, DOI 10.1007/s13404-011-0023-8
   McMahon SJ, 2011, RADIOTHER ONCOL, V100, P412, DOI 10.1016/j.radonc.2011.08.026
   Mesbahi A, 2013, BIOIMPACTS, V3, P29, DOI 10.5681/bi.2013.002
   Murphy CJ, 2010, J PHYS CHEM LETT, V1, P2867, DOI 10.1021/jz100992x
   Naahidi S, 2013, J CONTROL RELEASE, V166, P182, DOI 10.1016/j.jconrel.2012.12.013
   Narang J, 2015, BIOSENS BIOELECTRON, V66, P332, DOI 10.1016/j.bios.2014.11.038
   Ngwa W, 2014, NANOMEDICINE-UK, V9, P1063, DOI [10.2217/NNM.14.55, 10.2217/nnm.14.55]
   Ngwa W, 2013, NANOMED-NANOTECHNOL, V9, P25, DOI 10.1016/j.nano.2012.09.001
   Nicol JR, 2015, NANOMEDICINE-UK, V10, P1315, DOI 10.2217/nnm.14.219
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Oo MKK, 2008, NANOMEDICINE-UK, V3, P777, DOI 10.2217/17435889.3.6.777
   Pearce ME, 2007, PHARM RES-DORDR, V24, P2335, DOI 10.1007/s11095-007-9380-7
   Pissuwan D, 2011, SMALL, V7, P215, DOI 10.1002/smll.201001394
   Pissuwan D, 2010, TRENDS BIOTECHNOL, V28, P207, DOI 10.1016/j.tibtech.2009.12.004
   Qian YC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07490
   Resende RR, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-14
   Roux S, 2005, LANGMUIR, V21, P2526, DOI 10.1021/la048082i
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Sharma A, 2010, THIN SOLID FILMS, V519, P1213, DOI 10.1016/j.tsf.2010.08.071
   Sharma V, 2009, MAT SCI ENG R, V65, P1, DOI 10.1016/j.mser.2009.02.002
   Smith DK, 2009, LANGMUIR, V25, P9518, DOI 10.1021/la900757s
   Song JB, 2013, NANOSCALE, V5, P5816, DOI 10.1039/c3nr01350b
   Stone J, 2011, WIRES NANOMED NANOBI, V3, P100, DOI 10.1002/wnan.120
   Stone J, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/29/295102
   Strong LE, 2011, WIRES NANOMED NANOBI, V3, P307, DOI 10.1002/wnan.138
   Tang L, 2014, BIOSENS BIOELECTRON, V61, P70, DOI 10.1016/j.bios.2014.04.043
   Tao WQ, 2014, NANOMEDICINE-UK, V9, P237, DOI 10.2217/nnm.13.58
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   Vankayala R, 2014, SMALL, V10, P1612, DOI 10.1002/smll.201302719
   Vigderman L, 2013, ADV DRUG DELIVER REV, V65, P663, DOI 10.1016/j.addr.2012.05.004
   Vigderman L, 2012, ADV MATER, V24, P4811, DOI 10.1002/adma.201201690
   Vigderman L, 2012, ANGEW CHEM INT EDIT, V51, P636, DOI 10.1002/anie.201107304
   Wang J, 2012, ACS NANO, V6, P5070, DOI 10.1021/nn300694v
   Wang NN, 2014, NANO RES, V7, P1291, DOI 10.1007/s12274-014-0493-0
   Wu XJ, 2006, J AM CHEM SOC, V128, P12001, DOI 10.1021/ja063653+
   Yasui H, CANC LETT, V347, P151
   Young JK, 2012, ANN BIOMED ENG, V40, P438, DOI 10.1007/s10439-011-0472-5
   Zhang H, 2013, TALANTA, V115, P857, DOI 10.1016/j.talanta.2013.06.059
   Zhang YN, 2015, FARADAY DISCUSS, V178, P383, DOI 10.1039/c4fd00199k
   Zhang Y, 2007, IASTED INT CONF SIGN, P345
   Zhao TT, 2012, NANOSCALE, V4, P7712, DOI 10.1039/c2nr32196c
   Zheng Y, 2008, RADIAT RES, V169, P19, DOI 10.1667/RR1080.1
NR 98
TC 33
Z9 33
U1 2
U2 106
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD APR
PY 2016
VL 11
IS 4
BP 293
EP 309
DI 10.2217/fvl-2015-0010
PG 17
WC Virology
SC Virology
GA DI0WQ
UT WOS:000373218400009
DA 2020-12-08
ER

PT J
AU Luppi, MM
   Luiz, APMF
   Coelho, FM
   Ecco, R
   da Fonseca, FG
   Resende, M
AF Luppi, Marcela Miranda
   Franco Luiz, Ana Paula Moreira
   Coelho, Fabiana Magalhaes
   Ecco, Roselene
   da Fonseca, Flavio Guimaraes
   Resende, Mauricio
TI Genotypic characterization of psittacid herpesvirus isolates from Brazil
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Psittacid herpesvirus; PstI; RFLP; PCR
ID PACHECOS-DISEASE; IDENTIFICATION
AB Thirty-six isolates of psittacid herpesvirus (PsHV), obtained from 12 different species of psittacids in Brazil, were genotypically characterized by restriction fragment length polymorphism (RFLP) analysis and PCR amplification. RFLP analysis with the PstI enzyme revealed four distinct restriction patterns (A1, X, W and Y), of which only A1 (corresponding to PsHV-1) had previously been described. To study PCR amplification patterns, six pairs of primers were used. Using this method, six variants were identified, of which, variants 10, 8, and 9 (in this order) were most prevalent, followed by variants 1, 4, and 5. It was not possible to correlate the PCR and RFLP patterns. Twenty-nine of the 36 isolates were shown to contain a 419bp fragment of the UL16 gene, displaying high similarity to the PsHV-1 sequences available in GenBank. Comparison of the results with the literature data suggests that the 36 Brazilian isolates from this study belong to genotype 1 and serotype 1. (C) 2015 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda.
C1 [Luppi, Marcela Miranda; Franco Luiz, Ana Paula Moreira; Coelho, Fabiana Magalhaes; Resende, Mauricio] Univ Fed Minas Gerais, Dept Microbiol, Lab Virol Comparada, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [Ecco, Roselene] Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia, Lab Patol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
RP Luppi, MM (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Lab Virol Comparada, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM mmluppi@yahoo.com.br
RI Ecco, Roselene/L-4119-2014; Coelho, Fabiana Magalhaes/K-6001-2013
OI Ecco, Roselene/0000-0002-8052-5389; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEMIGMinas Gerais State Research Foundation
   (FAPEMIG)
FX We thank the entire team of Laboratorio de Virologia Comparada -
   Departamento de Microbiologia - UFMG for assistance during the search.
   CNPq, CAPES and FAPEMIG for financial support. We also thank to Prof.
   Dr. Erhard F. Kaleta from Klinik fur Vogel, Reptilien, Amphibien und
   Fische-Justus - Liebig - Universitat Giessen for kindly providing the
   isolate KS144/79 used as positive control.
CR AINI I, 1993, J WILDLIFE DIS, V29, P196, DOI 10.7589/0090-3558-29.2.196
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Buchen-Osmond C, 2006, ICTVDB UNIVERSAL VIR
   DAVIS LG, 1994, BASIC METHODS MOL BI, P16
   Ecco Roselene, 2009, Brazilian Journal of Veterinary Pathology, V2, P85
   GOUGH RE, 1993, VET REC, V132, P113, DOI 10.1136/vr.132.5.113
   Gravendyck M, 1996, AVIAN PATHOL, V25, P345, DOI 10.1080/03079459608419145
   Hernandez R., 2010, CURR PROTOC MICROBIO, V4, P41
   HORNER RF, 1992, J S AFR VET ASSOC, V63, P59
   Luppi MM, 2011, VET MICROBIOL, V154, P69, DOI 10.1016/j.vetmic.2011.06.027
   Magnino S, 1996, J VET MED B, V43, P631, DOI 10.1111/j.1439-0450.1996.tb00362.x
   Neto HMA, 2008, THESIS UFMG BELO HOR
   OTOOLE D, 1992, J VET DIAGN INVEST, V4, P203, DOI 10.1177/104063879200400220
   Pacheco G, 1930, C R SEANCES SOC BIOL, V105, P109
   Rohlf F. J., 1998, NTSYS PC NUMERICAL T
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Schroder-Gravendyck AS, 2001, AVIAN PATHOL, V30, P551, DOI 10.1080/03079450120078752
   SIMPSON CF, 1975, J INFECT DIS, V131, P390, DOI 10.1093/infdis/131.4.390
   Thureen DR, 2006, J VIROL, V80, P7863, DOI 10.1128/JVI.00134-06
   Tomaszewski E, 2001, J CLIN MICROBIOL, V39, P533, DOI 10.1128/JCM.39.2.533-538.2001
   Tomaszewski EK, 2003, J VIROL, V77, P11260, DOI 10.1128/JVI.77.20.11260-11267.2003
NR 21
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD JAN-MAR
PY 2016
VL 47
IS 1
BP 217
EP 224
DI 10.1016/j.bjm.2015.11.017
PG 8
WC Microbiology
SC Microbiology
GA DG4TE
UT WOS:000372064700029
PM 26887248
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Carvalho, LD
   Gadelha, SR
   Marin, LJ
   Brito-Melo, GEA
   Martins, CPS
   da Fonseca, FG
   Barbosa-Stancioli, EF
AF de Carvalho, Luciana Debortoli
   Gadelha, Sandra Rocha
   Marin, Lauro Juliano
   Alvim Brito-Melo, Gustavo Eustaquio
   Silveira Martins, Camila Pacheco
   da Fonseca, Flavio Guimaraes
   Barbosa-Stancioli, Edel Figueiredo
TI Are lipid disorders involved in the predominance of human T-lymphotropic
   virus-1 infections in women?
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE HTLV-1; Lipid disorders and sex differences
AB Introduction: The human T-lymphotropic virus-1 (HTLV-1) is associated with chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic inflammatory disease. Disturbances in lipid metabolism are involved in inflammatory and demyelinating diseases. Methods: Plasma levels of triglycerides, total cholesterol, and fractions of HTLV-1-infected individuals of both sexes with different clinical progressions were determined. Results: Elevated levels of triglyceride and very low-density lipoproteins (VLDL) were exclusively detected in HTLV-1-infected women from asymptomatic and HAM/TSP groups compared with uninfected individuals (p = 0.02). Conclusions: Elevated triglyceride and VLDL levels in HTLV-1-infected women may be related to the predominance of HAM/TSP in women.
C1 [de Carvalho, Luciana Debortoli; Gadelha, Sandra Rocha] Univ Estadual Santa Cruz, Dept Ciencias Biol, BR-45662900 Ilheus, BA, Brazil.
   [Marin, Lauro Juliano] Univ Estadual Santa Cruz, Dept Saude, BR-45662900 Ilheus, BA, Brazil.
   [Alvim Brito-Melo, Gustavo Eustaquio; Silveira Martins, Camila Pacheco; da Fonseca, Flavio Guimaraes; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Alvim Brito-Melo, Gustavo Eustaquio] Univ Fed Vales Jequitinhonha & Mucuri, Lab Imunol, Diamantina, MG, Brazil.
RP de Carvalho, LD (corresponding author), Univ Estadual Santa Cruz, Dept Ciencias Biol, Rodovia Jorge Amado,Km 16, BR-45662900 Ilheus, BA, Brazil.
EM ludebor.carvalho39@gmail.com
RI Barbosa-Stancioli, Edel F/J-7230-2012; Gadelha, Sandra/X-3373-2019
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Gadelha,
   Sandra/0000-0002-3079-488X
FU Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)Minas Gerais
   State Research Foundation (FAPEMIG); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Universidade Estadual
   de Santa Cruz (UESC)
FX This work was supported by Fundacao de Amparo a Pesquisa de Minas Gerais
   (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), and Universidade Estadual de Santa Cruz (UESC).
CR CABANA VG, 1989, J LIPID RES, V30, P39
   Catalan-Soares B, 2004, REV PANAM SALUD PUBL, V16, P387, DOI 10.1590/S1020-49892004001200004
   GALLIN JI, 1969, NEW ENGL J MED, V281, P1081, DOI 10.1056/NEJM196911132812001
   GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   JOHNSON AC, 1949, BIOCHEM J, V44, P494, DOI 10.1042/bj0440494
   Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200
   Lima MASD, 2005, J NEUROL NEUROSUR PS, V76, P294, DOI 10.1136/jnnp.2004.035709
   MATAS C, 1994, CLIN CHEM, V40, P404
   MELNICK JL, 1994, J MED VIROL, V42, P170, DOI 10.1002/jmv.1890420213
   Minami M, 2000, Nihon Yakurigaku Zasshi, V115, P193
   Nobre V, 2006, CLIN INFECT DIS, V43, P1257, DOI 10.1086/508177
NR 13
TC 3
Z9 4
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD NOV-DEC
PY 2015
VL 48
IS 6
BP 759
EP 761
DI 10.1590/0037-8682-0068-2015
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CZ5RA
UT WOS:000367158500017
PM 26676502
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Flesch, IEA
   Hollett, NA
   Wong, YC
   Quinan, BR
   Howard, D
   da Fonseca, FG
   Tscharke, DC
AF Flesch, Inge E. A.
   Hollett, Natasha A.
   Wong, Yik Chun
   Quinan, Barbara Resende
   Howard, Debbie
   da Fonseca, Flavio G.
   Tscharke, David C.
TI Extent of Systemic Spread Determines CD8(+) T Cell Immunodominance for
   Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia
   Virus
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID IMMUNOGENICITY; IMMUNIZATION; PROTECTION; VIRULENCE; EPITOPE; SAFETY;
   MVA; CHALLENGE; INFECTION; RESPONSES
AB CD8(+) T cells that recognize virus-derived peptides presented on MHC class I are vital antiviral effectors. Such peptides presented by any given virus vary greatly in immunogenicity, allowing them to be ranked in an immunodominance hierarchy. However, the full range of parameters that determine immunodominance and the underlying mechanisms remain unknown. In this study, we show across a range of vaccinia virus strains, including the current clonal smallpox vaccine, that the ability of a strain to spread systemically correlated with reduced immunodominance. Reduction in immunodominance was observed both in the lymphoid system and at the primary site of infection. Mechanistically, reduced immunodominance was associated with more robust priming and especially priming in the spleen. Finally, we show this is not just a property of vaccine and laboratory strains of virus, because an association between virulence and immunodominance was also observed in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.
C1 [Flesch, Inge E. A.; Hollett, Natasha A.; Wong, Yik Chun; Quinan, Barbara Resende; Howard, Debbie; Tscharke, David C.] Australian Natl Univ, Res Sch Biol, Canberra, ACT 2601, Australia.
   [Quinan, Barbara Resende; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Dept Microbiol, Lab Virol Basica & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
   [Howard, Debbie; Tscharke, David C.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
RP Tscharke, DC (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, 131 Garran Rd, Acton, ACT 2601, Australia.
EM david.tscharke@anu.edu.au
RI Tscharke, David/C-9133-2009
OI Tscharke, David/0000-0001-6825-9172
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 AI067401, U19
   AI100627]; National Health and Medical Research Council
   (Australia)National Health and Medical Research Council of Australia
   [APP1023141]; Australian Research Council Future FellowshipAustralian
   Research Council [FT110100310]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, R01AI067401, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, R01AI067401, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, R01AI067401, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627,
   U19AI100627, U19AI100627, U19AI100627, U19AI100627, U19AI100627] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants R01
   AI067401 and U19 AI100627, National Health and Medical Research Council
   (Australia) Grant APP1023141, and by Australian Research Council Future
   Fellowship FT110100310.
CR Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   ALCAMI A, 1995, J VIROL, V69, P4633
   Antrobus RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048322
   Artenstein AW, 2005, VACCINE, V23, P3301, DOI 10.1016/j.vaccine.2005.01.079
   Bar JJ, 2008, IMMUNITY, V28, P859, DOI 10.1016/j.immuni.2008.04.010
   BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0
   BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0
   Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834
   Duraffour S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055808
   Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331
   Fenner F, 1988, SMALLPOX ITS ERADICA
   Fischer MA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002374
   Flesch I.A., 2012, VACCINIA VIRUS POXVI, V890, P199
   Flesch IEA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039533
   Flesch IEA, 2010, J IMMUNOL, V184, P45, DOI 10.4049/jimmunol.0900999
   Garcel A, 2007, J GEN VIROL, V88, P1906, DOI 10.1099/vir.0.82708-0
   Garcia F, 2011, VACCINE, V29, P8309, DOI 10.1016/j.vaccine.2011.08.098
   Gordon SN, 2011, J INFECT DIS, V203, P1043, DOI 10.1093/infdis/jiq162
   Haeryfar SMM, 2008, J IMMUNOL, V181, P649, DOI 10.4049/jimmunol.181.1.649
   Haeryfar SMM, 2005, J IMMUNOL, V174, P3344, DOI 10.4049/jimmunol.174.6.3344
   Harrop R, 2012, CANCER IMMUNOL IMMUN, V61, P2283, DOI 10.1007/s00262-012-1302-9
   Karem KL, 2011, FUTURE VIROL, V6, P709, DOI 10.2217/FVL.10.79
   Kerr PJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002950
   Kotturi MF, 2008, J IMMUNOL, V181, P2124, DOI 10.4049/jimmunol.181.3.2124
   La Gruta NL, 2010, J CLIN INVEST, V120, P1885, DOI 10.1172/JCI41538
   Li Y, 2007, P NATL ACAD SCI USA, V104, P15787, DOI 10.1073/pnas.0609268104
   Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0
   Lin Leon C W, 2012, Methods Mol Biol, V890, P147, DOI 10.1007/978-1-61779-876-4_9
   Lin LCW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003329
   Liu LZ, 2006, IMMUNITY, V25, P511, DOI 10.1016/j.immuni.2006.06.019
   Monath TP, 2004, INT J INFECT DIS, V8, pS31, DOI 10.1016/j.ijid.2004.09.002
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762
   Pathan AA, 2012, VACCINE, V30, P5616, DOI 10.1016/j.vaccine.2012.06.084
   Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761
   Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299
   Remakus S, 2012, J VIROL, V86, P9748, DOI 10.1128/JVI.00981-12
   Russell TA, 2014, IMMUNOL CELL BIOL, V92, P466, DOI 10.1038/icb.2014.10
   Salek-Ardakani S, 2011, J CLIN INVEST, V121, P296, DOI 10.1172/JCI42056
   Salek-Ardakani S, 2008, J IMMUNOL, V181, P7969, DOI 10.4049/jimmunol.181.11.7969
   Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Smith CL, 2005, J IMMUNOL, V175, P8431, DOI 10.4049/jimmunol.175.12.8431
   Snyder JT, 2004, J VIROL, V78, P7052, DOI 10.1128/JVI.78.13.7052-7060.2004
   SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912
   Tscharke DC, 2002, J GEN VIROL, V83, P1977, DOI 10.1099/0022-1317-83-8-1977
   Tscharke DC, 1999, J GEN VIROL, V80, P2751, DOI 10.1099/0022-1317-80-10-2751
   Wang Y, 2009, J VIROL, V83, P9008, DOI 10.1128/JVI.00410-09
   Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101
   Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51
   Yewdell JW, 2005, ANNU REV IMMUNOL, V23, P651, DOI 10.1146/annurev.immunol.23.021704.115702
   Yuen TJ, 2010, J VIROL, V84, P10220, DOI 10.1128/JVI.01281-10
NR 54
TC 8
Z9 8
U1 0
U2 8
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD SEP 1
PY 2015
VL 195
IS 5
BP 2263
EP 2272
DI 10.4049/jimmunol.1402508
PG 10
WC Immunology
SC Immunology
GA CP6QY
UT WOS:000360014200039
PM 26195812
OA Green Accepted, Bronze
DA 2020-12-08
ER

PT J
AU Silva, LCF
   Almeida, GMF
   Assis, FL
   Albarnaz, JD
   Boratto, PVM
   Dornas, FP
   Andrade, KR
   La Scola, B
   Kroon, EG
   da Fonseca, FG
   Abrahao, JS
AF Silva, Lorena C. F.
   Almeida, Gabriel M. F.
   Assis, Felipe L.
   Albarnaz, Jonas D.
   Boratto, Paulo V. M.
   Dornas, Fabio P.
   Andrade, Ketyllen R.
   La Scola, Bernard
   Kroon, Erna G.
   da Fonseca, Flavio G.
   Abrahao, Jonatas S.
TI Modulation of the expression of mimivirus-encoded translation-related
   genes in response to nutrient availability during Acanthamoeba
   castellanii infection
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE mimivirus; tRNA; aminoacyl-tRNA-synthetases; translation; gene
   expression
ID TRANSFER-RNA SYNTHETASES; VIRUS
AB The complexity of giant virus genomes is intriguing, especially the presence of genes encoding components of the protein translation machinery such as transfer RNAs and aminoacyl-tRNA-synthetases; these features are uncommon among other viruses. Although orthologs of these genes are codified by their hosts, one can hypothesize that having these translation-related genes might represent a gain of fitness during infection. Therefore, the aim of this study was to evaluate the expression of translation-related genes by mimivirus during infection of Acanthamoeba castellanii under different nutritional conditions. In silico analysis of amino acid usage revealed remarkable differences between the mimivirus isolates and the A. castellanii host. Relative expression analysis by quantitative PCR revealed that mimivirus was able to modulate the expression of eight viral translation-related genes according to the amoebal growth condition, with a higher induction of gene expression under starvation. Some mimivirus isolates presented differences in translation-related gene expression; notably, polymorphisms in the promoter regions correlated with these differences. Two mimivirus isolates did not encode the tryptophanyl-tRNA in their genomes, which may be linked with low conservation pressure based on amino acid usage analysis. Taken together, our data suggest that mimivirus can modulate the expression of translation-related genes in response to nutrient availability in the host cell, allowing the mimivirus to adapt to different hosts growing under different nutritional conditions.
C1 [Silva, Lorena C. F.; Assis, Felipe L.; Albarnaz, Jonas D.; Boratto, Paulo V. M.; Dornas, Fabio P.; Andrade, Ketyllen R.; Kroon, Erna G.; da Fonseca, Flavio G.; Abrahao, Jonatas S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Avenida Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
   [Almeida, Gabriel M. F.] Univ Fed Minas Gerais, AQUACEN Lab Nacl Referencia Doencas Anim Aquat, Minist Pesca & Aquicultura, BR-31270901 Belo Horizonte, MG, Brazil.
   [La Scola, Bernard] Aix Marseille Univ, URMITE CNRS UMR IRD3R198 6236, Marseille, France.
   [da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
RP Abrahao, JS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Avenida Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM jonatas.abrahao@gmail.com
RI Dornas, Fabio/AAI-3582-2020; Kroon, Erna/V-5444-2019; LA SCOLA,
   Bernard/P-6477-2016; Kroon, Erna Geessien/B-3631-2015; R16, Direction
   Geoscience/H-9011-2012; Almeida, Gabriel MF/I-8910-2012; Albarnaz, Jonas
   Dutra/E-4526-2010; Oger, Phil M/C-8138-2012
OI Dornas, Fabio/0000-0001-7926-5551; LA SCOLA,
   Bernard/0000-0001-8006-7704; Kroon, Erna Geessien/0000-0003-2721-3826;
   Almeida, Gabriel MF/0000-0003-2317-5092; Albarnaz, Jonas
   Dutra/0000-0002-8792-813X; Oger, Phil M/0000-0001-6298-6870
FU CAPESCAPES; FAPEMIGMinas Gerais State Research Foundation (FAPEMIG);
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX We would like to thank colleagues from Gepvig, Laboratorio de Virus, and
   Aix Marseille Universite for their excellent technical support. We also
   would like to thank CAPES, FAPEMIG, and CNPq for financial support.
CR Abergel C, 2007, J VIROL, V81, P12406, DOI 10.1128/JVI.01107-07
   Boyer M, 2011, P NATL ACAD SCI USA, V108, P10296, DOI 10.1073/pnas.1101118108
   Claverie JM, 2010, TRENDS GENET, V26, P431, DOI 10.1016/j.tig.2010.07.003
   Colson P, 2013, INTERVIROLOGY, V56, P364, DOI 10.1159/000354557
   Colson P, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00091
   Colson Philippe, 2011, Genome Biol Evol, V3, P737, DOI 10.1093/gbe/evr048
   Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404
   Jeudy S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003122
   La Scola B, 2003, SCIENCE, V299, P2033
   Legendre M, 2010, GENOME RES, V20, P664, DOI 10.1101/gr.102582.109
   Moreira D, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-12
   NEIDHARDT FC, 1975, ANNU REV MICROBIOL, V29, P215, DOI 10.1146/annurev.mi.29.100175.001243
   Putzer H., 2000, MADAME CURIE BIOSCIE
   Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Ryckelynck M, 2005, J MOL BIOL, V354, P614, DOI 10.1016/j.jmb.2005.09.063
   Saini HK, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-115
   VISVESVARA GS, 1975, J PROTOZOOL, V22, P245, DOI 10.1111/j.1550-7408.1975.tb05860.x
   Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655
NR 19
TC 9
Z9 9
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 1
PY 2015
VL 6
AR 539
DI 10.3389/fmicb.2015.00539
PG 8
WC Microbiology
SC Microbiology
GA CK6AC
UT WOS:000356309000001
PM 26082761
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Abrahao, JS
   Campos, RK
   Trindade, GD
   da Fonseca, FG
   Ferreira, PCP
   Kroon, EG
AF Abrahao, Jonatas Santos
   Campos, Rafael Kroon
   Trindade, Giliane de Souza
   da Fonseca, Flavio Guimaraes
   Peregrino Ferreira, Paulo Cesar
   Kroon, Erna Geessien
TI Outbreak of Severe Zoonotic Vaccinia Virus Infection, Southeastern
   Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ORTHOPOXVIRUS; SMALLPOX; STRAINS
AB In 2010, a vaccinia virus isolate caused an atypically severe outbreak that affected humans and cattle in Brazil. Of 26 rural workers affected, 12 were hospitalized. Our data raise questions about the risk factors related to the increasing number and severity of vaccinia virus infections.
C1 [Abrahao, Jonatas Santos; Campos, Rafael Kroon; Trindade, Giliane de Souza; da Fonseca, Flavio Guimaraes; Peregrino Ferreira, Paulo Cesar; Kroon, Erna Geessien] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais ICB, Dept Microbiol, Virus Lab, Inst Ciencias Biol, Av Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Campos, Rafael Kroon/AAB-5135-2020; Kroon, Erna
   Geessien/B-3631-2015
OI Campos, Rafael Kroon/0000-0002-4852-0449; Kroon, Erna
   Geessien/0000-0003-2721-3826
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Pro-Reitoria de Pesquisa da Universidade Federal de Minas Gerais
   (PRPq-UFMG); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Ministerio da
   Agricultura, Pecuaria e Abastecimento (MAPA)
FX Financial support was provided by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Pro-Reitoria de Pesquisa da
   Universidade Federal de Minas Gerais (PRPq-UFMG), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo
   a Pesquisa do Estado de Minas Gerais (FAPEMIG) and Ministerio da
   Agricultura, Pecuaria e Abastecimento (MAPA). E.G.K., P.P.F., C.A.B.,
   G.S.T., and F.G.F. are CNPq researchers.
CR Abrahao JS, 2010, EMERG INFECT DIS, V16, P976, DOI 10.3201/eid1606.091187
   Abrahao JS, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-140
   Abrahao JS, 2010, J MED VIROL, V82, P692, DOI 10.1002/jmv.21617
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Damon IK, 2007, LIPPINCOTT WILLIAMS, VII, P2947
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Ducournau C, 2013, EMERG INFECT DIS, V19, P1996, DOI 10.3201/eid1912.130256
   Kroon EG, 2011, ANTIVIR RES, V92, P150, DOI 10.1016/j.antiviral.2011.08.018
   Leite JA, 2007, VIRUS GENES, V35, P531, DOI 10.1007/s11262-007-0133-9
   Reynolds MG, 2012, CURR OPIN VIROL, V2, P335, DOI 10.1016/j.coviro.2012.02.004
   ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995
   Shchelkunov SN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003756
   Singh R. K., 2007, Animal Health Research Reviews, V8, P105, DOI 10.1017/S1466252307001259
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
NR 15
TC 25
Z9 28
U1 0
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD APR
PY 2015
VL 21
IS 4
BP 695
EP 698
DI 10.3201/eid2104.140351
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CE2NK
UT WOS:000351652100024
PM 25811411
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Martins, CPS
   Gomes, OA
   Martins, ML
   de Carvalho, LD
   de Souza, JG
   Da Fonseca, FG
   dos Santos, RGS
   Andrade, MS
   Zani, CL
   de Souza-Fagundes, EM
   Barbosa-Stancioli, EF
AF Silveira Martins, Camila Pacheco
   Gomes, Orlando Abreu
   Martins, Marina Lobato
   de Carvalho, Luciana Debortoli
   de Souza, Jaqueline Gontijo
   Da Fonseca, Flavio Guimaraes
   Silva dos Santos, Rodrigo Gonalves
   Andrade, Margareth Spangler
   Zani, Carlos Leomar
   de Souza-Fagundes, Elaine Maria
   Barbosa-Stancioli, Edel Figueiredo
TI A reduction of viral mRNA, proteins and induction of altered
   morphogenesis reveals the anti-HTLV-1 activity of the labdane-diterpene
   myriadenolide in vitro
SO BMC MICROBIOLOGY
LA English
DT Article
DE HTLV-1; Diterpene myriadenolide; Antiviral activity; HAM/TSP; ATL
ID T-CELL LEUKEMIA; VIRUS TYPE-1; HTLV-I; DRUG DISCOVERY; MYELOPATHY;
   EXPRESSION; INSIGHTS; ALPHA; LINES; ACID
AB Background: Human T-lymphotropic virus 1 (HTLV-1) has been associated with leukemia/lymphoma (ATL) and myelopathy/tropical spastic paraparesis (HAM/TSP), in addition to other inflammatory diseases as well as infection complications. Therapeutic approaches for HTLV-1-related pathologies are limited. The labdane diterpene myriadenolide (AMY) is a natural product that exhibit biological activities, such as anti-inflammatory and antiviral activity as reported for HIV and herpesvirus.
   Results: We demonstrated that this natural product was able to inhibit the expression of gag-pol mRNA and substantially reduced the expression of the structural proteins p19 and gp46. Comparison of treated and untreated cells shows that AMY alters both the morphology and the release of viral particles. The Atomic Force Microscopy assay showed that the AMY treatment reduced the number of particles on the cell surface by 47%.
   Conclusion: We demonstrated that the labdane diterpene myriadenolide reduced the expression of the structural proteins and the budding of viral particles, besides induces altered morphogenesis of HTLV-1, conferring on AMY a new antiviral activity that may be useful for the development of new compounds with specific anti-HTLV-1 activity.
C1 [Silveira Martins, Camila Pacheco; de Carvalho, Luciana Debortoli; de Souza, Jaqueline Gontijo; Da Fonseca, Flavio Guimaraes; Silva dos Santos, Rodrigo Gonalves; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, LVBA, BR-6627 Belo Horizonte, MG, Brazil.
   [Silveira Martins, Camila Pacheco; Martins, Marina Lobato; de Carvalho, Luciana Debortoli; de Souza, Jaqueline Gontijo; Silva dos Santos, Rodrigo Gonalves; Barbosa-Stancioli, Edel Figueiredo] GIPH, Fundacao HEMOMINAS, Interdisciplinary HTLV Res Grp, Belo Horizonte, MG, Brazil.
   [Gomes, Orlando Abreu] Nucleo de Ciencias Exatas FACE Univ FUMEC, Belo Horizonte, MG, Brazil.
   [Martins, Marina Lobato] Fundacao HEMOMINAS, Serv Pesquisa, Belo Horizonte, MG, Brazil.
   [Andrade, Margareth Spangler] CETEC, SENAI, Ctr Tecnol, Belo Horizonte, MG, Brazil.
   [Zani, Carlos Leomar] Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [de Souza-Fagundes, Elaine Maria] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Fisiol Biofisica, Belo Horizonte, MG, Brazil.
RP Barbosa-Stancioli, EF (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, LVBA, Avenida Anonio Carlos, BR-6627 Belo Horizonte, MG, Brazil.
EM edelfb@icb.ufmg.br
RI Zani, Carlos L/A-9658-2008; Barbosa-Stancioli, Edel F/J-7230-2012
OI Zani, Carlos L/0000-0003-1859-177X; Barbosa-Stancioli, Edel
   F/0000-0001-6584-4333
FU Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)Minas Gerais
   State Research Foundation (FAPEMIG); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Pro-Reitoria
   de Pesquisa da UFMG (PRPq); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX Financial support was provided by Fundacao de Amparo a Pesquisa de Minas
   Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and Pro-Reitoria de Pesquisa da UFMG (PRPq). E.F.
   Barbosa-Stancioli, F.G. Da Fonseca, J.G. Souza, L.D. Carvalho and C.P.S.
   Martins received fellowships from CNPq. The authors also thank the
   Fundacao HEMOMINAS and Dr. Anna Barbara Carneiro-Proietti for supporting
   the Interdisciplinary HTLV Research Group (GIPH), which has contributed
   steadily to research on HTLV.
CR Coelho-dos-Reis JGA, 2009, J VIROL METHODS, V160, P138, DOI 10.1016/j.jviromet.2009.05.007
   AYISI NK, 1991, J VIROL METHODS, V33, P335, DOI 10.1016/0166-0934(91)90033-V
   Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, P186
   Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76
   Calabrese EJ, 2013, CRIT REV TOXICOL, V43, P580, DOI 10.3109/10408444.2013.808172
   Calabrese EJ, 2014, J CELL COMMUN SIGNAL
   Cook LB, 2013, VIROLOGY, V435, P131, DOI 10.1016/j.virol.2012.09.028
   Cornelius C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00120
   Cragg GM, 1999, PURE APPL CHEM, V71, P1619, DOI 10.1351/pac199971091619
   Delamarre L, 1999, J VIROL, V73, P9659, DOI 10.1128/JVI.73.11.9659-9663.1999
   Dimas K, 1998, PLANTA MED, V64, P208, DOI 10.1055/s-2006-957410
   Fernandez MA, 2001, J PHARM PHARMACOL, V53, P867, DOI 10.1211/0022357011776027
   Fogarty KH, 2011, VIRUSES-BASEL, V3, P770, DOI 10.3390/v3060770
   Gillet N, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-115
   GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607
   Grigsby IF, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-75
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Khan MTH, 2005, ANTIVIR RES, V67, P107, DOI 10.1016/j.antiviral.2005.05.002
   Le Blanc I, 2002, J VIROL, V76, P905, DOI 10.1128/JVI.76.2.905-911.2002
   Li M, 2007, J VIROL METHODS, V142, P159, DOI 10.1016/j.jviromet.2007.01.023
   Li M, 2012, AIDS RES HUM RETROV, V28, P405, DOI 10.1089/aid.2011.0130
   Li M, 2009, J VIROL, V83, P3788, DOI 10.1128/JVI.02315-08
   Majorovits E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002251
   Moens B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001729
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nakagawa M, 1996, J NEUROVIROL, V2, P345, DOI 10.3109/13550289609146899
   Navarro A, 2000, PLANTA MED, V66, P289, DOI 10.1055/s-2000-8567
   Oh U, 2005, ANN NEUROL, V57, P526, DOI 10.1002/ana.20429
   Ohyoshi T, 2012, ANGEW CHEM INT EDIT, V51, P4972, DOI 10.1002/anie.201201383
   OSAME M, 1986, LANCET, V1, P1031
   Pan LL, 2011, J NAT PROD, V74, P1508, DOI 10.1021/np200058c
   Sadqi M, 2006, NATURE, V442, P317, DOI 10.1038/nature04859
   Satou Yorifumi, 2012, Leuk Res Treatment, V2012, P213653, DOI 10.1155/2012/213653
   Satou Y, 2013, REV MED VIROL, V23, P269, DOI 10.1002/rmv.1745
   Severson WE, 2008, J BIOMOL SCREEN, V13, P879, DOI 10.1177/1087057108323123
   Simonis N, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-26
   Singh M, 1999, PLANTA MED, V65, P2, DOI 10.1055/s-1999-13952
   Souza-Fagundes EM, 2003, INT IMMUNOPHARMACOL, V3, P383, DOI 10.1016/S1567-5769(02)00296-5
   Tanaka A, 2013, LEUKEMIA, V27, P1621, DOI 10.1038/leu.2013.46
   Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428
   Verpoorte R, 2000, J PHARM PHARMACOL, V52, P253, DOI 10.1211/0022357001773931
   Verpoorte R, 1998, DRUG DISCOV TODAY, V3, P232, DOI 10.1016/S1359-6446(97)01167-7
   Watanabe T, 1997, INT J HEMATOL, V66, P257
   Yamano Y, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00389
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004
   Zani CL, 2000, PHYTOCHEMISTRY, V53, P877, DOI 10.1016/S0031-9422(99)00564-6
NR 49
TC 0
Z9 0
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD DEC 24
PY 2014
VL 14
AR 331
DI 10.1186/s12866-014-0331-2
PG 10
WC Microbiology
SC Microbiology
GA AZ4HW
UT WOS:000348183200001
PM 25539906
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Fonseca, FG
   Ribeiro, DM
   Carvalho, NP
   Stancioli, B
AF da Fonseca, Flavio Guimaraes
   Ribeiro, Daniel Mendes
   Carvalho, Nara Pereira
   Stancioli, Brunello
TI Human in vitro eugenics: close, yet far away
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Editorial Material
C1 [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Ribeiro, Daniel Mendes; Carvalho, Nara Pereira] UFJF, Dept Law, Governador Valadares, Brazil.
   [Stancioli, Brunello] Univ Fed Minas Gerais, Sch Law, Belo Horizonte, MG, Brazil.
RP Stancioli, B (corresponding author), Rua Benjamin Flores,280,700, BR-30350240 Belo Horizonte, MG, Brazil.
EM brunellostancioli@gmail.com
OI Stancioli, Brunello/0000-0001-7795-0395
CR Chocu S, 2012, SYST BIOL REPROD MED, V58, P179, DOI 10.3109/19396368.2012.691943
   Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270
   Sparrow R, 2014, J MED ETHICS, V40, P725, DOI 10.1136/medethics-2012-101200
NR 3
TC 3
Z9 3
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD NOV
PY 2014
VL 40
IS 11
DI 10.1136/medethics-2013-101674
PG 2
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA AS2BB
UT WOS:000344082900007
PM 23943786
DA 2020-12-08
ER

PT J
AU Trindade, GD
   Fernandes, ATD
   Costa, GB
   Figueiredo, PD
   Abrahao, JS
   Kroon, EG
   Figueiredo, LTM
   da Fonseca, FG
AF Trindade, Giliane de Souza
   da Silva Fernandes, Andre Tavares
   Costa, Galileu Barbosa
   Figueiredo, Poliana de Oliveira
   Abrahao, Jonatas Santos
   Kroon, Erna Geessien
   Moraes Figueiredo, Luiz Tadeu
   da Fonseca, Flavio Guimaraes
TI Could hantavirus circulation superpose areas of highly endemic vaccinia
   virus outbreaks? A retrospective seroepidemiological study in State of
   Minas Gerais
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Hantavirus; Rural population; Bovine vaccinia
ID INFECTION; REGIONS; PAULO
AB Introduction: Hantavirus infections have been described in several regions in Brazil through seroepidemiological studies. Usually, populations are associated with rural and wild environment mainly due to close contact to species of Sigmodontinae rodents, considered hantavirus reservoirs. Methods: A retrospective serosurvey was conducted to access the hantavirus seroprevalence in people living in regions affected by bovine vaccinia outbreaks. Results: Sera from 53 patients were analyzed and none of them presented anti-hantavirus IgG antibodies. Conclusions: This study presents an opportunity to analyze seronegativity despite close and recurrent contact with known hantavirus reservoirs. Aspects of hantavirus and bovine vaccinia emergence are also discussed.
C1 [Trindade, Giliane de Souza; Costa, Galileu Barbosa; Figueiredo, Poliana de Oliveira; Abrahao, Jonatas Santos; Kroon, Erna Geessien] Univ Fed Minas Gerais, ICB, Dept Microbiol, Virus Lab, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Silva Fernandes, Andre Tavares] Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol, Rio De Janeiro, RJ, Brazil.
   [Moraes Figueiredo, Luiz Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Ctr Pesquisa Virol, Ribeirao Preto, SP, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, ICB, Dept Microbiol, Lab Virol Basica & Aplicada, BR-31270901 Belo Horizonte, MG, Brazil.
RP Trindade, GD (corresponding author), Univ Fed Minas Gerais, ICB, Dept Microbiol, Virus Lab, Av Presidente Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM giliane@icb.ufmg.br
RI Costa, Galileu Barbosa/M-5768-2019; Kroon, Erna/V-5444-2019; Costa,
   Galileu/C-3319-2014; Kroon, Erna Geessien/B-3631-2015
OI Kroon, Erna Geessien/0000-0003-2721-3826; Barbosa Costa,
   Galileu/0000-0001-7360-6722
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES; Fundacao de Amparo a Pesquisa do Estado de Minas
   GeraisMinas Gerais State Research Foundation (FAPEMIG); Ministerio da
   Agricultura, Pecuaria e Abastecimento; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX Financial support was provided by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior, Fundacao de Amparo a
   Pesquisa do Estado de Minas Gerais, Ministerio da Agricultura, Pecuaria
   e Abastecimento. G.S. Trindade, E.G. Kroon and F.G. da Fonseca are CNPq
   fellowship recipients.
CR Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Badra SJ, 2012, REV SOC BRAS MED TRO, V45, P468, DOI [10.1590/S0037-86822012005000005, 10.1590/s0037-86822012005000005]
   de Souza WM, 2012, REV INST MED TROP SP, V54, P193, DOI 10.1590/S0036-46652012000400002
   Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09
   Kroon EG, 2011, ANTIVIR RES, V92, P150, DOI 10.1016/j.antiviral.2011.08.018
   Lima DM, 2011, REV SOC BRAS MED TRO, V44, P795, DOI 10.1590/S0037-86822011000600031
   Gimaque JBL, 2012, MEM I OSWALDO CRUZ, V107, P135, DOI 10.1590/S0074-02762012000100019
   Limongi JE, 2009, EMERG INFECT DIS, V15, P1981, DOI 10.3201/eid1512.090229
   Limongi JE, 2007, REV SOC BRAS MED TRO, V40, P295, DOI 10.1590/S0037-86822007000300009
   Medaglia MLG, 2009, EMERG INFECT DIS, V15, P1142, DOI 10.3201/eid1507.081702
   Medeiros DBA, 2010, MEM I OSWALDO CRUZ, V105, P665, DOI 10.1590/S0074-02762010000500011
   Figueiredo LTM, 2009, AM J TROP MED HYG, V81, P273, DOI 10.4269/ajtmh.2009.81.273
   Pereira GW, 2012, REV SOC BRAS MED TRO, V45, P117, DOI 10.1590/S0037-86822012000100022
   Peres MG, 2013, ARCH VIROL, V158, P2433, DOI 10.1007/s00705-013-1740-5
   Schatzmayr HG, 2011, VACCINE, V29, pD65, DOI 10.1016/j.vaccine.2011.09.105
NR 15
TC 1
Z9 1
U1 0
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD NOV-DEC
PY 2014
VL 47
IS 6
BP 778
EP 782
DI 10.1590/0037-8682-0033-2014
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AZ4PE
UT WOS:000348204000016
PM 25626659
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Quinan, BR
   Flesch, IEA
   Pinho, TMG
   Coelho, FM
   Tscharke, DC
   da Fonseca, FG
AF Quinan, Barbara R.
   Flesch, Inge E. A.
   Pinho, Tania M. G.
   Coelho, Fabiana M.
   Tscharke, David C.
   da Fonseca, Flavio G.
TI An intact signal peptide on dengue virus E protein enhances
   immunogenicity for CD8(+) T cells and antibody when expressed from
   modified vaccinia Ankara
SO VACCINE
LA English
DT Article
DE Dengue virus; MVA; Recombinant MVA; CD8(+) T cells; Cytotoxic T cells;
   CTL
ID IMMUNE-RESPONSE; RECOMBINANT VIRUSES; PROTECTIVE ROLE; IMMUNIZATION;
   VACCINATION; CORRELATE; DATABASE; PROGRESS; VECTORS; PROFILE
AB Dengue is a global public health concern and this is aggravated by a lack of vaccines or antiviral therapies. Despite the well-known role of CD8(+) T cells in the immunopathogenesis of Dengue virus (DENV), only recent studies have highlighted the importance of this arm of the immune response in protection against the disease. Thus, the majority of DENV vaccine candidates are designed to achieve protective titers of neutralizing antibodies, with less regard for cellular responses. Here, we used a mouse model to investigate CD8(+) T cell and humoral responses to a set of potential DENV vaccines based on recombinant modified vaccinia virus Ankara (rMVA). To enable this study, we identified two CD8(+) T cell epitopes in the DENV-3 E protein in C57BL/6 mice. Using these we found that all the rMVA vaccines elicited DENV-specific CD8(+) T cells that were cytotoxic in vivo and polyfunctional in vitro. Moreover, vaccines expressing the E protein with an intact signal peptide sequence elicited more DENV-specific CD8(+) T cells than those expressing E proteins in the cytoplasm. Significantly, it was these same ER-targeted E protein vaccines that elicited antibody responses. Our results support the further development of rMVA vaccines expressing DENV E proteins and add to the tools available for dengue vaccine development. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Quinan, Barbara R.; Pinho, Tania M. G.; Coelho, Fabiana M.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Quinan, Barbara R.; Flesch, Inge E. A.; Tscharke, David C.] Australian Natl Univ, Res Sch Biol, Div Biomed Sci & Biochem, Canberra, ACT 0200, Australia.
   [da Fonseca, Flavio G.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
RP Tscharke, DC (corresponding author), Australian Natl Univ, Res Sch Biol, Div Biomed Sci & Biochem, Bldg 134 Linnaeus Way, Canberra, ACT 0200, Australia.
EM david.tscharke@anu.edu.au; dafonseca@cpqrr.fiocruz.br
RI Coelho, Fabiana Magalhaes/K-6001-2013; Tscharke, David/C-9133-2009
OI Tscharke, David/0000-0001-6825-9172
FU Instituto Nacional de Ciencia e Tecnologia de Vacinas-INCTV (National
   Institute of Science and Technology of Vaccines); FAPEMIG PPM grant
   (CBB)Minas Gerais State Research Foundation (FAPEMIG) [PPM-00461-11];
   CAPES/PDSE [8815-11-9]; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We thank Prof John Aaskov and the W.H.O. Arbovirus Reference Centre at
   the Queensland University of Technology for provision of DENV-3
   isolates. We also thank Dr. Ricardo Gazzinelli for continuous support.
   Parts of this work were supported by the Instituto Nacional de Ciencia e
   Tecnologia de Vacinas-INCTV (National Institute of Science and
   Technology of Vaccines) and by a FAPEMIG PPM grant (CBB, PPM-00461-11).
   BRQ was a CAPES/PDSE fellowship recipient (8815-11-9). FGF is a CNPq
   fellowship recipient. DCT is an ARC Future Fellow (FT110100310).
CR Almeida JR, 2009, BLOOD, V113, P6351, DOI 10.1182/blood-2009-02-206557
   Beaumier CM, 2008, J INFECT DIS, V197, P608, DOI 10.1086/526790
   Beaumier CM, 2013, TRANSL RES, V162, P144, DOI 10.1016/j.trsl.2013.03.006
   Belyakov IM, 1999, P NATL ACAD SCI USA, V96, P4512, DOI 10.1073/pnas.96.8.4512
   Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Coller BAG, 2011, CURR OPIN IMMUNOL, V23, P391, DOI 10.1016/j.coi.2011.03.005
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Duan ZL, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-259
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Flesch Inge E A, 2012, Methods Mol Biol, V890, P199, DOI 10.1007/978-1-61779-876-4_12
   Flesch IEA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039533
   Forbes EK, 2008, J IMMUNOL, V181, P4955, DOI 10.4049/jimmunol.181.7.4955
   Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Gubler DJ, 2012, AM J TROP MED HYG, V86, P743, DOI 10.4269/ajtmh.2012.12-0157
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Halstead SB, 2012, LANCET, V380, P1535, DOI 10.1016/S0140-6736(12)61510-4
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Hernandez Raquel, 2010, Curr Protoc Microbiol, VAppendix 4, p4I, DOI 10.1002/9780471729259.mca04is17
   La Gruta NL, 2004, J IMMUNOL, V172, P5553, DOI 10.4049/jimmunol.172.9.5553
   Lin Leon C W, 2012, Methods Mol Biol, V890, P147, DOI 10.1007/978-1-61779-876-4_9
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Lindow JC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001742
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Park SH, 2012, GASTROENTEROLOGY, V143, P1048, DOI 10.1053/j.gastro.2012.06.005
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Rocha CD, 2004, INT MICROBIOL, V7, P83
   Rollier CS, 2011, CURR OPIN IMMUNOL, V23, P377, DOI 10.1016/j.coi.2011.03.006
   Rothman AL, 1996, J VIROL, V70, P6540, DOI 10.1128/JVI.70.10.6540-6546.1996
   Russell TA, 2014, IMMUNOL CELL BIOL, V92, P466, DOI 10.1038/icb.2014.10
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sanchez-Burgos G, 2010, VIRUS RES, V153, P113, DOI 10.1016/j.virusres.2010.07.014
   Singh R, 2010, J INFECT DIS, V202, P223, DOI 10.1086/653486
   Souza APD, 2005, BRAZ J MED BIOL RES, V38, P509, DOI 10.1590/S0100-879X2005000400004
   St Leger AJ, 2011, J IMMUNOL, V186, P3927, DOI 10.4049/jimmunol.1003735
   Verheust C, 2012, VACCINE, V30, P2623, DOI 10.1016/j.vaccine.2012.02.016
   Vita R, 2010, NUCLEIC ACIDS RES, V38, pD854, DOI 10.1093/nar/gkp1004
   Webster DP, 2009, LANCET INFECT DIS, V9, P678, DOI 10.1016/S1473-3099(09)70254-3
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wittke V, 2002, VIROLOGY, V301, P148, DOI 10.1006/viro.2002.1549
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Yuen TJ, 2010, J VIROL, V84, P10220, DOI 10.1128/JVI.01281-10
NR 48
TC 8
Z9 8
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 2972
EP 2979
DI 10.1016/j.vaccine.2014.03.093
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000010
PM 24726244
OA Bronze
DA 2020-12-08
ER

PT J
AU Moreira-Silva, EAD
   Medeiros-Silva, DC
   Gomes, JDS
   da Fonseca, FG
   Correa-Oliveira, R
AF dos Santos Moreira-Silva, Eduardo Augusto
   Medeiros-Silva, Daniela Carla
   Silva Gomes, Juliana de Assis
   da Fonseca, Flavio Guimaraes
   Correa-Oliveira, Rodrigo
TI Profile of natural killer cells after a previous natural Vaccinia virus
   infection in an in vitro viral re-exposure
SO VIRUS RESEARCH
LA English
DT Article
DE Vaccinia virus; Poxviridae infections; NK cells; Zoonoses; Smallpox
   vaccine
ID MEDIATED RESISTANCE; ANTIVIRAL IMMUNITY; CUTTING EDGE; NK; CD94;
   RECOGNITION; SMALLPOX; CYTOTOXICITY; EXPRESSION; RECEPTOR
AB The present study compares the profile of NI(cells in an in vitro re-exposure by Vaccinia virus (VACV), in groups that have had a previous vaccination or natural infection. Our data suggests that stimulation with VACV triggers a cytotoxic response by NK cells marked by an increase of NCRs: NKp30, NKp44, and NKp46 in infected (vaccinated and. unvaccinated) subjects and in non-infected vaccinated patients, when compared with non-infected unvaccinated individuals. However, the degranulation and secretion processes are inhibited in infected (vaccinated and unvaccinated) subjects and in the non-infected vaccinated patients, when compared with non-infected unvaccinated individuals. We demonstrated that stimulation with VACV downregulates the percentage of expression of Perforin, Granzyme A, and CD107a, but upregulate CD94 in infected (vaccinated and unvaccinated) subjects and in non-infected vaccinated patients, when compared with non-infected unvaccinated individuals. Furthermore, the percentage of IFN-gamma(+) NK cells was significantly lower in non-infected unvaccinated subjects, when compared with infected (vaccinated and unvaccinated) and non-infected vaccinated individuals. Our results also show that the percentage of TNF-alpha(+) NI(cells was significantly higher in infected (vaccinated and unvaccinated) subjects and in non-infected vaccinated patients, when compared with non-infected unvaccinated individuals, after in vitro stimulation with UV-inactivated VACV. Our data suggest that the expression of NCRs NKp30, NKp44, NKp46 and cytokines by NK cells are important in the innate response against VACV. (C) 2014 Elsevier B.V. All rights reserved.
C1 [dos Santos Moreira-Silva, Eduardo Augusto; Medeiros-Silva, Daniela Carla; Correa-Oliveira, Rodrigo] Minist Saude, Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Rene Rachou CPqRR, Belo Horizonte, MG, Brazil.
   [dos Santos Moreira-Silva, Eduardo Augusto; Medeiros-Silva, Daniela Carla; Correa-Oliveira, Rodrigo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Silva Gomes, Juliana de Assis] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Moreira-Silva, EAD (corresponding author), Univ Fed Minas Gerais, Dept Bioquim & Imunol, Av Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM duduaugusto1@yahoo.com.br
RI Gomes, Juliana A. S./M-4083-2017
OI Gomes, Juliana A. S./0000-0002-8332-2907; Correa-Oliveira,
   Rodrigo/0000-0001-6419-9459
FU CAPES/CNPQ/FAPEMIG.
FX CAPES/CNPQ/FAPEMIG.
CR Aldemir H, 2005, J IMMUNOL, V175, P7791, DOI 10.4049/jimmunol.175.12.7791
   Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008
   Azzoni L, 1998, J IMMUNOL, V161, P3493
   BABLANIAN R, 1975, PROG MED VIROL, V19, P40
   BUKOWSKI JF, 1983, J IMMUNOL, V131, P1531
   Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438
   CAMPOS MAD, 1993, REV MICROBIOL, V24, P104
   Carretero M, 1997, EUR J IMMUNOL, V27, P563, DOI 10.1002/eji.1830270230
   Chisholm SE, 2006, J VIROL, V80, P2225, DOI 10.1128/JVI.80.5.2225-2233.2006
   Combadiere B, 2004, J EXP MED, V199, P1585, DOI 10.1084/jem.20032083
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   Daniels KA, 2001, J EXP MED, V194, P29, DOI 10.1084/jem.194.1.29
   Di Santo JP, 2006, ANNU REV IMMUNOL, V24, P257, DOI 10.1146/annurev.immunol.24.021605.090700
   Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714
   Fang M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040030
   Fang M, 2011, IMMUNITY, V34, P579, DOI 10.1016/j.immuni.2011.02.015
   Fang M, 2010, J EXP MED, V207, P2369, DOI 10.1084/jem.20100282
   Germain C, 2011, J BIOL CHEM, V286, P37964, DOI 10.1074/jbc.M111.285312
   Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917
   Hammarlund E, 2010, J VIROL, V84, P12754, DOI 10.1128/JVI.01763-10
   Heymann DL, 1998, BRIT MED BULL, V54, P693, DOI 10.1093/oxfordjournals.bmb.a011720
   Hsieh SM, 2004, CLIN INFECT DIS, V38, P86, DOI 10.1086/380460
   Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209
   Konjevic G, 2009, J MEMBRANE BIOL, V230, P113, DOI 10.1007/s00232-009-9191-3
   Lazetic S, 1996, J IMMUNOL, V157, P4741
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102
   Medeiros-Silva Daniela Carla, 2013, Results Immunol, V3, P104, DOI 10.1016/j.rinim.2013.10.002
   Medeiros-Silva DC, 2010, BRAZ J INFECT DIS, V14, P129, DOI 10.1590/S1413-86702010000200003
   Mullbacher A, 1999, P NATL ACAD SCI USA, V96, P13950, DOI 10.1073/pnas.96.24.13950
   NATUK RJ, 1987, J IMMUNOL, V138, P877
   Orr MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015184
   Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6
   Prlic M, 2005, J IMMUNOL, V175, P2152, DOI 10.4049/jimmunol.175.4.2152
   Puissant-Lubrano B, 2010, J CLIN INVEST, V120, P1636, DOI 10.1172/JCI38506
   Reading PC, 2003, J VIROL, V77, P9960, DOI 10.1128/JVI.77.18.9960-9968.2003
   Rosen DB, 2005, J IMMUNOL, V175, P7796, DOI 10.4049/jimmunol.175.12.7796
   STITZ L, 1986, J IMMUNOL, V136, P4674
   Tsung KL, 1996, J VIROL, V70, P165, DOI 10.1128/JVI.70.1.165-171.1996
NR 39
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD MAY 12
PY 2014
VL 184
BP 20
EP 29
DI 10.1016/j.virusres.2014.02.001
PG 10
WC Virology
SC Virology
GA AG7RB
UT WOS:000335614400004
PM 24530576
OA Green Published
DA 2020-12-08
ER

PT J
AU Silvestre, BT
   Rabelo, EML
   Versiani, AF
   da Fonseca, FG
   Silveira, JAG
   Bueno, LL
   Fujiwara, RT
   Ribeiro, MFB
AF Silvestre, Bruna T.
   Rabelo, Elida M. L.
   Versiani, Alice F.
   da Fonseca, Flavio G.
   Silveira, Julia A. G.
   Bueno, Lilian L.
   Fujiwara, Ricardo T.
   Ribeiro, Mucio F. B.
TI Evaluation of humoral and cellular immune response of BALB/c mice
   immunized with a recombinant fragment of MSP1 a from Anaplasma marginale
   using carbon nanotubes as a carrier molecule
SO VACCINE
LA English
DT Article
DE Anaplasma marginale; Vaccine; rMSPla; Carbon nanotubes
ID CD4+ T-LYMPHOCYTE; SURFACE PROTEIN; BOVINE ERYTHROCYTES;
   GAMMA-INTERFERON; CATTLE; PROTECTION; ANTIGENS; COMPLEX; VACCINE; CELLS
AB Bovine anaplasmosis is a disease caused by the intraeiythrocytic rickettsia Anaplasma marginate. Surface proteins (MSPs) of A. marginate are important in the interaction of the pathogen with the host and constitute potential vaccine targets against this pathogen. Currently, there is no commercial inactivated vaccine against bovine anaplasmosis that can generate a protective immune response that effectively prevents the development of clinical disease. The objective of this study was to evaluate the humoral and cellular immune responses of BALB/c mice immunized with the recombinant fragment of rMSPla from A. marginale using carbon nanotubes as a carrier molecule. The fragment of rMSPla comprising the N-terminal region of the protein was expressed in Escherichia coli BL21, purified by nickel affinity chromatography and covalently linked to multiwalled carbon nanotubes (MWNTs). After this functionalization, thirty BALB/c mice were divided into five groups, G1 (rMSP1a), G2 (MWNT+ rMSP1a), G3 (MWNT), G4 (adjuvant) and G5 (unimmunized). The mice were immunized subcutaneously at days 0,21 and 42. Blood samples were collected on day 11 after immunization. The spleens were collected, and the splenocytes were cultured for cell proliferation assays and cell immunophenotyping. Mice immunized with rMSP1a (G1 and G2) produced high levels of anti-rMSP1a IgG, demonstrating that the functionalization to carbon nanotubes did not interfere with protein immunogenicity. Immunization with MWNT + rMSPla significantly induced higher percentages of CD4(+)CD44(+) and CD4(+)CD62L(+) lymphocytes, high levels of TNF alpha, and a higher proliferative rate of splenocytes compared to mice immunized with rMSPla alone (G1 group). Therefore, additional experiments using cattle should be performed to determine the efficacy, safety, immunogenicity and protection induced by rMSPla associated with MWNT. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Silvestre, Bruna T.; Rabelo, Elida M. L.; Silveira, Julia A. G.; Bueno, Lilian L.; Fujiwara, Ricardo T.; Ribeiro, Mucio F. B.] Univ Fed Minas Gerais, Dept Parasitol, Belo Horizonte, MG, Brazil.
   [Versiani, Alice F.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
RP Ribeiro, MFB (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, Lab Protozool Vet, Setor E4,Sala 242, Belo Horizonte, MG, Brazil.
EM muciobr@icb.ufmg.br
RI Bueno, Lilian/AAQ-1939-2020; Fujiwara, Ricardo Toshio/J-7579-2012;
   Rabelo, Elida ML/C-2401-2015; Versiani, Alice/M-9782-2018
OI Bueno, Lilian/0000-0003-3510-4590; Fujiwara, Ricardo
   Toshio/0000-0002-4713-575X; Rabelo, Elida ML/0000-0002-2566-5012;
   SILVESTRE, BRUNA/0000-0002-1192-2938; Versiani,
   Alice/0000-0003-1378-5380
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX This study was financially supported by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). The authors thank to
   researches Jamil S. Oliveira, Dr Silvia R. C. Dias and Dr Ana Cristina
   P. P. Bello. We thank AJE (American Journal Experts) for improved the
   English and for our contributions that allowed us to execute the present
   study.
CR Akkoyunlu M, 2000, INFECT IMMUN, V68, P1827, DOI 10.1128/IAI.68.4.1827-1833.2000
   Astigarraga RG, 2012, THESIS FEDERAL U MIN
   Bastos CV, 2010, VET J, V186, P374, DOI 10.1016/j.tvjl.2009.09.013
   Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   Brown WC, 2001, INFECT IMMUN, V69, P6853, DOI 10.1128/IAI.69.11.6853-6862.2001
   Brown WC, 1998, INFECT IMMUN, V66, P5406, DOI 10.1128/IAI.66.11.5406-5413.1998
   Brown WC, 1998, INFECT IMMUN, V66, P5414, DOI 10.1128/IAI.66.11.5414-5422.1998
   de la Fuente J, 2003, VET MICROBIOL, V91, P265, DOI 10.1016/S0378-1135(02)00309-7
   de la Fuente J, 2002, VET MICROBIOL, V89, P239, DOI 10.1016/S0378-1135(02)00206-7
   de la Fuente J, 2001, INT J PARASITOL, V31, P145, DOI 10.1016/S0020-7519(00)00162-4
   Lasmar PVF, 2012, REV BRAS PARASITOL V, V21, P112, DOI 10.1590/S1984-29612012000200008
   FENG HM, 1994, INFECT IMMUN, V62, P1952, DOI 10.1128/IAI.62.5.1952-1960.1994
   Foldvari M, 2008, NANOMED-NANOTECHNOL, V4, P183, DOI 10.1016/j.nano.2008.04.003
   Garcia-Garcia JC, 2004, VET IMMUNOL IMMUNOP, V98, P137, DOI 10.1016/j.vetimm.2003.11.003
   Hamada S, 2008, J IMMUNOL, V181, P3456, DOI 10.4049/jimmunol.181.5.3456
   Jiang KY, 2004, J MATER CHEM, V14, P37, DOI 10.1039/b310359e
   Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kano FS, 2008, VACCINE, V26, P3522, DOI 10.1016/j.vaccine.2008.04.047
   Kawasaki PM, 2007, RES VET SCI, V83, P347, DOI 10.1016/j.rvsc.2007.02.002
   Kocan KM, 2010, VET PARASITOL, V167, P95, DOI 10.1016/j.vetpar.2009.09.012
   Kocan KM, 2003, CLIN MICROBIOL REV, V16, P698, DOI 10.1128/CMR.16.4.698-712.2003
   Kocan KM, 2001, VET PARASITOL, V102, P151, DOI 10.1016/S0304-4017(01)00519-2
   KUTTLER KL, 1984, J WILDLIFE DIS, V20, P12, DOI 10.7589/0090-3558-20.1.12
   Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662
   MCGAREY DJ, 1994, INFECT IMMUN, V62, P4587, DOI 10.1128/IAI.62.10.4587-4593.1994
   MCGAREY DJ, 1994, INFECT IMMUN, V62, P4594, DOI 10.1128/IAI.62.10.4594-4601.1994
   MCGUIRE TC, 1994, VACCINE, V12, P465, DOI 10.1016/0264-410X(94)90126-0
   Noh SM, 2013, CLIN VACCINE IMMUNOL, V20, P651, DOI 10.1128/CVI.00600-12
   Ojogun N, 2011, INFECT IMMUN, V79, P2717, DOI 10.1128/IAI.00181-11
   PALMER GH, 1987, INT J PARASITOL, V17, P1279, DOI 10.1016/0020-7519(87)90093-2
   Palmer GH, 1999, PARASITOL TODAY, V15, P281, DOI 10.1016/S0169-4758(99)01469-6
   PALMER GH, 1988, INFECT IMMUN, V56, P1526, DOI 10.1128/IAI.56.6.1526-1531.1988
   PALMER GH, 1986, SCIENCE, V231, P1299, DOI 10.1126/science.3945825
   PALMER GH, 1989, INFECT IMMUN, V57, P3666, DOI 10.1128/IAI.57.11.3666-3669.1989
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743
   RISTIC M, 1977, ADV EXPT MED BIOL, P151
   Santos PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060311
   Shoda LKM, 2001, J LEUKOCYTE BIOL, V70, P103
   TEBELE N, 1991, INFECT IMMUN, V59, P3199, DOI 10.1128/IAI.59.9.3199-3204.1991
   Yandara N, 2008, VACCINE, V26, P5864, DOI 10.1016/j.vaccine.2008.08.014
NR 43
TC 11
Z9 11
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2014
VL 32
IS 19
BP 2160
EP 2166
DI 10.1016/j.vaccine.2014.02.062
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AG7XN
UT WOS:000335632200005
PM 24606864
DA 2020-12-08
ER

PT J
AU Quinan, BR
   Daian, DSO
   Coelho, FM
   da Fonseca, FG
AF Quinan, Barbara R.
   Daian, Danielle S. O.
   Coelho, Fabiana M.
   da Fonseca, Flavio G.
TI Modified vaccinia virus Ankara as vaccine vectors in human and
   veterinary medicine
SO FUTURE VIROLOGY
LA English
DT Article
DE human vaccines; MVA; recombinant MVA; poxvirus; vaccine; vaccinia virus;
   veterinary vaccines; viral vectors
ID JAPANESE ENCEPHALITIS-VIRUS; PRIME-BOOST IMMUNIZATION; CELL
   IMMUNE-RESPONSES; RECOMBINANT MVA; TUBERCULOSIS VACCINE;
   CANINE-DISTEMPER; POXVIRUS VECTORS; PHASE-1 SAFETY; CLINICAL-TRIAL;
   HEALTHY-ADULTS
AB Disease prevention through vaccination is one of the most important achievements of medicine. Today, we have a substantial number of vaccines against a variety of pathogens. In this context, poxviruses and vaccinology are closely related, as the birth of modern vaccinology was marked by the use of poxviruses as immunogens and so was the eradication of smallpox, one of the world's most feared diseases ever. Nowadays, poxviruses continue to notoriously contribute to vaccinology since their use as vaccine vectors has become popular and widespread. One of the most promising vectors is the modified vaccinia ankara. In this review we provide an overview of the contribution of poxvirus to vaccine immunology, particularly focusing on modified vaccinia ankara-based vaccines developed to date.
C1 [Quinan, Barbara R.; Daian, Danielle S. O.; Coelho, Fabiana M.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio G.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
RI Daian+e+Silva, Danielle/AAF-8852-2020; Coelho, Fabiana
   Magalhaes/K-6001-2013
FU CNPq fellowshipNational Council for Scientific and Technological
   Development (CNPq); National Institute of Science and Technology of
   Vaccines (Instituto Nacional de Ciencia e Tecnologia de Vacinas -
   INCTV); FAPEMIG PPM grant [CBB - PPM-00461-11]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [470914/2012-2]
FX da Fonseca is a CNPq fellowship recipient. Projects on vaccine
   development at the Laboratory of Basic and Applied Virology have been
   supported by the National Institute of Science and Technology of
   Vaccines (Instituto Nacional de Ciencia e Tecnologia de Vacinas -
   INCTV), by a FAPEMIG PPM grant (CBB - PPM-00461-11) and by a CNPq
   Universal Grant (470914/2012-2). da Fonseca and Daian declare that the
   development of a modified vaccinia virus Ankara-based Circovirus vaccine
   was done through a partnership between the Federal University of Minas
   Gerais and the company Hertape-Calier LTDA. Remaining authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ba L, 2007, APPL MICROBIOL BIOT, V76, P1131, DOI 10.1007/s00253-007-1073-y
   Bakari M, 2011, VACCINE, V29, P8417, DOI 10.1016/j.vaccine.2011.08.001
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   Bertran K, 2013, VACCINE, V31, P3572, DOI 10.1016/j.vaccine.2013.05.039
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Calvo-Pinilla E, 2009, VACCINE, V28, P437, DOI 10.1016/j.vaccine.2009.10.027
   Carson C, 2009, VACCINE, V27, P1080, DOI 10.1016/j.vaccine.2008.11.094
   Castillo-Olivares J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016503
   Cavenaugh JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014626
   Chandran D, 2010, INDIAN J MICROBIOL, V50, P266, DOI 10.1007/s12088-010-0026-9
   Chiam R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005997
   Cottingham MG, 2013, VACCINE, V31, P4247, DOI 10.1016/j.vaccine.2013.03.021
   Currier JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013983
   da Fonseca FG, 2011, FUTURE VIROL, V6, P697, DOI 10.2217/FVL.11.46
   Draper SJ, 2013, VACCINE, V31, P4223, DOI 10.1016/j.vaccine.2013.05.091
   Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240
   Dunachie SJ, 2006, INFECT IMMUN, V74, P5933, DOI 10.1128/IAI.00590-06
   Dunachie SJ, 2006, VACCINE, V24, P2850, DOI 10.1016/j.vaccine.2005.12.041
   Earl PL, 2009, VACCINE, V27, P5885, DOI 10.1016/j.vaccine.2009.07.039
   El Garch H, 2008, VET IMMUNOL IMMUNOP, V123, P230, DOI 10.1016/j.vetimm.2008.02.002
   Gomez CE, 2012, HUM VACC IMMUNOTHER, V8, P1192, DOI 10.4161/hv.20778
   Gomez CE, 2011, J VIROL, V85, P11468, DOI 10.1128/JVI.05165-11
   Esteban M, 2009, HUM VACCINES, V5, P867, DOI 10.4161/hv.9693
   Ferrer MF, 2011, VIRAL IMMUNOL, V24, P331, DOI 10.1089/vim.2011.0018
   Fournillier A, 2013, J INFECT DIS, V208, P1008, DOI 10.1093/infdis/jit267
   Fry TL, 2013, VACCINE, V31, P2811, DOI 10.1016/j.vaccine.2013.04.016
   Garcia F, 2011, VACCINE, V29, P8309, DOI 10.1016/j.vaccine.2011.08.098
   Garcia-Arriaza J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024244
   Goepfert PA, 2011, J INFECT DIS, V203, P610, DOI 10.1093/infdis/jiq105
   Gomez CE, 2013, J VIROL, V87, P7282, DOI 10.1128/JVI.03246-12
   Gomez CE, 2007, VACCINE, V25, P2863, DOI 10.1016/j.vaccine.2006.09.090
   Gray G, 2010, CURR OPIN HIV AIDS, V5, P357, DOI 10.1097/COH.0b013e32833d2d2b
   Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185
   Hayes P, 2013, CLIN VACCINE IMMUNOL, V20, P397, DOI 10.1128/CVI.00637-12
   Jas D, 2012, VACCINE, V30, P6991, DOI 10.1016/j.vaccine.2012.09.068
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327
   Mackowiak M, 1999, ADV VETER MED AP, V41, P571
   MAYR A, 1964, ZENTBL BAKTERIOLOG P, V195, P24
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07
   Mehendale S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055831
   Meisinger-Henschel C, 2007, J GEN VIROL, V88, P3249, DOI 10.1099/vir.0.83156-0
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031
   Mooij P, 2008, J VIROL, V82, P2975, DOI 10.1128/JVI.02216-07
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moss B, 2007, FIELDS VIROLOGY, V2, P2905
   Moss B, 2013, VACCINE, V31, P4220, DOI 10.1016/j.vaccine.2013.03.042
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   Nam JH, 1999, VACCINE, V17, P261, DOI 10.1016/S0264-410X(98)00156-X
   Nam JH, 2002, MICROBIOL IMMUNOL, V46, P23, DOI 10.1111/j.1348-0421.2002.tb02672.x
   Ober BT, 2002, J VIROL, V76, P7713, DOI 10.1128/JVI.76.15.7713-7723.2002
   OGAWA R, 1990, VACCINE, V8, P486, DOI 10.1016/0264-410X(90)90251-G
   Ogwang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057726
   Olszewska W, 2004, VACCINE, V23, P215, DOI 10.1016/j.vaccine.2004.05.015
   Papin JF, 2011, P NATL ACAD SCI USA, V108, P14926, DOI 10.1073/pnas.1112149108
   Pardo MC, 1997, AM J VET RES, V58, P833
   Pathan AA, 2012, VACCINE, V30, P5616, DOI 10.1016/j.vaccine.2012.06.084
   Perez-Jimenez E, 2006, MICROBES INFECT, V8, P810, DOI 10.1016/j.micinf.2005.10.004
   Ramanathan VD, 2009, AIDS RES HUM RETROV, V25, P1107, DOI 10.1089/aid.2009.0096
   Ramirez JC, 2000, J VIROL, V74, P923, DOI 10.1128/JVI.74.2.923-933.2000
   Ramos I, 2008, VACCINE, V26, P333, DOI 10.1016/j.vaccine.2007.11.021
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Roth JA, 2011, PROCEDIA VACCINOL, V5, P127, DOI 10.1016/j.provac.2011.10.009
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507
   Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0
   Schulze K, 2008, VACCINE, V26, P6678, DOI 10.1016/j.vaccine.2008.09.006
   Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754
   Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223
   Sheehy SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031208
   Soboll G, 2010, VET IMMUNOL IMMUNOP, V135, P100, DOI 10.1016/j.vetimm.2009.11.007
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   TARTAGLIA J, 1993, J VIROL, V67, P2370, DOI 10.1128/JVI.67.4.2370-2375.1993
   TAYLOR J, 1991, J VIROL, V65, P4263, DOI 10.1128/JVI.65.8.4263-4274.1991
   Vasan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008816
   Verardi PH, 2012, HUM VACC IMMUNOTHER, V8, P961, DOI 10.4161/hv.21080
   Verheust C, 2012, VACCINE, V30, P2623, DOI 10.1016/j.vaccine.2012.02.016
   Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Weli SC, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-49
   Weyer J, 2009, VACCINE, V27, P7198, DOI 10.1016/j.vaccine.2009.09.033
   Wyatt LS, 1999, VACCINE, V18, P392, DOI 10.1016/S0264-410X(99)00257-1
   Zavala F, 2001, VIROLOGY, V280, P155, DOI 10.1006/viro.2000.0792
NR 89
TC 2
Z9 2
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD FEB
PY 2014
VL 9
IS 2
BP 173
EP 187
DI 10.2217/fvl.13.129
PG 15
WC Virology
SC Virology
GA AB9CU
UT WOS:000332088000011
DA 2020-12-08
ER

PT J
AU da Fonseca, FG
   Flores, LA
AF da Fonseca, Flavio Guimaraes
   Flores, Luis Adan
TI Immune responses to acute orthopoxvirus infections: what lessons can be
   learned?
SO FUTURE VIROLOGY
LA English
DT Editorial Material
DE human immune responses to poxviruses; immunity to orthopoxviruses;
   poxvirus immune evasion; poxvirus primary infection
ID VACCINIA-VIRUS-INFECTION; HUMAN MONKEYPOX; T-CELLS; ANTIBODIES
C1 [da Fonseca, Flavio Guimaraes; Flores, Luis Adan] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Basic & Appl Virol, Belo Horizonte, MG, Brazil.
EM fdafonseca@icb.ufmg.br
CR Amanna IJ, 2006, IMMUNOL REV, V211, P320, DOI 10.1111/j.0105-2896.2006.00392.x
   Burshtyn DN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00007
   Chaudhri G, 2006, J VIROL, V80, P6339, DOI 10.1128/JVI.00116-06
   Costa GB, 2013, VACCINE, V31, P4706, DOI [10.1016/j.vac, 10.1016/j.vaccine.2013.08.023]
   Damon IK, 2011, VACCINE, V29, pD54, DOI 10.1016/j.vaccine.2011.04.014
   Moreira-Silva EAD, 2014, VIRUS RES, V184, P20, DOI 10.1016/j.virusres.2014.02.001
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Fang M, 2005, J IMMUNOL, V175, P6829, DOI 10.4049/jimmunol.175.10.6829
   Gillard GO, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002141
   Goulding J, 2012, J IMMUNOL, V189, P2432, DOI 10.4049/jimmunol.1200799
   Martinez J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000811
   Medeiros-Silva Daniela Carla, 2013, Results Immunol, V3, P104, DOI 10.1016/j.rinim.2013.10.002
   Panchanathan V, 2008, IMMUNOL CELL BIOL, V86, P80, DOI 10.1038/sj.icb.7100118
   Parker AK, 2007, J VIROL, V81, P4070, DOI 10.1128/JVI.02061-06
   Reynolds MG, 2007, EMERG INFECT DIS, V13, P1332, DOI 10.3201/eid1309.070175
   Gomes JAS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/974067
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
   Yin LS, 2013, J IMMUNOL, V190, P6023, DOI 10.4049/jimmunol.1202523
NR 20
TC 0
Z9 0
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PY 2014
VL 9
IS 8
BP 699
EP 702
DI 10.2217/FVL.14.49
PG 4
WC Virology
SC Virology
GA AR8DL
UT WOS:000343805600002
DA 2020-12-08
ER

PT J
AU Rocha, ESD
   de Oliveira, JG
   dos Santos, JR
   Rodrigues, GOL
   Figueiredo, LB
   Pessanha, JEM
   Proietti, FA
   da Fonseca, FG
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF de Oliveira Rocha, Eliseu Soares
   de Oliveira, Jaquelline Germano
   dos Santos, Joao Rodrigues
   Libanio Rodrigues, Gisele Olinto
   Figueiredo, Leandra Barcelos
   Marques Pessanha, Jose Eduardo
   Proietti, Fernando Augusto
   da Fonseca, Flavio Guimaraes
   Bonjardim, Claudio Antonio
   Peregrino Ferreira, Paulo Cesar
   Kroon, Erna Geessien
TI Recombinant envelope protein-based enzyme immunoassay for IgG antibodies
   is comparable to neutralization tests for epidemiological studies of
   dengue infection
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Dengue virus; Serology; Diagnosis; ELISA; Recombinant envelope proteins
ID LINKED-IMMUNOSORBENT-ASSAY; RAPID IMMUNOCHROMATOGRAPHIC TEST; PLAQUE
   REDUCTION NEUTRALIZATION; CAPTURE ELISA; VIRUS-INFECTIONS; DIAGNOSIS;
   FEVER; IMMUNOGENICITY; GLYCOPROTEINS; POLYPEPTIDES
AB Dengue virus (DENV) is the most prevalent arbovirus in the world, found mainly in tropical regions. As clinical manifestations present frequently as nonspecific febrile illness, laboratory diagnosis is essential to confirm DENV infections and for epidemiological studies. Recombinant envelope (E) antigens of four serotypes of DENV were used to develop an immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA). To evaluate the IgG-ELISA, a panel of serum samples that had been tested previously by a plaque reduction neutralization test (PRNT) was investigated for the presence of anti-E antibodies against the four DENV serotypes. IgG-ELISA was found to have a sensitivity (91%) and specificity (98%) at a receiver-operating characteristic (ROC) optimized cutoff and demonstrated high performance as well as good indexes. A concordance of 97% was achieved between both assays, and only 21/704(3%) samples were not concordant. The results of the present study demonstrate a moderate correlation between neutralizing antibody titers and IgG-ELISA values. These findings indicate that the recombinant protein-based IgG-ELISA is a suitable method for routine serodiagnosis, monitoring and seroepidemiological studies of DENV infections. (C) 2012 Elsevier B.V. All rights reserved.
C1 [de Oliveira Rocha, Eliseu Soares; de Oliveira, Jaquelline Germano; dos Santos, Joao Rodrigues; Libanio Rodrigues, Gisele Olinto; Figueiredo, Leandra Barcelos; Bonjardim, Claudio Antonio; Peregrino Ferreira, Paulo Cesar; Kroon, Erna Geessien] Univ Fed Minas Gerais, Inst Ciencias Biol, Virus Lab, BR-31270901 Belo Horizonte, MG, Brazil.
   [de Oliveira, Jaquelline Germano] Fundacao Oswaldo Cruz, Lab Imunol Celular & Mol, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [Marques Pessanha, Jose Eduardo] Prefeitura Municipal Belo Horizonte, Secretaria Municipal Saude, Belo Horizonte, MG, Brazil.
   [Proietti, Fernando Augusto] Univ Fed Minas Gerais, Fac Med, Dept Prevent & Social Med, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Virol Comparada, BR-31270901 Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Virus Lab, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Kroon, Erna Geessien/B-3631-2015; Bonjardim,
   Claudio A/J-2601-2014
OI Kroon, Erna Geessien/0000-0003-2721-3826; Rocha,
   Eliseu/0000-0002-2854-0768
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); INCT and
   PRONEX-Dengue; Departamento de Ciencia e Tecnologia do Ministerio da
   Saude (DECIT/MS)
FX The authors are grateful to Angela Sana Lopes, Ilda V. Gama, Andresa A.
   Carvalho, Edel F.B. Stancioli, Mauricio L. Nogueira and Jordana G.A.
   Coelho-dos-Reis, Glaura C. Franco and colleagues from Laboratbrio de
   Virus (ICB-UFMG) for their excellent technical support. The authors are
   also thankful to all of the volunteers, without whom this work would not
   have been possible, and for the financial support provided by Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), INCT and
   PRONEX-Dengue, Departamento de Ciencia e Tecnologia do Ministerio da
   Saude (DECIT/MS). FGF, CAB, PCP and EGK are fellows from CNPq.
CR ANVISA, 2003, PROJ AV COMP PROD US
   Buerano Corazon C., 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P524
   de Lima VLC, 2007, CAD SAUDE PUBLICA, V23, P669, DOI 10.1590/S0102-311X2007000300025
   Clements DE, 2010, VACCINE, V28, P2705, DOI 10.1016/j.vaccine.2010.01.022
   Cuzzubbo AJ, 1999, CLIN DIAGN LAB IMMUN, V6, P705, DOI 10.1128/CDLI.6.5.705-712.1999
   Cuzzubbo AJ, 2001, CLIN DIAGN LAB IMMUN, V8, P1150, DOI 10.1128/CDLI.8.6.1150-1155.2001
   Figueiredo Regina Maria Pinto De, 2004, Rev. Soc. Bras. Med. Trop., V37, P476, DOI 10.1590/S0037-86822004000600009
   De Paula Sérgio Oliveira, 2004, Braz J Infect Dis, V8, P390, DOI 10.1590/S1413-86702004000600002
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   DELENDA C, 1994, J GEN VIROL, V75, P1569, DOI 10.1099/0022-1317-75-7-1569
   Dos Santos FB, 2004, AM J TROP MED HYG, V71, P144, DOI 10.4269/ajtmh.2004.71.144
   Dos Santos FB, 2007, CLIN VACCINE IMMUNOL, V14, P641, DOI 10.1128/CVI.00474-06
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Koraka P, 2002, MICROBES INFECT, V4, P1209, DOI 10.1016/S1286-4579(02)01647-7
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lima V L, 1999, Rev Saude Publica, V33, P566
   LIN B, 1994, VIROLOGY, V202, P885, DOI 10.1006/viro.1994.1410
   Ludolfs D, 2002, J CLIN MICROBIOL, V40, P4317, DOI 10.1128/JCM.40.11.4317-4320.2002
   MAKINO Y, 1991, AM J TROP MED HYG, V45, P636, DOI 10.4269/ajtmh.1991.45.636
   Pessanha JEM, 2010, REV PANAM SALUD PUBL, V27, P252, DOI 10.1590/S1020-49892010000400003
   Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3
   MEN R, 1991, J VIROL, V65, P1400, DOI 10.1128/JVI.65.3.1400-1407.1991
   MORENS DM, 1985, MICROBIOL IMMUNOL, V29, P1197, DOI 10.1111/j.1348-0421.1985.tb00909.x
   Nawa M, 2000, CLIN DIAGN LAB IMMUN, V7, P774, DOI 10.1128/CDLI.7.5.774-777.2000
   Nunes MRT, 2011, J VIROL METHODS, V171, P13, DOI 10.1016/j.jviromet.2010.09.021
   Osanai C H, 1983, Rev Inst Med Trop Sao Paulo, V25, P53
   Palmer CJ, 1999, J CLIN MICROBIOL, V37, P1600, DOI 10.1128/JCM.37.5.1600-1601.1999
   Parida MM, 2001, ACTA VIROL, V45, P299
   Putnak JR, 2005, VACCINE, V23, P4442, DOI 10.1016/j.vaccine.2005.03.042
   Putnak R., 1994, MODERN VACCINOLOGY
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Rivetz B, 2009, CLIN BIOCHEM, V42, P180, DOI 10.1016/j.clinbiochem.2008.10.017
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Sathish N, 2002, INDIAN J MED RES, V115, P31
   Siqueira JB, 2004, AM J TROP MED HYG, V71, P646, DOI 10.4269/ajtmh.2004.71.646
   SVS (Secretaria de Vigilancia em Saude), 2007, INF EP DENG
   Teixeira Maria da Glória, 2005, Cad. Saúde Pública, V21, P1307, DOI 10.1590/S0102-311X2005000500002
   Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625
   Tripathi NK, 2008, J BIOTECHNOL, V134, P278, DOI 10.1016/j.jbiotec.2008.02.001
   Vasconcelos P F, 2000, Rev Soc Bras Med Trop, V33, P61
   Vasconcelos P F, 1999, Rev Soc Bras Med Trop, V32, P171
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   Videa E, 2005, CLIN DIAGN LAB IMMUN, V12, P882, DOI 10.1128/CDLI.12.7.882-884.2005
   WHO, 2007, GUID PLAQ RED NEUTR
   Wu SJL, 1997, CLIN DIAGN LAB IMMUN, V4, P452, DOI 10.1128/CDLI.4.4.452-457.1997
   Yew YW, 2009, ANN ACAD MED SINGAP, V38, P667
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 49
TC 10
Z9 10
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JAN
PY 2013
VL 187
IS 1
BP 114
EP 120
DI 10.1016/j.jviromet.2012.09.012
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 058BR
UT WOS:000312609600019
PM 23018061
DA 2020-12-08
ER

PT J
AU Gomes, JAS
   de Araujo, FF
   Trindade, GD
   Quinan, BR
   Drumond, BP
   Ferreira, JMS
   Mota, BEF
   Nogueira, ML
   Kroon, EG
   Abrahao, JS
   Correa-Oliveira, R
   da Fonseca, FG
AF Silva Gomes, Juliana Assis
   de Araujo, Fernanda Fortes
   Trindade, Giliane de Souza
   Quinan, Barbara Resende
   Drumond, Betania Paiva
   Siqueira Ferreira, Jaqueline Maria
   Fernandes Mota, Bruno Eduardo
   Nogueira, Mauricio Lacerda
   Kroon, Erna Geessien
   Abrahao, Jonatas Santos
   Correa-Oliveira, Rodrigo
   da Fonseca, Flavio Guimaraes
TI Immune Modulation in Primary Vaccinia virus Zoonotic Human Infections
SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY
LA English
DT Article
ID T-CELL RESPONSES; MHC CLASS-II; SMALLPOX VACCINATION; ANTIGEN
   PRESENTATION; POXVIRUS INFECTION; MONKEYPOX VIRUS; BRAZIL; IMMUNIZATION;
   PROTECTION; EVASION
AB In 2010, the WHO celebrated the 30th anniversary of the smallpox eradication. Ironically, infections caused by viruses related to smallpox are being increasingly reported worldwide, including Monkeypox, Cowpox, and Vaccinia virus (VACV). Little is known about the human immunological responses elicited during acute infections caused by orthopoxviruses. We have followed VACV zoonotic outbreaks taking place in Brazil and analyzed cellular immune responses in patients acutely infected by VACV. Results indicated that these patients show a biased immune modulation when compared to noninfected controls. Amounts of B cells are low and less activated in infected patients. Although present, T CD4(+) cells are also less activated when compared to noninfected individuals, and so are monocytes/macrophages. Similar results were obtained when Balb/C mice were experimentally infected with a VACV sample isolated during the zoonotic outbreaks. Taking together, the data suggest that zoonotic VACVs modulate specific immune cell compartments during an acute infection in humans.
C1 [Trindade, Giliane de Souza; Quinan, Barbara Resende; Drumond, Betania Paiva; Fernandes Mota, Bruno Eduardo; Kroon, Erna Geessien; Abrahao, Jonatas Santos; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Silva Gomes, Juliana Assis] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Silva Gomes, Juliana Assis; de Araujo, Fernanda Fortes; Siqueira Ferreira, Jaqueline Maria; Correa-Oliveira, Rodrigo; da Fonseca, Flavio Guimaraes] Fundacao Oswaldo Cruz, IRR, BR-30190002 Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto FAMERP, Dept Doencas Infecciosas & Parasitarias, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
RP Abrahao, JS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM jonatas.abrahao@gmail.com; fdafonseca@cpqrr.fiocruz.br
RI Nogueira, Mauricio L/B-7599-2012; Ferreira, Jaqueline/E-4630-2018;
   Abrahao, Jonatas/B-3895-2015; Kroon, Erna Geessien/B-3631-2015; Gomes,
   Juliana A. S./M-4083-2017; Kroon, Erna/V-5444-2019
OI Nogueira, Mauricio L/0000-0003-1102-2419; Ferreira,
   Jaqueline/0000-0002-1779-1975; Abrahao, Jonatas/0000-0001-9420-1791;
   Kroon, Erna Geessien/0000-0003-2721-3826; Gomes, Juliana A.
   S./0000-0002-8332-2907; Mota, Bruno/0000-0003-0348-4875;
   Correa-Oliveira, Rodrigo/0000-0001-6419-9459
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [473205/2009-2]; FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-00299-08]; National Institute of Science and Technology in
   Vaccines (INCTV)
FX The authors thank all patients for their willingness to participate in
   this study and Jaqueline de Oliveira and Luciana Arruda for critical
   reading of the paper. Special thanks to Clari Gandra, for administrative
   support. They also thank health officials and professionals from the
   cities of Serro, Ponte Nova, and Bambui, MG, Brazil. J. A. S. Gomes, G.
   S. Trindade, M. L. Nogueira, E. G. Kroon, R. Correa-Oliveira, and F. G.
   da Fonseca are CNPq fellowship recipients. This work was supported by
   Grants from FAPEMIG (CBB-APQ-00299-08, Universal Demand), CNPq
   (473205/2009-2, Universal Demand) and by the National Institute of
   Science and Technology in Vaccines (INCTV). Other than funding,
   supporting agencies had no role in conducting the study or writing the
   paper.
CR Abrahao JS, 2010, EMERG INFECT DIS, V16, P976, DOI 10.3201/eid1606.091187
   AlYaman F, 1997, PARASITE IMMUNOL, V19, P207, DOI 10.1046/j.1365-3024.1997.d01-198.x
   Amanna IJ, 2006, IMMUNOL REV, V211, P320, DOI 10.1111/j.0105-2896.2006.00392.x
   Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123
   Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100
   Blendon RJ, 2003, NEW ENGL J MED, V348, P426, DOI 10.1056/NEJMsa023184
   Chaudhri G, 2006, J VIROL, V80, P6339, DOI 10.1128/JVI.00116-06
   da Fonseca FG, 2011, FUTURE VIROL, V6, P697, DOI 10.2217/FVL.11.46
   Dasgupta A, 2007, J IMMUNOL, V178, P1654, DOI 10.4049/jimmunol.178.3.1654
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Dunlop LR, 2003, MICROBES INFECT, V5, P1049, DOI 10.1016/S1286-4579(03)00194-1
   Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261
   Essbauer S, 2010, VET MICROBIOL, V140, P229, DOI 10.1016/j.vetmic.2009.08.026
   Fang M, 2005, J IMMUNOL, V175, P6829, DOI 10.4049/jimmunol.175.10.6829
   Frey SE, 2004, NEW ENGL J MED, V350, P324, DOI 10.1056/NEJMp038208
   Haga IR, 2005, PARASITOLOGY, V130, pS11, DOI 10.1017/S0031182005008127
   Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917
   Hammarlund E, 2008, P NATL ACAD SCI USA, V105, P14567, DOI 10.1073/pnas.0800589105
   Johnston JB, 2003, J VIROL, V77, P6093, DOI 10.1128/JVI.77.11.6093-6100.2003
   Kennedy RB, 2009, CURR OPIN IMMUNOL, V21, P314, DOI 10.1016/j.coi.2009.04.004
   Lauterbach H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009659
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Li GY, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-88
   Li P, 2005, J IMMUNOL, V175, P6481, DOI 10.4049/jimmunol.175.10.6481
   Martinez J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000811
   Mathew A, 2000, CLIN IMMUNOL, V96, P100, DOI 10.1006/clim.2000.4887
   Mota BEF, 2010, ARCH VIROL, V155, P1139, DOI 10.1007/s00705-010-0675-3
   Moulton EA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000249
   Moyron-Quiroz JE, 2009, VACCINE, V28, P140, DOI 10.1016/j.vaccine.2009.09.086
   Panchanathan V, 2010, IMMUNOL CELL BIOL, V88, P461, DOI 10.1038/icb.2009.110
   Parker AK, 2007, J VIROL, V81, P4070, DOI 10.1128/JVI.02061-06
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Putz MM, 2006, NAT MED, V12, P1310, DOI 10.1038/nm1457
   Rehm KE, 2010, VIROLOGY, V397, P176, DOI 10.1016/j.virol.2009.11.008
   Rehm KE, 2009, IMMUNOLOGY, V128, P381, DOI 10.1111/j.1365-2567.2009.03120.x
   RILEY E, 1990, IMMUNOL LETT, V25, P221, DOI 10.1016/0165-2478(90)90119-B
   Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049
   Sejvar JJ, 2004, J INFECT DIS, V190, P1833, DOI 10.1086/425039
   Sepkowitz KA, 2003, NEW ENGL J MED, V348, P439, DOI 10.1056/NEJMra022500
   Singh R. K., 2007, Animal Health Research Reviews, V8, P105, DOI 10.1017/S1466252307001259
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912
   Venkatesan G, 2010, VET ITAL, V46, P439
   Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668
   Vorou RM, 2008, CURR OPIN INFECT DIS, V21, P153, DOI 10.1097/QCO.0b013e3282f44c74
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
NR 49
TC 4
Z9 4
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1740-2522
EI 1740-2530
J9 CLIN DEV IMMUNOL
JI Clin. Dev. Immunol.
PY 2012
AR 974067
DI 10.1155/2012/974067
PG 11
WC Immunology
SC Immunology
GA 872OX
UT WOS:000298820300001
PM 22229039
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Luppi, MM
   Luiz, APMF
   Coelho, FM
   Malta, MDC
   Preis, IS
   Ecco, R
   da Fonseca, FG
   Resende, M
AF Luppi, Marcela Miranda
   Moreira Franco Luiz, Ana Paula
   Coelho, Fabiana Magalhaes
   Cordeiro Malta, Marcelo de Campos
   Preis, Ingred Sales
   Ecco, Roselene
   da Fonseca, Flavio Guimaraes
   Resende, Mauricio
TI Identification and isolation of psittacid herpesvirus from psittacids in
   Brazil
SO VETERINARY MICROBIOLOGY
LA English
DT Article
DE Psittacid herpesvirus; PsHV; Cell culture; Histopathology
ID PACHECOS-DISEASE; PURIFICATION; PARROTS
AB Psittacid herpesvirus (PsHV) was isolated from 41 birds kept in captivity in Belo Horizonte, Minas Gerais/Brazil using chicken embryo fibroblasts (CEF) cell cultures. For this study, leukocytes or cloacal swabs of live birds were used. Also, portions of liver, spleen or kidney from birds collected at necropsy were utilized for these tests. PCR tests confirmed the presence of PsHV in 100% of samples. Thirty-three of the PCR products were sequenced and the results disclosed a 99% and 100% identity when compared with other sequences PsHV-1 (AY372243.1 and AF261756.1), previously deposited in GenBank. In addition, histopathology was performed and 19 of the 29 birds contained random multifocal lymphoplasmacytic hepatitis with necrotic foci, suggestive of viral infection. Three samples were examined by electron microscopy to visualize the viral particles obtained from cell culture. The viral structures measured 269 nm in average, had envelopes with an icosahedral capsid and tegument, consistent with herpesvirus. Thus, a total of 41 isolates were obtained from PsHV cell cultivation in CEF, confirming the circulation of the virus between parrots kept in captivity in Belo Horizonte, and affirming the importance of further studies in this area. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Luppi, Marcela Miranda; Moreira Franco Luiz, Ana Paula; Coelho, Fabiana Magalhaes; da Fonseca, Flavio Guimaraes; Resende, Mauricio] Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Virol Comparada, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Cordeiro Malta, Marcelo de Campos] Hosp Vet Fundacao Zoo Bot Belo Horizonte, Belo Horizonte, MG, Brazil.
   [Preis, Ingred Sales; Ecco, Roselene] Univ Fed Minas Gerais, Lab Patol, Dept Clin & Cirurgia, Escola Vet, Belo Horizonte, MG, Brazil.
RP Luppi, MM (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Virol Comparada, Dept Microbiol, Av Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
EM mmluppi@yahoo.com.br
RI Ecco, Roselene/L-4119-2014; Coelho, Fabiana Magalhaes/K-6001-2013
OI Ecco, Roselene/0000-0002-8052-5389; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEMIGMinas Gerais State Research Foundation
   (FAPEMIG)
FX We thank the entire team of Fundacao Zoo-Botanica of Belo Horizonte, the
   CETAS IBAMA BH, and Laboratorio de Virologia Comparada - Departamento de
   Microbiologia - UFMG for contribution in providing samples and
   assistance during the search. CNPq, CAPES and FAPEMIG for financial
   support. And, also Prof. Dr. Erhard F. Kaleta's Klinik fur Vogel,
   Reptilien, Amphibien und Fische - Justus-Liebig-Universitat Giessen for
   kindly provided the sample KS144/79 used as positive control.
CR Altschul S. F., 1997, NUCLEIC ACIDS RES, V48, P984
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   CHO BR, 1979, AVIAN DIS, V24, P268
   DIEFFENBACH CW, 1993, PCR METH APPL, V3, pS30
   Ecco Roselene, 2009, Brazilian Journal of Veterinary Pathology, V2, P85
   Gerlach Helga, 1994, P862
   Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3
   Magnino S, 1996, J VET MED B, V43, P631, DOI 10.1111/j.1439-0450.1996.tb00362.x
   NETO HMA, 2008, THESIS U FEDERAL MIN
   OTOOLE O, 1992, J VET DIAGN INVEST, V4, P203
   Pacheco G, 1930, CR SOC BIOL, V105, P109
   RAMIS A, 1994, AVIAN PATHOL, V23, P643, DOI 10.1080/03079459408419034
   Ritchie BW, 1995, AVIAN VIRUSES FUNCTI, P171
   ROIZMAN B, 2001, FIELDS VIROLOGY, pCH71
   Sambrook J, 1989, MOL CLONING LAB MANU, P1
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Tomaszewski E, 2001, J CLIN MICROBIOL, V39, P533, DOI 10.1128/JCM.39.2.533-538.2001
   Tomaszewski EK, 2003, J VIROL, V77, P11260, DOI 10.1128/JVI.77.20.11260-11267.2003
   TOTH TE, 1992, J VIROL METHODS, V36, P185, DOI 10.1016/0166-0934(92)90150-C
NR 19
TC 5
Z9 5
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
J9 VET MICROBIOL
JI Vet. Microbiol.
PD DEC 29
PY 2011
VL 154
IS 1-2
BP 69
EP 77
DI 10.1016/j.vetmic.2011.06.027
PG 9
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA 858EH
UT WOS:000297778200008
PM 21782357
DA 2020-12-08
ER

PT J
AU Kroon, EG
   Mota, BEF
   Abrahao, JS
   da Fonseca, FG
   Trindade, GD
AF Kroon, Erna Geessien
   Mota, Bruno Eduardo F.
   Abrahao, Jonatas Santos
   da Fonseca, Flavio Guimaraes
   Trindade, Giliane de Souza
TI Zoonotic Brazilian Vaccinia virus: From field to therapy
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Orthopoxvirus; Vaccinia virus (VACV); Bovine vaccinia (BV); Antiviral
   drugs; Zoonosis; Occupational disease
ID ANTIPOXVIRUS COMPOUND ST-246; RIO-DE-JANEIRO; MOLLUSCUM CONTAGIOSUM;
   CANTAGALO VIRUS; BOVINE VACCINIA; CUTANEOUS INFECTIONS; CLINICAL
   DESCRIPTION; CYTOKINE INDUCTION; ANTIVIRAL ACTIVITY; TOPICAL IMIQUIMOD
AB Vaccinia virus (VACV), the prototype species of the Orthopoxvirus (OPV) genus, causes an occupational zoonotic disease in Brazil that is primarily associated with the handling of infected dairy cattle. Cattle and human outbreaks have been described in southeastern Brazil since 1999 and have now occurred in almost half of the territory. Phylogenetic studies have shown high levels of polymorphisms among isolated VACVs, which indicate the existence of at least two genetically divergent clades; this has also been proven in virulence assays in a mouse model system. In humans, VACV infection is characterized by skin lesions, primarily on the hands, accompanied by systemic symptoms such as fever, myalgia, headache. and lymphadenopathy. In this review, we will discuss the virological, epidemiological, ecological and clinical aspects of VACV infection, its diagnosis and compounds that potentially could be used for the treatment of severe cases. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Kroon, Erna Geessien; Mota, Bruno Eduardo F.; Abrahao, Jonatas Santos; da Fonseca, Flavio Guimaraes; Trindade, Giliane de Souza] Univ Fed Minas Gerais UFMG, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Fundacao Oswaldo Cruz, Inst Rene Rachou IRR, BR-30190002 Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais UFMG, Dept Microbiol, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Abrahao, Jonatas/B-3895-2015; Kroon, Erna
   Geessien/B-3631-2015
OI Abrahao, Jonatas/0000-0001-9420-1791; Kroon, Erna
   Geessien/0000-0003-2721-3826; Mota, Bruno/0000-0003-0348-4875
CR Abrahao JS, 2010, EMERG INFECT DIS, V16, P976, DOI 10.3201/eid1606.091187
   Abrahao JS, 2010, J CLIN VIROL, V48, P69, DOI 10.1016/j.jcv.2010.02.001
   Abrahao JS, 2009, FOODBORNE PATHOG DIS, V6, P1141, DOI 10.1089/fpd.2009.0324
   Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Abrahao JS, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-140
   Abrahao JS, 2009, ARCH VIROL, V154, P1551, DOI 10.1007/s00705-009-0470-1
   Altmann SE, 2009, VIROLOGY, V388, P248, DOI 10.1016/j.virol.2009.03.023
   Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375
   Ara M, 2008, J AM ACAD DERMATOL, V58, pS39, DOI 10.1016/j.jaad.2006.04.027
   Arican O, 2006, PEDIATR INT, V48, P403, DOI 10.1111/j.1442-200X.2006.02229.x
   Batista V. H., 2009, VIRUS REV RES, V14, P1
   Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100
   Berhanu A, 2010, VACCINE, V29, P289, DOI 10.1016/j.vaccine.2010.10.039
   Berhanu A, 2009, ANTIMICROB AGENTS CH, V53, P4999, DOI 10.1128/AAC.00678-09
   Bhanuprakash V, 2010, ZOONOSES PUBLIC HLTH, V57, pE149, DOI 10.1111/j.1863-2378.2009.01314.x
   BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991
   Brandao GC, 2010, LETT APPL MICROBIOL, V51, P469, DOI 10.1111/j.1472-765X.2010.02924.x
   Brandao GC, 2010, PHYTOMEDICINE, V17, P926, DOI 10.1016/j.phymed.2010.03.004
   Bray M, 2003, CLIN INFECT DIS, V36, P766, DOI 10.1086/374244
   Bristol N, 2007, DISASTER MED PUBLIC, V1, P11, DOI 10.1097/DMP.0b013e3180690d58
   Brum MCS, 2010, J VET DIAGN INVEST, V22, P143
   Campos RK, 2011, ARCH VIROL, V156, P275, DOI 10.1007/s00705-010-0857-z
   Charrel RN, 2010, VET MICROBIOL, V140, P213, DOI 10.1016/j.vetmic.2009.08.027
   Chaudhri G, 2006, J VIROL, V80, P6339, DOI 10.1128/JVI.00116-06
   Condit RC, 2006, ADV VIRUS RES, V66, P31, DOI 10.1016/S0065-3527(06)66002-8
   Coras B, 2005, LANCET, V365, P446
   Costa R.V.C., 2007, VIRUS REV RES, V12, P33
   D'Anunciacao L., VECTOR BORN IN PRESS
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   da Fonseca FG, 2011, FUTURE VIROL, V6, P697, DOI 10.2217/FVL.11.46
   da Silva AC, 2008, REV SOC BRAS MED TRO, V41, P507, DOI 10.1590/S0037-86822008000500015
   Damaso CRA, 2007, DIAGN MICR INFEC DIS, V57, P39, DOI 10.1016/j.diagmicrobio.2006.07.012
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Dave RS, 2006, VIROLOGY, V348, P489, DOI 10.1016/j.virol.2006.01.013
   De Clercq E, 2002, ANTIVIR RES, V55, P1, DOI 10.1016/S0166-3542(02)00008-6
   de Magalhaes JC, 2001, J BIOL CHEM, V276, P38353, DOI 10.1074/jbc.M100183200
   Dearing MD, 2010, ANN NY ACAD SCI, V1195, P99, DOI 10.1111/j.1749-6632.2010.05452.x
   DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0
   Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9
   Diniz S, 2001, ARQ BRAS MED VET ZOO, V53, P152, DOI 10.1590/S0102-09352001000200003
   Donatele D. M., 2007, Brazilian Journal of Veterinary Research and Animal Science, V44, P275
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Duraffour S, 2007, ANTIVIR THER, V12, P1205
   Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261
   Emonet SF, 2009, INFECT GENET EVOL, V9, P417, DOI 10.1016/j.meegid.2009.03.005
   Erbagci Z, 2005, J DERMATOL TREAT, V16, P353, DOI 10.1080/09546630500375734
   Fang M, 2005, J IMMUNOL, V175, P6829, DOI 10.4049/jimmunol.175.10.6829
   Fenner F., 1989, ORTHOPOXVIRUSES
   Fenner F, 1988, SMALLPOX ITS ERADICA
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Frandsen Jonathan, 2011, Dermatol Online J, V17, P9
   Fundacao Nacional de Saude, 2002, MAN CONTR ROED
   Gammon DB, 2008, J VIROL, V82, P12520, DOI 10.1128/JVI.01528-08
   Geerinck K, 2001, J MED VIROL, V64, P543, DOI 10.1002/jmv.1084
   Grosenbach DW, 2010, P NATL ACAD SCI USA, V107, P838, DOI 10.1073/pnas.0912134107
   Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Henderson D.A., 2009, SAMLLPOX DEATH DIS, P79
   Honlinger B, 2005, BRIT J DERMATOL, V153, P451, DOI 10.1111/j.1365-2133.2005.06731.x
   Huggins J, 2009, ANTIMICROB AGENTS CH, V53, P2620, DOI 10.1128/AAC.00021-09
   Jesus DM, 2009, INT J ANTIMICROB AG, V33, P75, DOI 10.1016/j.ijantimicag.2008.07.015
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Jordan R, 2009, ANTIMICROB AGENTS CH, V53, P1817, DOI 10.1128/AAC.01596-08
   Keith KA, 2003, ANTIMICROB AGENTS CH, V47, P2193, DOI 10.1128/AAC.47.7.2193-2198.2003
   Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   LAI ACK, 1989, MICROB PATHOGENESIS, V6, P219, DOI 10.1016/0882-4010(89)90071-5
   Langhammer S, 2011, ANTIVIR RES, V89, P64, DOI 10.1016/j.antiviral.2010.11.006
   Lanier R, 2010, VIRUSES-BASEL, V2, P2740, DOI 10.3390/v2122740
   Lauterbach H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009659
   Lederman ER, 2007, CLIN INFECT DIS, V44, pE100, DOI 10.1086/517509
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Leite JA, 2007, VIRUS GENES, V35, P531, DOI 10.1007/s11262-007-0133-9
   Lin HY, 2010, J LOW GENIT TRACT DI, V14, P134, DOI 10.1097/LGT.0b013e3181bf1a50
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   LOPES ODS, 1965, AM J TROP MED HYG, V14, P156
   de Oliveira TML, 2010, FOODBORNE PATHOG DIS, V7, P1491, DOI 10.1089/fpd.2010.0597
   MAIBORODA AD, 1982, ACTA VIROL, V26, P288
   McLysaght A, 2003, P NATL ACAD SCI USA, V100, P15655, DOI 10.1073/pnas.2136653100
   Medaglia MLG, 2009, EMERG INFECT DIS, V15, P1142, DOI 10.3201/eid1507.081702
   Medeiros-Silva DC, 2010, BRAZ J INFECT DIS, V14, P129, DOI 10.1590/S1413-86702010000200003
   Megid J, 2008, AM J TROP MED HYG, V79, P647, DOI 10.4269/ajtmh.2008.79.647
   Moss B, 2007, FIELDS VIROLOGY, P2906
   Mota BEF, 2010, ARCH VIROL, V155, P1139, DOI 10.1007/s00705-010-0675-3
   Mota BEF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018924
   Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258
   Myskiw C, 2010, ANTIVIR RES, V88, P304, DOI 10.1016/j.antiviral.2010.10.001
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Neyts J, 2004, ANTIMICROB AGENTS CH, V48, P2267, DOI 10.1128/AAC.48.6.2267-2273.2004
   Nitsche A, 2007, J CLIN VIROL, V40, P160, DOI 10.1016/j.jcv.2007.07.014
   Panchanathan V, 2010, IMMUNOL CELL BIOL, V88, P461, DOI 10.1038/icb.2009.110
   Parker S, 2008, FUTURE VIROL, V3, P595, DOI 10.2217/17460794.3.6.595
   Quenelle DC, 2004, ANTIVIR RES, V63, P33, DOI 10.1016/j.antiviral.2004.02.003
   Quenelle DC, 2003, ANTIMICROB AGENTS CH, V47, P3275, DOI 10.1128/AAC.47.10.3275-3280.2003
   Quenelle DC, 2007, ANTIMICROB AGENTS CH, V51, P4118, DOI 10.1128/AAC.00762-07
   Quixabeira-Santos JC, 2011, EMERG INFECT DIS, V17, P726, DOI 10.3201/eid1704.101581
   Reeves PM, 2011, J VIROL, V85, P21, DOI 10.1128/JVI.01814-10
   Reeves PM, 2005, NAT MED, V11, P731, DOI 10.1038/nm1265
   REITER MJ, 1994, J LEUKOCYTE BIOL, V55, P234
   Saijo M, 2008, JPN J INFECT DIS, V61, P140
   Sbrana E, 2007, AM J TROP MED HYG, V76, P768, DOI 10.4269/ajtmh.2007.76.768
   Schatzmayr HG, 2009, REV SOC BRAS MED TRO, V42, P672, DOI 10.1590/S0037-86822009000600012
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   Silva-Fernandes AT, 2009, J CLIN VIROL, V44, P308, DOI 10.1016/j.jcv.2009.01.007
   Simonetti B.R., 2007, VIRUS REV RES, V12, P32, DOI DOI 10.17525/VRR.V12I1-2.10
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Ferreira JMS, 2008, J GEN VIROL, V89, P2986, DOI 10.1099/vir.0.2008/003947-0
   Skinner RB, 2002, J AM ACAD DERMATOL, V47, pS221, DOI 10.1067/mjd.2002.126578
   Sliva K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-8
   Smee DF, 2004, J INFECT DIS, V190, P1132, DOI 10.1086/422696
   Smith SK, 2009, ANTIMICROB AGENTS CH, V53, P1007, DOI 10.1128/AAC.01044-08
   Stittelaar KJ, 2006, NATURE, V439, P745, DOI 10.1038/nature04295
   Strenger V, 2009, CLIN INFECT DIS, V48, P91, DOI 10.1086/595004
   Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309
   Tarbet EB, 2011, ANTIVIR RES, V90, P126, DOI 10.1016/j.antiviral.2011.03.181
   TESTERMAN TL, 1995, J LEUKOCYTE BIOL, V58, P365
   Theos AU, 2004, CUTIS, V74, P134
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Toutous-Trellu L, 2004, ANN DERMATOL VENER, V131, P445, DOI 10.1016/S0151-9638(04)93637-X
   Trindade GS, 2007, J VIROL METHODS, V141, P198, DOI 10.1016/j.jviromet.2006.12.006
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GD, 2008, J VIROL METHODS, V152, P63, DOI 10.1016/j.jviromet.2008.05.028
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
   Tulman ER, 2006, J VIROL, V80, P9244, DOI 10.1128/JVI.00945-06
   Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948
   Valadares YM, 2009, Z NATURFORSCH C, V64, P813
   Vestergaard L, 2008, ACTA DERM-VENEREOL, V88, P188, DOI 10.2340/00015555-0375
   Vigne S, 2008, ANTIVIR THER, V13, P357
   Vigne S, 2009, ANTIMICROB AGENTS CH, V53, P2579, DOI 10.1128/AAC.01626-08
   Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668
   Wagner TL, 1999, CELL IMMUNOL, V191, P10, DOI 10.1006/cimm.1998.1406
   Wilson D. E., 2005, MAMMAL SPECIES WORLD, P142
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
   Yang G, 2005, J VIROL, V79, P13139, DOI 10.1128/JVI.79.20.13139-13149.2005
NR 138
TC 54
Z9 55
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD NOV
PY 2011
VL 92
IS 2
BP 150
EP 163
DI 10.1016/j.antiviral.2011.08.018
PG 14
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 853LG
UT WOS:000297427200003
PM 21896287
DA 2020-12-08
ER

PT J
AU Costa, EA
   Luppi, MM
   Malta, MDC
   Luiz, APMF
   de Araujo, MR
   Coelho, FM
   da Fonseca, FG
   Ecco, R
   Resende, M
AF Costa, Erica Azevedo
   Luppi, Marcela Miranda
   Cordeiro Malta, Marcelo de Campos
   Moreira Franco Luiz, Ana Paula
   de Araujo, Marina Rios
   Coelho, Fabiana Magalhaes
   da Fonseca, Flavio Guimaraes
   Ecco, Roselene
   Resende, Mauricio
TI Outbreak of Human Herpesvirus Type 1 Infection in Nonhuman Primates
   (Callithrix penincillata)
SO JOURNAL OF WILDLIFE DISEASES
LA English
DT Article
DE Brazil; Callithrix penincillata; human herpesvirus 1; intranuclear
   inclusion body; nonhuman primates; stomatitis
ID SIMPLEX INFECTION; VIRUS; JACCHUS
AB Human herpesvirus type 1 (HHV-1) is widely dispersed among the human population. Although infection is often asymptomatic in humans, nonhuman primates develop a severe and often fatal infection. In August 2006, 13 black-tufted marmosets (Callithrix penincillata) from a group of 14 presented with clinical apathy, anorexia, and ataxia. Physical examination revealed conjunctivitis, erosive or ulcerative lesions on the skin, and swollen lymph nodes. Of the 14 animals captured, 10 died. Grossly, ulcers and erosions were observed on the skin of face, nasal planum, lips, and oral mucosa. Histologically, superficial vesicular and erosive stomatitis with associated basophilic intranuclear inclusion bodies in the squamous epithelium were observed. Swabs from oral lesions and tissue samples from necropsied animals were positive for HHV-1 by nested polymerase chain reaction for eight animals.
C1 [Costa, Erica Azevedo; de Araujo, Marina Rios; Ecco, Roselene] Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia Vet, BR-31270901 Belo Horizonte, MG, Brazil.
   [Luppi, Marcela Miranda; Cordeiro Malta, Marcelo de Campos] Fundacao Zoo Bot Belo Horizonte, BR-31365450 Belo Horizonte, MG, Brazil.
   [Moreira Franco Luiz, Ana Paula; Coelho, Fabiana Magalhaes; da Fonseca, Flavio Guimaraes; Resende, Mauricio] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Costa, EA (corresponding author), Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia Vet, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM azevedoec@yahoo.com.br
RI Ecco, Roselene/L-4119-2014; Coelho, Fabiana Magalhaes/K-6001-2013
OI Ecco, Roselene/0000-0002-8052-5389; 
FU Fundaao de Amparo a Pesquisa (FAPEMIG)Minas Gerais State Research
   Foundation (FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Coordenaao de Aperfeioamento de Pessoal de Nivel
   Superior (CAPES)CAPES
FX This study was supported by the Fundaao de Amparo a Pesquisa (FAPEMIG),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   Coordenaao de Aperfeioamento de Pessoal de Nivel Superior (CAPES).
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   CASAGRANDE RA, 2007, THESIS U SAO PAULO S
   Hatt JM, 2004, J ZOO WILDLIFE MED, V35, P387, DOI 10.1638/03-041
   Huemer HP, 2002, EMERG INFECT DIS, V8, P639, DOI 10.3201/eid0806.010341
   HUNT R, 2010, MICROBIOL IMMUNOL, pCH11
   Kik MJL, 2005, J ZOO WILDLIFE MED, V36, P131, DOI 10.1638/03-004
   Landolfi JA, 2005, J VET DIAGN INVEST, V17, P369, DOI 10.1177/104063870501700412
   Matz-Rensing K, 2003, VET PATHOL, V40, P405, DOI 10.1354/vp.40-4-405
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schmutzhard J, 2004, J CLIN VIROL, V29, P120, DOI 10.1016/S1386-6532(03)00113-6
   Schrenzel MD, 2003, J MED PRIMATOL, V32, P7, DOI 10.1034/j.1600-0684.2003.01040.x
NR 12
TC 7
Z9 7
U1 0
U2 7
PU WILDLIFE DISEASE ASSOC, INC
PI LAWRENCE
PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA
SN 0090-3558
J9 J WILDLIFE DIS
JI J. Wildl. Dis.
PD JUL
PY 2011
VL 47
IS 3
BP 690
EP 693
DI 10.7589/0090-3558-47.3.690
PG 4
WC Veterinary Sciences
SC Veterinary Sciences
GA 793CR
UT WOS:000292798500022
PM 21719834
DA 2020-12-08
ER

PT J
AU da Fonseca, FG
   Kroon, EG
   Nogueira, ML
   Trindade, GD
AF da Fonseca, Flavio Guimaraes
   Kroon, Erna Geessien
   Nogueira, Mauricio Lacerda
   Trindade, Giliane de Souza
TI Zoonotic vaccinia virus outbreaks in Brazil
SO FUTURE VIROLOGY
LA English
DT Review
DE bovine vaccinia; orthopoxvirus; phylogenetic analysis; vaccinia virus;
   zoonosis
ID GENERALIZED COWPOX INFECTION; RIO-DE-JANEIRO; HUMAN MONKEYPOX; CLINICAL
   CHARACTERISTICS; SMALLPOX VACCINES; CANTAGALO VIRUS; UNITED-STATES;
   RISK-FACTORS; COTIA VIRUS; ORTHOPOXVIRUS
AB The vaccinia virus (VACV) was used as a live vaccine during the WHO-led smallpox eradication campaign in the second half of the 20th century. The program culminated with the obliteration of the disease, one of the most important achievements in modern medicine. Interestingly, one of the key factors in the successful vaccination campaign - the VACV itself - is poorly understood in relation to its natural reservoirs, evolutionary history and origins, being frequently considered extinct as a naturally occurring virus. Nevertheless, orthopoxviruses other than variola virus have been known to circulate in Brazil since the early 1960s. More specifically, VACV has been associated with naturally acquired infections in humans, cattle and possibly other reservoirs since 1999, when bovine vaccinia outbreaks started to be consistently described year after year. In this article, we list and discuss the most important VACV outbreaks that have occurred in Brazil in the last 20 years. Phylogenetic issues are considered, as the latest studies point to large genetic variance among isolates. Clinical and epidemiological data, both published and new, are presented.
C1 [da Fonseca, Flavio Guimaraes; Kroon, Erna Geessien; Trindade, Giliane de Souza] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Fundacao Oswaldo Cruz, IRR, BR-30190002 Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto FAMERP, Dept Doencas Infecciosas & Parasitarias, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
RI Nogueira, Mauricio L/B-7599-2012; Kroon, Erna/V-5444-2019; Kroon,
   Erna/B-3631-2015
OI Nogueira, Mauricio L/0000-0003-1102-2419; Kroon,
   Erna/0000-0003-2721-3826
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [473205/2009-2]
FX FG da Fonseca, EG Kroon, ML Nogueira and G de Souza Trindade are CNPq
   fellowship recipients. Parts of the work described in this article were
   supported by a CNPq grant, process number 473205/2009-2. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abrahao JS, 2010, EMERG INFECT DIS, V16, P976, DOI 10.3201/eid1606.091187
   Abrahao JS, 2010, J CLIN VIROL, V48, P69, DOI 10.1016/j.jcv.2010.02.001
   Abrahao JS, 2009, FOODBORNE PATHOG DIS, V6, P1141, DOI 10.1089/fpd.2009.0324
   Abrahao JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007428
   Baxby D, 1997, ARCH VIROL, P1
   Brum MCS, 2010, J VET DIAGN INVEST, V22, P143
   Campos RK, 2011, ARCH VIROL, V156, P275, DOI 10.1007/s00705-010-0857-z
   Condit RC, 2006, ADV VIRUS RES, V66, P31, DOI 10.1016/S0065-3527(06)66002-8
   Coras B, 2005, LANCET, V365, P446
   Croft DR, 2007, EMERG INFECT DIS, V13, P1150, DOI 10.3201/eid1308.061365
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Damon I, 2007, FIELDS VIROLOGY, P2947
   Dhar AD, 2004, NEW ENGL J MED, V350, P361, DOI 10.1056/NEJMoa031467
   Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Esposito JJ, 2006, SCIENCE, V313, P807, DOI 10.1126/science.1125134
   Essbauer S, 2010, VET MICROBIOL, V140, P229, DOI 10.1016/j.vetmic.2009.08.026
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Fuller T, 2011, ECOHEALTH, V8, P14, DOI 10.1007/s10393-010-0355-5
   Haase O, 2011, BRIT J DERMATOL, V164, P1116, DOI 10.1111/j.1365-2133.2011.10226.x
   Haenssle HA, 2006, J AM ACAD DERMATOL, V54, pS1, DOI 10.1016/j.jaad.2005.09.040
   Honlinger B, 2005, BRIT J DERMATOL, V153, P451, DOI 10.1111/j.1365-2133.2005.06731.x
   Huhn GD, 2005, CLIN INFECT DIS, V41, P1742, DOI 10.1086/498115
   Hutson CL, 2007, AM J TROP MED HYG, V76, P757, DOI 10.4269/ajtmh.2007.76.757
   JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551
   Lederman ER, 2007, PEDIATR INFECT DIS J, V26, P740, DOI 10.1097/INF.0b013e31806211bf
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Li Y, 2007, P NATL ACAD SCI USA, V104, P15787, DOI 10.1073/pnas.0609268104
   Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0
   LOPES ODS, 1965, AM J TROP MED HYG, V14, P156
   de Oliveira TML, 2010, FOODBORNE PATHOG DIS, V7, P1491, DOI 10.1089/fpd.2010.0597
   MacNeil A, 2009, AM J TROP MED HYG, V80, P503, DOI 10.4269/ajtmh.2009.80.503
   Medaglia MLG, 2009, EMERG INFECT DIS, V15, P1142, DOI 10.3201/eid1507.081702
   Megid J, 2008, AM J TROP MED HYG, V79, P647, DOI 10.4269/ajtmh.2008.79.647
   Moss B., 2007, VIROLOGY, V2905-2946
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   Mota BEF, 2010, ARCH VIROL, V155, P1139, DOI 10.1007/s00705-010-0675-3
   Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Paran N, 2009, HUM VACCINES, V5, P824, DOI 10.4161/hv.10295
   Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299
   Reynolds MG, 2007, EMERG INFECT DIS, V13, P1332, DOI 10.3201/eid1309.070175
   Reynolds MG, 2006, J INFECT DIS, V194, P773, DOI 10.1086/505880
   Reynolds MG, 2010, AM J TROP MED HYG, V82, P746, DOI 10.4269/ajtmh.2010.09-0716
   SAMBYAL DS, 1983, INDIAN VET J, V60, P327
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   Sejvar JJ, 2004, J INFECT DIS, V190, P1833, DOI 10.1086/425039
   SILVA P L D, 1986, Arquivo Brasileiro de Medicina Veterinaria e Zootecnia, V38, P323
   Silva-Fernandes AT, 2009, J CLIN VIROL, V44, P308, DOI 10.1016/j.jcv.2009.01.007
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
   UEDA Y, 1995, VIROLOGY, V210, P67, DOI 10.1006/viro.1995.1317
   Venkatesan G, 2010, VET ITAL, V46, P439
   Vorou RM, 2008, CURR OPIN INFECT DIS, V21, P153, DOI 10.1097/QCO.0b013e3282f44c74
   Wellenberg GJ, 2002, VET MICROBIOL, V88, P27, DOI 10.1016/S0378-1135(02)00098-6
NR 61
TC 9
Z9 9
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD JUN
PY 2011
VL 6
IS 6
BP 697
EP 707
DI 10.2217/FVL.11.46
PG 11
WC Virology
SC Virology
GA 788DI
UT WOS:000292425200008
DA 2020-12-08
ER

PT J
AU de Souza, JG
   da Fonseca, FG
   Martins, ML
   Martins, CPS
   de Carvalho, LD
   Coelho-dos-Reis, JGA
   Carneiro-Proietti, ABF
   Martins, OA
   Barbosa-Stancioli, EF
AF de Souza, Jaqueline Gontijo
   da Fonseca, Flavio Guimaraes
   Martins, Marina Lobato
   Silveira Martins, Camila Pacheco
   de Carvalho, Luciana Debortoli
   Alves Coelho-dos-Reis, Jordana Grazziela
   Freitas Carneiro-Proietti, Anna Barbara
   Martins-Filho, Olindo Assis
   Barbosa-Stancioli, Edel Figueiredo
CA GIPH
TI Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic
   carriers, patients with rheumatologic disease or with HAM/TSP do not
   correlate with HTLV-1 proviral load
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE HTLV-1; Tax; HAM/TSP; Rheumatologic diseases
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL LEUKEMIA; PERIPHERAL-BLOOD;
   PROTEINS
AB Background: HTLV-1 infects millions of people around the world and induces myelopathy (HAM/TSP), adult T-cell leukemia (ATL) or other inflammatory or rheumatologic diseases. The host-virus interaction causes asymptomatic carriers to develop HAM/TSP. Biomarkers are needed to predict patients who are at risk for HAM/TSP. Tax is highly immunogenic and is a major target protein recognized by cytotoxic T lymphocytes. Anti-Tax antibodies are involved in HAM/TSP pathogenesis.
   Objectives: To assess anti-Tax IgG reactivity with a flow cytometry assay (FCA) using an infection/transfection system with Vaccinia virus and pLW44/Tax-expressing Tax and to correlate the anti-Tax response and the HTLV-1 proviral load.
   Study design: : We enrolled 81 individuals: 9 HTLV-1 seronegative (NP) and 72 HTLV-1 positive (23 HTLV-1 asymptomatic carriers (AC), 12 oligosymptomatic patients (OL), 7 with rheumatologic diseases (DR) and 30 with HAM/TSP (HT)). Anti-Tax reactivity was assessed by FCA, and HTLV-1 proviral load was measured with real time PCR.
   Results: The HT and DR groups showed greater anti-Tax IgG reactivity (p < 0.001 and p < 0.05 comparing HT to the OL and AC group, respectively; p < 0.05 comparing DR to the OL group), and the reactivity in the DR + HT group was significantly different when compared to the AC group (p < 0.05) and to the OL group (p < 0.001). The proviral load was higher in the HT group compared to the OL (p < 0.001) and in the HT + DR group compared to OL (p < 0.001). There was no correlation between anti-Tax IgG reactivity and proviral load in any of the HTLV-1-infected groups.
   Conclusion: These findings suggest that although anti-Tax IgG reactivity and the HTLV-1 proviral load are important markers of the development of HTLV-1-associated diseases, their levels are not correlated. (C) 2010 Elsevier B.V. All rights reserved.
C1 [de Souza, Jaqueline Gontijo; Silveira Martins, Camila Pacheco; de Carvalho, Luciana Debortoli; Alves Coelho-dos-Reis, Jordana Grazziela; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Biol Microrganismos Intracelulares, BR-31270901 Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Comparada, BR-31270901 Belo Horizonte, MG, Brazil.
   [Martins, Marina Lobato] Fundacao HEMOMINAS, Belo Horizonte, MG, Brazil.
   [Martins-Filho, Olindo Assis] Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [de Souza, Jaqueline Gontijo; Martins, Marina Lobato; Silveira Martins, Camila Pacheco; de Carvalho, Luciana Debortoli; Alves Coelho-dos-Reis, Jordana Grazziela; Freitas Carneiro-Proietti, Anna Barbara; Martins-Filho, Olindo Assis; Barbosa-Stancioli, Edel Figueiredo; GIPH] Interdisciplinary HTLV Res Grp, Belo Horizonte, MG, Brazil.
RP Barbosa-Stancioli, EF (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Biol Microrganismos Intracelulares, Ave Antonio Carlos 6627,POB 864, BR-31270901 Belo Horizonte, MG, Brazil.
EM edelfb@mono.icb.ufmg.br
RI Barbosa-Stancioli, Edel F/J-7230-2012
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Martins-Filho, Olindo
   Assis/0000-0002-5494-4889
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG) [APQ-02396-07];
   CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX The authors are grateful for the financial support provided by FAPEMIG -
   Grant APQ-02396-07, CNPq and CAPES. Barbosa-Stancioli, E.F.,
   Martins-Filho, O.A., Da Fonseca, F.G., Souza, J.G., Coelho-dos-Reis,
   J.G.A., Debortoli, L.C. and Martins, C.P.S. received fellowships from
   CNPq.
CR Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0
   Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2
   Best I, 2006, CLIN EXP IMMUNOL, V146, P226, DOI 10.1111/j.1365-2249.2006.03208.x
   Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76
   Burbelo PD, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-96
   Carneiro-Proietti ABF, 2002, J BIOMED SCI, V9, P587, DOI 10.1007/BF02254986
   Cruz Boris A., 2005, Rev. Bras. Reumatol., V45, P71, DOI 10.1590/S0482-50042005000200005
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0
   Kazanji Mirdad, 2003, Cad. Saúde Pública, V19, P1227, DOI 10.1590/S0102-311X2003000500002
   KUBOTA R, 1993, J NEUROIMMUNOL, V42, P147, DOI 10.1016/0165-5728(93)90004-I
   Kubota R, 1998, J IMMUNOL, V161, P482
   LAL RB, 1994, J INFECT DIS, V169, P496, DOI 10.1093/infdis/169.3.496
   Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509
   Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4
   MATHIEUX R, 2000, J CLIN MICROBIOL, V38, P4049
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824
   NORAZ N, 1993, VIROLOGY, V193, P80, DOI 10.1006/viro.1993.1105
   OSAME M, 1999, J ACQ IMMUN DEF SYND, V20, pPA22
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Rouet F, 2001, J CLIN MICROBIOL, V39, P1247, DOI 10.1128/JCM.39.4.1247-1253.2001
   Royer-Leveau C, 2002, J VIROL METHODS, V105, P133, DOI 10.1016/S0166-0934(02)00097-6
   SOUZA JG, 2010, J VIROL METHODS, V166, P65
   STEVEN J, 2002, J INFECT DIS, V186, P187
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608
   Yakova M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-4
NR 30
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JAN
PY 2011
VL 50
IS 1
BP 13
EP 18
DI 10.1016/j.jcv.2010.09.007
PG 6
WC Virology
SC Virology
GA 704YV
UT WOS:000286094300004
PM 20951636
DA 2020-12-08
ER

PT J
AU de Souza, JG
   da Fonseca, FG
   Martins, OA
   Teixeira-Carvalho, A
   Martins, CPS
   Carvalho, LD
   Coelho-dos-Reis, JGA
   Barbosa-Stancioli, EF
AF de Souza, Jaqueline Gontijo
   da Fonseca, Flavio Guimaraes
   Martins-Filho, Olindo Assis
   Teixeira-Carvalho, Andrea
   Silveira Martins, Camila Pacheco
   Carvalho, Luciana Debortoli
   Alves Coelho-dos-Reis, Jordana Grazziela
   Barbosa-Stancioli, Edel Figueiredo
CA GIPH
TI Diagnostic tool based on an HTLV-1-Tax expression system in eukaryotic
   cells using a poxvirus vector
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HTLV-1; Tax; HAM/TSP; Vaccinia virus; Infection/transfection system
ID VIRUS TYPE-I; TYPE-1 HTLV-1; TAX; LEUKEMIA; ANTIBODIES; GENE
AB Human T-Iymphotropic virus 1 (HTLV-1) induces an immune-mediated inflammatory disease affecting the nervous system that eventually is accompanied by ocular, rheumatic and dermatologic manifestations (HTLV-1 associated myelopathy/tropical spastic paraparesis, or HAM/TSP). Proviral load and HTLV-1 protein expression, mainly of Tax, is correlated with disease progression and induction of host-virus equilibrium breakdown that, reportedly, involves the presence of Tax-specific cytotoxic T lymphocytes (CTL), T regulatory cells and anti-Tax antibodies. Based on knowledge of anti-Tax antibodies as markers of disease progression, the objectives of this study were both to design an infection/transfection system using the Vaccinia virus and a tax-encoding plasmid for the expression of Tax protein as well as to use this cell support to evaluate anti-Tax IgG by flow cytometry. The flow cytometry assay was standardized using pooled sera from each test group (negative, asymptomatic and HAM/TSP patients). The HAM/TSP group presented higher IgG anti-Tax reactivity (above 70%) than the asymptomatic group (nearly 40% reactivity). The data indicate that the infection/transfection system is useful for assessing Tax expression. This is a promising assay for use as a diagnostic tool to detect IgG anti-Tax and monitor HTLV-1 infected individuals. (C) 2010 Elsevier B.V. All rights reserved.
C1 [de Souza, Jaqueline Gontijo; da Fonseca, Flavio Guimaraes; Silveira Martins, Camila Pacheco; Carvalho, Luciana Debortoli; Alves Coelho-dos-Reis, Jordana Grazziela; Barbosa-Stancioli, Edel Figueiredo] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andrea] Fundacao Osvaldo Cruz, Inst Rene Rachou, Belo Horizonte, MG, Brazil.
RP Barbosa-Stancioli, EF (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM edelfb@mono.icb.ufmg.br
RI Barbosa-Stancioli, Edel F/J-7230-2012
OI Barbosa-Stancioli, Edel F/0000-0001-6584-4333; Martins-Filho, Olindo
   Assis/0000-0002-5494-4889
FU Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)Minas Gerais
   State Research Foundation (FAPEMIG) [APQ-02396-07]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacdo de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES;
   Interdisciplinary HTLV Research Group (GIPH); Coelho-dos-Reis;
   Universidade Federal de Minas Gerais (UFMG); HEMOMINAS foundation
FX Financial support for this study was provided by Fundacao de Amparo a
   Pesquisa de Minas Gerais (FAPEMIG) Grant APQ-02396-07, Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq) and Coordenacdo de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). Barbosa-Stancioli,
   E.F., Martins-Filho, OA., Da Fonseca, F.G., Souza, J.G., Debortoli, L.C.
   and Martins, C.P.S. received fellowships from CNPq and Coelho-dos-Reis,
   J.G.A. from CAPES. The authors also thank the Universidade Federal de
   Minas Gerais (UFMG), the HEMOMINAS foundation and its president, Dr.
   Anna Barbara Freitas Carneiro Proietti, for supporting the
   Interdisciplinary HTLV Research Group (GIPH), which has contributed
   steadily to research on HTLV.
CR Akimoto M, 2007, J MED VIROL, V79, P977, DOI 10.1002/jmv.20807
   Coelho-dos-Reis JGA, 2009, J VIROL METHODS, V160, P138, DOI 10.1016/j.jviromet.2009.05.007
   ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76
   Burbelo PD, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-96
   EARL PL, 1991, GENERATION RECOMBINA
   Feuer G, 2005, ONCOGENE, V24, P5996, DOI 10.1038/sj.onc.1208971
   GESSAIN A, 1985, LANCET, V2, P407
   Hisada M, 2002, CLIN INFECT DIS, V34, P1551, DOI 10.1086/340537
   JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0
   JEANG KT, 1987, J VIROL, V61, P708, DOI 10.1128/JVI.61.3.708-713.1987
   KEIL W, 1989, VIROLOGY, V170, P392, DOI 10.1016/0042-6822(89)90430-3
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAL RB, 1994, J INFECT DIS, V169, P496, DOI 10.1093/infdis/169.3.496
   LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629
   Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509
   LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490
   MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984
   MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273
   Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341
   Moss B, 1990, Semin Immunol, V2, P317
   NORAZ N, 1993, VIROLOGY, V193, P80, DOI 10.1006/viro.1993.1105
   OSAME M, 1986, LANCET, V1, P1031
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0
   ROSE JK, 1991, BIOTECHNIQUES, V10, P520
   Royer-Leveau C, 2002, J VIROL METHODS, V105, P133, DOI 10.1016/S0166-0934(02)00097-6
   RUDOLPH DL, 1994, CLIN DIAGN LAB IMMUN, V1, P176, DOI 10.1128/CDLI.1.2.176-181.1994
   SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 35
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2010
VL 166
IS 1-2
BP 65
EP 71
DI 10.1016/j.jviromet.2010.02.021
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 601AF
UT WOS:000278029600010
PM 20219542
DA 2020-12-08
ER

PT J
AU Medeiros-Silva, DC
   Moreira-Silva, EAD
   Gomes, JDS
   da Fonseca, FG
   Correa-Oliveira, R
AF Medeiros-Silva, Daniela Carla
   dos Santos Moreira-Silva, Eduardo Augusto
   Silva Gomes, Juliana de Assis
   da Fonseca, Flavio Guimaraes
   Correa-Oliveira, Rodrigo
TI Clinical signs, diagnosis, and case reports of Vaccinia virus infections
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Poxviridae infections; virology; outbreaks; zoonoses; Vaccinia virus
ID RIO-DE-JANEIRO; COTIA VIRUS; LABORATORY WORKER; BOVINE VACCINIA;
   POXVIRUS; HUMANS; CATTLE; ASSAY; TRANSMISSION; MONKEYPOX
AB Vaccinia virus is responsible for a zoonosis that usually affects cattle and human beings in Brazil. The initial clinical signs of the infection are focal red skin areas, fever, and general symptoms similar to those of a cold. Then, pustules and ulcerated lesions surrounded by edema and erythema follow, as well as local lymphadenopathy that can last for weeks. Cure and healing of the lesions occur over several weeks, leaving a typical scar in the skin of people and animals affected. The infection definitive diagnosis is made through morphological characterization of the virus by use of electron microscopy, followed by PCR for specific viral genes. Since 1963, circulating orthopoxviruses in infectious outbreaks in several regions of Brazil have been reported. Later, the etiological agent of those infections was characterized as samples of Vaccinia virus. In addition, the widespread use of those viruses in research laboratories and mass vaccination of militaries have contributed to increase the cases of those infections worldwide. Thus, several epidemiological and clinical studies are required, as well as studies of viral immunology, public health, and economic impact, because little is known about those Vaccinia virus outbreaks in Brazil.
C1 [Medeiros-Silva, Daniela Carla; dos Santos Moreira-Silva, Eduardo Augusto; Silva Gomes, Juliana de Assis; da Fonseca, Flavio Guimaraes; Correa-Oliveira, Rodrigo] Fundacao Oswaldo Cruz Fiocruz, CPqRR, Belo Horizonte, MG, Brazil.
   [Medeiros-Silva, Daniela Carla; dos Santos Moreira-Silva, Eduardo Augusto] Univ Fed Minas Gerais, ICB, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
   [Silva Gomes, Juliana de Assis] Univ Fed Minas Gerais, ICB, Dept Morphol, Belo Horizonte, MG, Brazil.
   [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Biol Sci Inst ICB, Dept Microbiol, Belo Horizonte, MG, Brazil.
RP Moreira-Silva, EAD (corresponding author), Av Dom Orione 75, BR-31310020 Belo Horizonte, MG, Brazil.
EM duduaugusto1@cpqrr.fiocruz.br
RI Gomes, Juliana A. S./M-4083-2017
OI Gomes, Juliana A. S./0000-0002-8332-2907; Correa-Oliveira,
   Rodrigo/0000-0001-6419-9459
CR ANDREEV V C, 1969, Dermatologia Internationalis, V8, P5
   BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P537
   Condit RC, 2006, ADV VIRUS RES, V66, P31, DOI 10.1016/S0065-3527(06)66002-8
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2007, DIAGN MICR INFEC DIS, V57, P39, DOI 10.1016/j.diagmicrobio.2006.07.012
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Egan C, 2004, J CLIN MICROBIOL, V42, P5409, DOI 10.1128/JCM.42.11.5409-5411.2004
   ESPOSITO JJ, 1980, J GEN VIROL, V47, P37, DOI 10.1099/0022-1317-47-1-37
   Fenner F, 1988, SMALLPOX ITS ERADICA
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Hu G, 2004, AM J OPHTHALMOL, V137, P554, DOI 10.1016/j.ajo.2003.09.013
   HUMPHREY DC, 1963, AM J OBSTET GYNECOL, V86, P460
   *ICTVDB MAN, 2006, ICTVDB UN VIR DAT VE
   Lane JM, 2003, CLIN INFECT DIS, V37, P281, DOI 10.1086/377236
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lewis FMT, 2006, EMERG INFECT DIS, V12, P134, DOI 10.3201/eid1201.051126
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   Loeb M, 2003, Can Commun Dis Rep, V29, P134
   LOPES ODS, 1965, AM J TROP MED HYG, V14, P156
   Marques JT, 2001, VIRUS GENES, V23, P291, DOI 10.1023/A:1012521322845
   Melchreit R., 2008, Morbidity and Mortality Weekly Report, V57, P401
   Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6
   MOSS B, 2001, PM FIELDS VIROLOGY
   Moussatche N, 2003, EMERG INFECT DIS, V9, P724
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299
   Rupprecht CE, 2001, NEW ENGL J MED, V345, P582, DOI 10.1056/NEJMoa010560
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   Simonetti B.R., 2007, VIRUS REV RES, V12, P32, DOI DOI 10.17525/VRR.V12I1-2.10
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GD, 2008, J VIROL METHODS, V152, P63, DOI 10.1016/j.jviromet.2008.05.028
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
   UEDA Y, 1995, VIROLOGY, V210, P67, DOI 10.1006/viro.1995.1317
   UEDA Y, 1978, J GEN VIROL, V40, P263, DOI 10.1099/0022-1317-40-2-263
   Wlodaver CG, 2004, J CLIN VIROL, V29, P167, DOI 10.1016/S1386-6532(03)00118-5
NR 42
TC 12
Z9 13
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2010
VL 14
IS 2
BP 129
EP 134
DI 10.1016/S1413-8670(10)70025-8
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 613DY
UT WOS:000278959300003
PM 20563437
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bicalho, KA
   Gilioli, R
   Demolin, DM
   Gomes, AA
   Da Fonseca, FG
   Volpini, C
   Romanha, AJ
AF Bicalho, K. A.
   Gilioli, R.
   Demolin, D. M.
   Gomes, A. A.
   Da Fonseca, F. G.
   Volpini, C.
   Romanha, A. J.
TI Occurrence of Mouse Parvovirus and Mouse Minute Virus in Mouse Colonies
   in Facilities in Minas Gerais, Brazil
SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE
LA English
DT Meeting Abstract
C1 [Bicalho, K. A.; Gomes, A. A.; Volpini, C.; Romanha, A. J.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Parasitol Celular & Mol, BR-30190 Belo Horizonte, MG, Brazil.
   [Gilioli, R.; Demolin, D. M.] Univ Estadual Campinas, Ctr Multidisciplinar Invest Biol CEMIB, Campinas, SP, Brazil.
   [Da Fonseca, F. G.] Univ Fed Minas Gerais, Dept Microbiol ICB, Belo Horizonte, MG, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI MEMPHIS
PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA
SN 1559-6109
J9 J AM ASSOC LAB ANIM
JI J. Amer. Assoc. Lab. Anim. Sci.
PD SEP
PY 2009
VL 48
IS 5
BP 624
EP 625
PG 2
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 502SI
UT WOS:000270480000314
DA 2020-12-08
ER

PT J
AU Costa, EA
   Bomfim, MRQ
   da Fonseca, FG
   Drumond, BP
   Coelho, FM
   Vasconcelos, AC
   Furtini, R
   Paixao, TA
   Tsolis, RM
   Santos, RL
   Resende, M
AF Costa, Erica A.
   Bomfim, Maria Rosa Q.
   da Fonseca, Flavio G.
   Drumond, Betania P.
   Coelho, Fabiana Magalhaes
   Vasconcelos, Anilton C.
   Furtini, Ronaldo
   Paixao, Tatiane A.
   Tsolis, Renee M.
   Santos, Renato L.
   Resende, Mauricio
TI Ovine Herpesvirus 2 Infection in Foal, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID MALIGNANT CATARRHAL FEVER; VIRUS
C1 [Costa, Erica A.] Univ Fed Minas Gerais, Lab Patol Mol, Dept Clin & Cirurgia Vet, Escola Vet, BR-30123970 Belo Horizonte, MG, Brazil.
   [Furtini, Ronaldo] Inst Mineiro Agropecuaria, Belo Horizonte, MG, Brazil.
   [Tsolis, Renee M.] Univ Calif Davis, Davis, CA 95616 USA.
RP Costa, EA (corresponding author), Univ Fed Minas Gerais, Lab Patol Mol, Dept Clin & Cirurgia Vet, Escola Vet, Av Antonio Carlos 6627, BR-30123970 Belo Horizonte, MG, Brazil.
EM azevedoec@yahoo.com.br
RI brasileira, Inct Pecuaria/J-9542-2013; Coelho, Fabiana
   Magalhaes/K-6001-2013; de Lima Santos, Renato/A-1134-2008; Paixao,
   Tatiane/A-2871-2013; BOMFIM, MARIA ROSA/AAT-8359-2020
OI de Lima Santos, Renato/0000-0002-4830-0470; Paixao,
   Tatiane/0000-0001-8284-9902; BOMFIM, MARIA ROSA/0000-0001-5738-3952;
   Tsolis, Renee/0000-0001-9131-6657
CR *AN HLTH AUSTR, MAL CAT FEV AUSTR SI
   Anderson IE, 2007, J COMP PATHOL, V136, P156, DOI 10.1016/j.jcpa.2007.01.007
   BAXTER SIF, 1993, ARCH VIROL, V132, P145, DOI 10.1007/BF01309849
   Echeverria MG, 2003, REV SCI TECH OIE, V22, P1029, DOI 10.20506/rst.22.3.1458
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Katz J, 1991, J Vet Diagn Invest, V3, P193
   Li H, 2001, J GEN VIROL, V82, P227, DOI 10.1099/0022-1317-82-1-227
   OTOOLE D, 1995, J VET DIAGN INVEST, V7, P108, DOI 10.1177/104063879500700118
   Simon S, 2003, J GEN VIROL, V84, P2009, DOI 10.1099/vir.0.19048-0
   Varrasso A, 2001, AUST VET J, V79, P563, DOI 10.1111/j.1751-0813.2001.tb10751.x
NR 10
TC 5
Z9 5
U1 0
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2009
VL 15
IS 5
BP 844
EP 845
DI 10.3201/eid1505.081664
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 437WY
UT WOS:000265518800041
PM 19402994
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Trindade, GS
   Guedes, MIC
   Drumond, BP
   Mota, BEF
   Abrahao, JS
   Lobato, ZIP
   Gomes, JAS
   Correa-Oliveira, R
   Nogueira, ML
   Kroon, EG
   da Fonseca, FG
AF Trindade, Giliane S.
   Guedes, Maria I. C.
   Drumond, Betania P.
   Mota, Bruno E. F.
   Abrahao, Jonatas S.
   Lobato, Zelia I. P.
   Gomes, Juliana A. S.
   Correa-Oliveira, Rodrigo
   Nogueira, Mauricio L.
   Kroon, Erna G.
   da Fonseca, Flavio G.
TI Zoonotic Vaccinia Virus: Clinical and Immunological Characteristics in a
   Naturally Infected Patient
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID COWPOX; BRAZIL; HUMANS
AB Vaccinia virus was used as vaccine to eradicate smallpox. We report a zoonotic case of vaccinia virus infection in a 30-year-old patient who became infected after handling sick dairy cattle. The patient had inflamed lesions and systemic symptoms. Laboratory findings were indicative of down-modulated immune responses to the virus.
C1 [Trindade, Giliane S.; Guedes, Maria I. C.; Drumond, Betania P.; Mota, Bruno E. F.; Abrahao, Jonatas S.; Kroon, Erna G.; da Fonseca, Flavio G.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Lobato, Zelia I. P.] Univ Fed Minas Gerais, Escola Vet, BR-31270901 Belo Horizonte, MG, Brazil.
   [Gomes, Juliana A. S.; Correa-Oliveira, Rodrigo; da Fonseca, Flavio G.] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Dept Doencas Infecciosas & Parasitarias, Sao Jose Do Rio Preto, Brazil.
RP da Fonseca, FG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM fdafonseca@cpqrr.fiocruz.br
RI Abrahao, Jonatas/B-3895-2015; Gomes, Juliana A. S./M-4083-2017;
   Nogueira, Mauricio L/B-7599-2012; Kroon, Erna Geessien/B-3631-2015;
   Kroon, Erna/V-5444-2019
OI Abrahao, Jonatas/0000-0001-9420-1791; Gomes, Juliana A.
   S./0000-0002-8332-2907; Nogueira, Mauricio L/0000-0003-1102-2419; Kroon,
   Erna Geessien/0000-0003-2721-3826; Mota, Bruno/0000-0003-0348-4875;
   Correa-Oliveira, Rodrigo/0000-0001-6419-9459; Lobato,
   Zelia/0000-0002-9399-3691
FU Brazilian National Council of Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas GeraisMinas
   Gerais State Research Foundation (FAPEMIG); Division of Microbiology and
   Infectious Diseases; National Institute of Allergy and Infectious
   DiseaseUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA
FX Brazilian National Council of Scientific and Technological Development
   (through a Strategic Program for Health Research IV grant and
   fellowships to F.G.d.F., E.G.K., Z.I.P.L., and R.C.-O.), Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais, and the Division of
   Microbiology and Infectious Diseases, National Institute of Allergy and
   Infectious Disease, National Institutes of Health Opportunity Pool fund.
CR Amanna IJ, 2006, IMMUNOL REV, V211, P320, DOI 10.1111/j.0105-2896.2006.00392.x
   Coras B, 2005, LANCET, V365, P446
   Ferrier-Rembert A, 2007, VACCINE, V25, P4809, DOI 10.1016/j.vaccine.2007.04.011
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Honlinger B, 2005, BRIT J DERMATOL, V153, P451, DOI 10.1111/j.1365-2133.2005.06731.x
   Johnston JB, 2003, J VIROL, V77, P6093, DOI 10.1128/JVI.77.11.6093-6100.2003
   Kolhapure RM, 1997, INDIAN J MED RES, V106, P441
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668
NR 13
TC 27
Z9 27
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 1
PY 2009
VL 48
IS 3
BP E37
EP E40
DI 10.1086/595856
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 392GM
UT WOS:000262291200022
PM 19115976
OA Bronze
DA 2020-12-08
ER

PT J
AU Catalan-Soares, BC
   Carneiro-Proietti, ABF
   Da Fonseca, FG
   Correa-Oliveira, R
   Peralva-Lima, D
   Portela, R
   Ribas, JG
   Goncalves, DU
   Proietti, FA
AF Catalan-Soares, B. C.
   Carneiro-Proietti, Anna Barbara F.
   Da Fonseca, F. G.
   Correa-Oliveira, R.
   Peralva-Lima, D.
   Portela, R.
   Ribas, J. G.
   Goncalves, D. U.
   Proietti, F. A.
CA Interdisciplinary HTLV Res Grp GIP
TI HLA class I alleles in HTLV-1-associated myelopathy and asymptomatic
   carriers from the Brazilian cohort GIPH
SO MEDICAL MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE HTLV-1; HAM/TSP; HLA
ID HTLV-I; INFECTION; DISEASES
AB The development of HTLV-1-associated myelopathy (HAM/TSP) in HTLV-1-infected individuals is probably a multi-factor event, in which the immune system plays a crucial role. The efficiency of the host immunity seems to be one of the in vivo determining factors of the proviral load levels and is regulated by genes associated with MHC class I alleles (HLA). Protection or predisposition to HTLV-1-associated diseases according to individual HLA profile was shown in Japanese studies. The present work tested for HLA alleles previously related to protection or susceptibility to HTLV-1-associated myelopathy in a cohort study (GIPH) from Brazil.
   A total of 93 HTLV-1-infected individuals participated in the study, as follows: 84 (90.3%) asymptomatic and 9 (9.7%) with HAM/TSP. Alleles related to protection (A*02, Cw*08) and susceptibility (B*07, Cw*08 and B*5401) were tested by the PCR-SSP method.
   Allele A*02 was more frequent in the asymptomatic group and in its absence, Cw*07 was correlated with HAM/TSP (P = 0.002). Allele B*5401 was not present in the Brazilian population. Alleles B*07 and Cw*08 were not different between the groups
   The presence of HLA-A2 elicits a stronger cytotoxic response, which is involved in the HTLV-1 proviral load reduction. This study confirmed a tendency of this allele to protect against HAM-TSP. Therefore, A*02 might be of interest for researches involved with HTLV-1 vacine.
C1 [Catalan-Soares, B. C.; Carneiro-Proietti, Anna Barbara F.; Portela, R.] Fundacao Hemominas, BR-30150340 Belo Horizonte, MG, Brazil.
   [Da Fonseca, F. G.; Correa-Oliveira, R.; Peralva-Lima, D.] Ctr Pesquisas Rene Rachou Fiocruz, Belo Horizonte, MG, Brazil.
   [Ribas, J. G.] Rede Sarah Hosp Aparelho Locomotor, Belo Horizonte, MG, Brazil.
   [Goncalves, D. U.; Proietti, F. A.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil.
RP Carneiro-Proietti, ABF (corresponding author), Fundacao Hemominas, Rua Grao Para 882, BR-30150340 Belo Horizonte, MG, Brazil.
EM annaproietti@hemominas.mg.gov.br
RI Goncalves, Denise Utsch/A-8203-2013
OI Goncalves, Denise Utsch/0000-0002-9154-7436; Correa-Oliveira,
   Rodrigo/0000-0001-6419-9459; RIBAS, JOAO GABRIEL/0000-0002-7352-8602
FU Minas Gerais State Centre of Hematology and Blood Transfusion (Fundacao
   Hemominas); Fundacao de Amparo a Pesquisa de Minas Gerais (Fapemig)Minas
   Gerais State Research Foundation (FAPEMIG); Conselho Nacional de
   Desen-volvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX Minas Gerais State Centre of Hematology and Blood Transfusion (Fundacao
   Hemominas), Fundacao de Amparo a Pesquisa de Minas Gerais (Fapemig) and
   Conselho Nacional de Desen-volvimento Cientifico e Tecnologico (CNPq)
   supported this work. This work was performed by researchers
   participating in the HTLV Interdisciplinary Research Group (GIPH),
   Brazil.
CR Borducchi DM, 2003, BRIT J HAEMATOL, V123, P954, DOI 10.1046/j.1365-2141.2003.04711.x
   GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933
   IMANISHI T, 1992, HLA 1991, P1065
   Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
   Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278
   OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   Rafatpanah Houshang, 2007, Iran J Immunol, V4, P94
NR 8
TC 12
Z9 12
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0300-8584
EI 1432-1831
J9 MED MICROBIOL IMMUN
JI Med. Microbiol. Immunol.
PD FEB
PY 2009
VL 198
IS 1
BP 1
EP 3
DI 10.1007/s00430-008-0096-z
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA 396FC
UT WOS:000262576600001
PM 18521626
DA 2020-12-08
ER

PT J
AU Trindade, GD
   Li, Y
   Olson, VA
   Emerson, G
   Regnery, RL
   da Fonseca, FG
   Kroon, EG
   Damon, I
AF Trindade, Giliane de Souza
   Li, Yu
   Olson, Victoria A.
   Emerson, Ginny
   Regnery, Russell L.
   da Fonseca, Flavio Guimaraes
   Kroon, Erna Geessien
   Damon, Inger
TI Real-time PCR assay to identify variants of Vaccinia virus: Implications
   for the diagnosis of bovine vaccinia in Brazil
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE vaccinia virus; bovine vaccinia outbreaks; diagnostic; real-time PCR
ID RIO-DE-JANEIRO; VARIOLA VIRUS; SMALLPOX; POXVIRUS; ORTHOPOXVIRUSES;
   DIFFERENTIATION; STRAINS; CATTLE; IDENTIFICATION; INFECTION
AB Naturally occurring infections of Vaccinia virus (VACV) have been recognized in Brazil during the past 10 years. Human Brazilian Vaccinia virus (BVV) infections typically occur as a zoonosis transferred from affected dairy cows to their handlers. Outbreaks have caused notable economic losses to the rural community in the region. The origins of BVV are unclear but previous analyses have shown that at least two distinct clades of BVV exist. The aim of this study was to develop a rapid and inexpensive process for identification and differentiation of BVV that should facilitate epidemiological and ecological investigations including the improved diagnosis of Brazilian Orthopoxvirus infections. A SYBR green quantitative real-time polymerase chain reaction (PCR) targeting the hernagglutinin gene was developed to identify different populations of BVV, VACV vaccine strains used in Brazil during the smallpox eradication campaign (Vaccinia Lister (VACV-LIS) and New York City Board of Health (VACV-NYCBH)), and currently available vaccines (VACV-NYCBH DRYVAX and VACV-NYCBH Acambis 2000). Three primer combinations (one to amplify many orthopoxviruses including all vaccinia viruses described so far; one to differentiate BVV from vaccine strains (VACV-LIS, VACV-NYCBH DRYVAX and VACV-NYCBH Acambis 2000); and one to differentiate BVV clades) were designed to work at the same annealing temperature and reaction conditions. In addition, these methods were able to detect orthopoxvirus viral DNA in lesion biopsy material without the need for DNA extraction. Published by Elsevier B.V.
C1 [Trindade, Giliane de Souza; Li, Yu; Olson, Victoria A.; Emerson, Ginny; Regnery, Russell L.; Damon, Inger] Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, Poxvirus & Rabies Branch, Div Viral & Rickettsial Dis,Natl Ctr Zoonot Vecto, Atlanta, GA 30333 USA.
   [Trindade, Giliane de Souza] Atlanta Res & Educ Fdn, Atlanta, GA USA.
   [da Fonseca, Flavio Guimaraes; Kroon, Erna Geessien] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Damon, I (corresponding author), Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, Poxvirus & Rabies Branch, Div Viral & Rickettsial Dis,Natl Ctr Zoonot Vecto, 1600 Clifton Rd NE,Mailstop G-06, Atlanta, GA 30333 USA.
EM gitrindade@yahoo.com.br; lay4@cdc.gov; vao9@cdc.gov; dtt4@cdc.gov;
   rur1@cdc.gov; fdafonseca@cpqrr.fiocruz.br; kroone@icb.ufmg.br;
   idamon@cdc.gov
RI Kroon, Erna/V-5444-2019; Kroon, Erna Geessien/B-3631-2015
OI Kroon, Erna Geessien/0000-0003-2721-3826
CR Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P478
   Carletti F, 2005, J VIROL METHODS, V129, P97, DOI 10.1016/j.jviromet.2005.05.020
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P537
   Damaso CRA, 2007, DIAGN MICR INFEC DIS, V57, P39, DOI 10.1016/j.diagmicrobio.2006.07.012
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005
   Fedele CG, 2006, J CLIN MICROBIOL, V44, P4464, DOI 10.1128/JCM.00276-06
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Gallina L, 2006, J VIROL METHODS, V134, P140, DOI 10.1016/j.jviromet.2005.12.014
   JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Li Y, 2007, P NATL ACAD SCI USA, V104, P15787, DOI 10.1073/pnas.0609268104
   Li Y, 2006, J CLIN VIROL, V36, P194, DOI 10.1016/j.jcv.2006.03.012
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   Loparev VN, 2001, J CLIN MICROBIOL, V39, P94, DOI 10.1128/JCM.39.1.94-100.2001
   McLaughlin J., 2007, Morbidity and Mortality Weekly Report, V56, P417
   Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6
   MOSS B, 2001, POXVIRIDAE VIRUSES T, P2849
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Nitsche A, 2006, CLIN CHEM, V52, P316, DOI 10.1373/clinchem.2005.060335
   Nitsche A, 2005, J VIROL METHODS, V126, P187, DOI 10.1016/j.jviromet.2005.02.007
   Olson VA, 2004, J CLIN MICROBIOL, V42, P1940, DOI 10.1128/JCM.42.5.1940-1946.2004
   Panning M, 2004, CLIN CHEM, V50, P702, DOI 10.1373/clinchem.2003.026781
   ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995
   Scaramozzino N, 2007, CLIN CHEM, V53, P606, DOI 10.1373/clinchem.2006.068635
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   SOFI IM, 2003, J CLIN MICROBIOL, V41, P3835, DOI DOI 10.1128/JCM.41.8.3835-3839.2003
   Trindade GS, 2007, J VIROL METHODS, V141, P198, DOI 10.1016/j.jviromet.2006.12.006
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2007, EMERG INFECT DIS, V13, P965, DOI 10.3201/eid1307.061404
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916
NR 34
TC 25
Z9 26
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD SEP
PY 2008
VL 152
IS 1-2
BP 63
EP 71
DI 10.1016/j.jviromet.2008.05.028
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 344BR
UT WOS:000258900800011
PM 18602170
DA 2020-12-08
ER

PT J
AU Drumond, BP
   Leite, JA
   da Fonseca, FG
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF Drumond, Betania Paiva
   Leite, Juliana Almeida
   da Fonseca, Flavio Guimaraes
   Bonjardim, Claudio Antonio
   Peregrino Ferreira, Paulo Cesar
   Kroon, Erna Geessien
TI Brazilian Vaccinia virus strains are genetically divergent and differ
   from the Lister vaccine strain
SO MICROBES AND INFECTION
LA English
DT Article
DE poxvirus; Vaccinia virus; smallpox; vaccine; poxvirus infections;
   phylogeny; genetic diversity; genetic polymorphisms
ID GENOME SEQUENCE; POXVIRUS; ATI
AB Vaccinia virus is responsible for an important zoonotic disease affecting dairy cattle and humans in Brazil, but little is known about the origin, epidemiology and evolution of these Brazilian Vaccinia virus strains. In this work, seven Brazilian Vaccinia virus strains and the Lister-derived Brazilian vaccine strain, named Lister-Butantan, were compared based on the sequences of ten host range and virulence related genes. Comparison of Brazilian Vaccinia virus strains with Lister-Butantan revealed several differences. Phylogenetic analyses confirmed the existence of genetically distinct Brazilian Vaccinia virus groups and has not thus far demonstrated a close relationship between Brazilian strains and Lister-Butantan. In this study, the BeAn58058 and SPAn232 strains were grouped together with the Belo Horizonte and Guarani PI strains. Additionally, genetic polymorphisms in host range and virulence genes as well as differences in the deduced amino acid sequences were detected among Brazilian Vaccinia virus. This genetic diversity may result in a plethora of different biological properties presented by Brazilian Vaccinia virus, including differences in adaptation to the host as well as pathogenic properties. Furthermore, co-circulation of these divergent strains could increase the possibility of recombination events in nature, leading to the formation of new variants with unpredictable pathogenic potential. (C) 2007 Elsevier Masson SAS. All rights reserved.
C1 [Drumond, Betania Paiva; Leite, Juliana Almeida; da Fonseca, Flavio Guimaraes; Bonjardim, Claudio Antonio; Peregrino Ferreira, Paulo Cesar; Kroon, Erna Geessien] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, BR-31270901 Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, Avenida Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna Geessien/B-3631-2015; Bonjardim, Claudio A/J-2601-2014;
   Kroon, Erna/V-5444-2019
OI Kroon, Erna Geessien/0000-0003-2721-3826; 
CR Aldaz-Carroll L, 2005, J VIROL, V79, P6260, DOI 10.1128/JVI.79.10.6260-6271.2005
   BULLER RM, 2005, POXVIRIDAE VIRUS TAX, P117
   Chen NH, 2005, VIROLOGY, V340, P46, DOI 10.1016/j.virol.2005.05.030
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Esposito JJ, 2006, SCIENCE, V313, P807, DOI 10.1126/science.1125134
   FENNER R, 1988, SMALLPOX ITS ERADICA
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Leite JA, 2007, VIRUS GENES, V35, P531, DOI 10.1007/s11262-007-0133-9
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Li G, 2005, J GEN VIROL, V86, P2969, DOI 10.1099/vir.0.81331-0
   Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0
   Marques JT, 2001, VIRUS GENES, V23, P291, DOI 10.1023/A:1012521322845
   Martin DP, 2005, BIOINFORMATICS, V21, P260, DOI 10.1093/bioinformatics/bth490
   Meng XZ, 2006, VIROLOGY, V353, P220, DOI 10.1016/j.virol.2006.05.032
   Morikawa S, 2005, J VIROL, V79, P11873, DOI 10.1128/JVI.79.18.11873-11891.2005
   Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   RISI JB, 1968, ARQUIVOS HIGIENE, V24, P119
   ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995
   Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
   Tulman ER, 2006, J VIROL, V80, P9244, DOI 10.1128/JVI.00945-06
   Turner PC, 2006, VIROLOGY, V347, P88, DOI 10.1016/j.virol.2005.11.012
NR 30
TC 35
Z9 36
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD FEB
PY 2008
VL 10
IS 2
BP 185
EP 197
DI 10.1016/j.micinf.2007.11.005
PG 13
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 285OF
UT WOS:000254785400011
PM 18248758
DA 2020-12-08
ER

PT J
AU Trindade, GD
   da Fonseca, FG
   Lobato, ZIP
   Guedes, MIMC
   Kroon, EG
   Damon, I
AF Trindade, Giliane de Souza
   da Fonseca, Flavio Guimaraes
   Portela Lobato, Zelia Ines
   Guedes, Maria Isabel M. C.
   Kroon, Erna Geessien
   Damon, Inger
TI The emergence of vaccinia virus in Brazil
SO INDIAN JOURNAL OF VIROLOGY
LA English
DT Meeting Abstract
C1 [Trindade, Giliane de Souza; Damon, Inger] Ctr Dis Control & Prevent CCID CDC, Coordinating Ctr Infect Dis, Atlanta, GA USA.
   [Trindade, Giliane de Souza] Atlanta Res & Educ Fdn, Atlanta, GA USA.
   [Trindade, Giliane de Souza; da Fonseca, Flavio Guimaraes; Portela Lobato, Zelia Ines; Kroon, Erna Geessien] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RI Kroon, Erna/V-5444-2019
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INDIAN VIROLOGICAL SOC
PI HISAR
PA CCS HARYANA AGRICULTURAL UNIV, DEPT PLANT PATHOLOGY, HISAR, 125 004,
   INDIA
SN 0970-2822
J9 INDIAN J VIROL
JI Indian J. Virol.
PD JAN
PY 2008
VL 19
IS 1
BP 63
EP 63
PG 1
WC Virology
SC Virology
GA 349TB
UT WOS:000259305100051
DA 2020-12-08
ER

PT J
AU Trindade, G
   Emerson, G
   Sammons, S
   Frace, M
   Govil, D
   Olsen-Rasmussen, M
   Li, Y
   Carroll, D
   Regnery, R
   Da Fonseca, FG
   Kroon, E
   Damon, I
AF Trindade, Giliane
   Emerson, Ginny
   Sammons, Scott
   Frace, Mike
   Govil, Dhwani
   Olsen-Rasmussen, Melissa
   Li, Yu
   Carroll, Darin
   Regnery, Russell
   Da Fonseca, Flavio Guimaraes
   Kroon, Erna
   Damon, Inger
TI Characterization of a novel Brazilian vaccinia virus isolated from human
   and comparative analysis with orthopoxviruses
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Trindade, Giliane; Emerson, Ginny; Li, Yu; Carroll, Darin; Regnery, Russell; Damon, Inger] Ctr Dis Control & Prevent, CCID, DVRD, PRB, Atlanta, GA USA.
   [Sammons, Scott; Frace, Mike; Govil, Dhwani; Olsen-Rasmussen, Melissa] Ctr Dis Control & Prevent, CCID, Atlanta, GA USA.
   [Da Fonseca, Flavio Guimaraes; Kroon, Erna] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RI Kroon, Erna/V-5444-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 991
BP 283
EP 283
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758201449
DA 2020-12-08
ER

PT J
AU Trindade, GS
   Vilela, JMC
   Ferreira, JMS
   Aguiar, PHN
   Leite, JA
   Guedes, MIMC
   Lobato, ZIP
   Madureira, MC
   da Silva, MIN
   da Fonseca, FG
   Kroon, EG
   Andrade, MS
AF Trindade, G. S.
   Vilela, J. M. C.
   Ferreira, J. M. S.
   Aguiar, P. H. N.
   Leite, J. A.
   Guedes, M. I. M. C.
   Lobato, Z. I. P.
   Madureira, M. C.
   da Silva, M. I. N.
   da Fonseca, F. G.
   Kroon, E. G.
   Andrade, M. S.
TI Use of atomic force microscopy as a diagnostic tool to identify
   orthopoxvirus
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE AFM; diagnosis; bovine vaccinia outbreaks; orthopoxviruses; Vaccinia
   virus; biosecurity
ID VACCINIA-VIRUS; ELECTRON-MICROSCOPY; HIGH-RESOLUTION; POXVIRUS; HUMANS;
   CATTLE; OUTBREAK; STRAINS; REGION; BRAZIL
AB Atomic force microscopy (AFM) is a versatile technique that permits the imaging of surfaces and generates topographical images from a variety of materials. Due to the fact that AFM requires minimum sample manipulation, it is a valuable tool for studying biological materials such as cells, DNA, bacteria and viruses. The aim of the present study was to standardize the AFM technique as a diagnostic tool for detection of naturally occurring orthopox viruses. The samples analyzed were collected during natural outbreaks of Vaccinia virus (VACV) in dairy cattle in Brazil. These viruses are zoonotic infections; and therefore safe manipulation of all samples is required. The AFM technique would provide a more secure way to diagnose infection. By using the "in air" AFM technique after purification and inactivation process, relatively crude preparations of viruses were visualized rapidly. Details for efficient sample preparation and AFM imaging are described. The AFM technique provides a rapid and biosecure tool for the diagnosis of emerging orthopoxviruses and has potential as a tool for screening bioterrorism samples. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Escola Vet, Dept Med Vet Prevent, BR-31270901 Belo Horizonte, MG, Brazil.
   CETEC, Lab Nanoscopia, Fdn Ctr Tecnol Minas Gerais, BR-31170000 Belo Horizonte, MG, Brazil.
   CETEC, Lab Reol, Fdn Ctr Tecnol Minas Gerais, BR-31170000 Belo Horizonte, MG, Brazil.
   Inst Mineiro Agropecuaria, BR-30120010 Belo Horizonte, MG, Brazil.
   Fiocruz MS, Lab Imunol Celular & Mol, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virus, Av Antonio Carlos,6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM gitrindade@yahoo.com.br; jose.mario.vilela@cetec.br; jackie@icb.ufmg.br;
   phnaguiar@uol.com.br; ju@icb.ufmg.br; isabelguedes@icb.ufmg.br;
   ziplobat@vet.ufmg.br; marietacristinam@yahoo.com.br;
   ivonete.nogueira@cetec.br; fdafonseca@cpqrr.fiocruz.br;
   masc.egk@terra.com.br; margareth.spangler@cetec.br
RI Kroon, Erna/V-5444-2019; Kroon, Erna Geessien/B-3631-2015
OI Kroon, Erna Geessien/0000-0003-2721-3826; Lobato,
   Zelia/0000-0002-9399-3691; Aguiar, Pedro/0000-0002-4942-5021
CR BRENNER S, 1959, BIOCHIM BIOPHYS ACTA, V34, P103, DOI 10.1016/0006-3002(59)90237-9
   CAMPOS MAD, 1993, REV MICROBIOL, V24, P104
   CARDOSO AV, 2005, MICROSCI MICROANAL, V11, P86
   Cyrklaff M, 2005, P NATL ACAD SCI USA, V102, P2772, DOI 10.1073/pnas.0409825102
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   DUBOCHET J, 1994, J VIROL, V68, P1935, DOI 10.1128/JVI.68.3.1935-1941.1994
   Dufrene YF, 2004, NAT REV MICROBIOL, V2, P451, DOI 10.1038/nrmicro905
   Hazelton PR, 2003, EMERG INFECT DIS, V9, P294, DOI 10.3201/eid0903.020327
   Johnsen CK, 2006, J VIROL METHODS, V134, P92, DOI 10.1016/j.jviromet.2005.12.007
   JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1
   Kitamoto N, 2005, MICROBIOL IMMUNOL, V49, P219, DOI 10.1111/j.1348-0421.2005.tb03723.x
   Kuznetsov YG, 2005, J VIROL, V79, P1970, DOI 10.1128/JVI.79.3.1970-1974.2005
   Kuznetsov YG, 2001, J GEN VIROL, V82, P2025, DOI 10.1099/0022-1317-82-9-2025
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   Loparev VN, 2001, J CLIN MICROBIOL, V39, P94, DOI 10.1128/JCM.39.1.94-100.2001
   Malkin AJ, 1999, J STRUCT BIOL, V127, P35, DOI 10.1006/jsbi.1999.4128
   Malkin AJ, 2003, J VIROL, V77, P6332, DOI 10.1128/JVI.77.11.6332-6340.2003
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Nettikadan SR, 2003, BIOCHEM BIOPH RES CO, V311, P540, DOI 10.1016/j.bbrc.2003.10.022
   Plomp M, 2002, AM J PATHOL, V160, P1959, DOI 10.1016/S0002-9440(10)61145-5
   SOFI IM, 2003, J CLIN MICROBIOL, V41, P3835, DOI DOI 10.1128/JCM.41.8.3835-3839.2003
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
NR 26
TC 13
Z9 16
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD MAY
PY 2007
VL 141
IS 2
BP 198
EP 204
DI 10.1016/j.jviromet.2006.12.006
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 162JN
UT WOS:000246083200011
PM 17239966
DA 2020-12-08
ER

PT J
AU Trindade, GDS
   Drumond, BP
   Guedes, MIMC
   Leite, JA
   Mota, BEF
   Campos, MA
   da Fonseca, FG
   Nogueira, ML
   Lobato, ZIP
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF Trindade, Giliane de Souza
   Drumond, Betania Paiva
   Maldonado Coelho Guedes, Maria Isabel
   Leite, Juliana Almeida
   Fernandes Mota, Bruno Eduardo
   Campos, Marco Antnio
   da Fonseca, Flavio Guimaraes
   Nogueira, Mauricio Lacerda
   Portela Lobato, Zelia Ines
   Bonjardim, Claudio Antnio
   Peregrino Ferreira, Paulo Cesar
   Kroon, Erna Geessien
TI Zoonotic vaccinia virus infection in Brazil: Clinical description and
   implications for health professionals
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SEQUENCE ALIGNMENT; HUMANS; POXVIRUS; CATTLE
AB Bovine vaccinia virus outbreaks have been occurring in different regions of Brazil. We report here the time course of natural human infection by vaccinia virus and describe important clinical and epidemiological aspects of this zoonotic infection. The diagnosis of vaccinia virus infection was based on clinical, serological, and molecular procedures.
C1 Univ Fed Minas Gerais, Inst Ciencias Biol, Virus Lab, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunopatol, BR-30190002 Belo Horizonte, MG, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol Celular & Mol, BR-30190002 Belo Horizonte, MG, Brazil.
   Fac Med Sao Jose Do Rio Preto, Dept Doencas Infecc & Parasitarias, Lab Pesquisas Virol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   Univ Fed Minas Gerais, Dept Prevent Med, Escola Vet, BR-31270901 Belo Horizonte, MG, Brazil.
RP Ferreira, PCP (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Virus Lab, Dept Microbiol, Av Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM masc.egk@terra.com.br
RI Nogueira, Mauricio L/B-7599-2012; Kroon, Erna/V-5444-2019; Bonjardim,
   Claudio A/J-2601-2014; Kroon, Erna Geessien/B-3631-2015; Campos, Marco
   A/C-4000-2013
OI Nogueira, Mauricio L/0000-0003-1102-2419; Kroon, Erna
   Geessien/0000-0003-2721-3826; Campos, Marco A/0000-0003-4683-0176;
   Lobato, Zelia/0000-0002-9399-3691; Mota, Bruno/0000-0003-0348-4875
CR Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003
   Malkin AJ, 2003, J VIROL, V77, P6332, DOI 10.1128/JVI.77.11.6332-6340.2003
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GS, 2006, AM J TROP MED HYG, V75, P486, DOI 10.4269/ajtmh.2006.75.486
NR 10
TC 40
Z9 40
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2007
VL 45
IS 4
BP 1370
EP 1372
DI 10.1128/JCM.00920-06
PG 3
WC Microbiology
SC Microbiology
GA 158GI
UT WOS:000245779300055
PM 17287326
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Mondini, A
   Cardeal, ILS
   Lazaro, E
   Nunes, SH
   Moreira, CC
   Rahal, P
   Maia, IL
   Franco, C
   Gongora, DVN
   Gongora-Rubio, F
   Cabrera, EMS
   Figueiredo, LTM
   da Fonseca, FG
   Bronzoni, RVM
   Chiaravalloti-Neto, F
   Nogueira, ML
AF Mondini, Adriano
   Soares Cardeal, Izabela Lidia
   Lazaro, Eduardo
   Nunes, Silva H.
   Moreira, Cibele C.
   Rahal, Paula
   Maia, Irineu L.
   Franco, Celia
   Gongora, Delzi V. N.
   Gongora-Rubio, Fernando
   Sotello Cabrera, Eliana Marcia
   Moraes Figueiredo, Luiz Tadeu
   da Fonseca, Flavio Guimaraes
   Moraes Bronzoni, Roberta Vieira
   Chiaravalloti-Neto, Franscisco
   Nogueira, Mauricio Lacerda
TI Saint Louis encephalitis virus, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
C1 FAMERP, Fac Med Sao Jose Do Rio Preto, Dept Doencas Infecc & Parasit, Lab Pesquisas Virol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   Secretaria Municipal Saude, Sao Paulo, Brazil.
   Univ Estadual Paulista, BR-01405 Sao Paulo, Brazil.
   Hosp Base Sao Jose Do Rio Preto, Sao Paulo, Brazil.
   Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil.
   Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RP Nogueira, ML (corresponding author), FAMERP, Fac Med Sao Jose Do Rio Preto, Dept Doencas Infecc & Parasit, Lab Pesquisas Virol, Av Brigadeiro Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM mnogueira@famerp.br
RI Cabrera, Eliana/B-3190-2016; Mondini, Adriano/F-7446-2012; Figueiredo,
   Luiz T/E-3702-2012; Neto, Francisco Chiaravalloti/F-8006-2012; Rahal,
   Paula/D-3871-2012; Mondini, Adriano/AAB-4358-2020; Bronzoni,
   Roberta/J-8917-2012; Nogueira, Mauricio L/B-7599-2012
OI Cabrera, Eliana/0000-0002-6967-5773; Mondini,
   Adriano/0000-0002-5557-9721; Neto, Francisco
   Chiaravalloti/0000-0003-2686-8740; Rahal, Paula/0000-0001-5693-6148;
   Mondini, Adriano/0000-0002-5557-9721; Nogueira, Mauricio
   L/0000-0003-1102-2419
CR Bronzoni RVD, 2005, J CLIN MICROBIOL, V43, P696, DOI 10.1128/JCM.43.2.696-702.2005
   da Silva ANM, 2006, MEM I OSWALDO CRUZ, V101, P547, DOI 10.1590/S0074-02762006000500011
   Figueiredo LTM, 2000, MICROBES INFECT, V2, P1643, DOI 10.1016/S1286-4579(00)01320-4
   LOPES ODS, 1979, AM J TROP MED HYG, V28, P583
   Mondini A, 2005, REV SAUDE PUBL, V39, P444, DOI [10.1590/S0034-89102005000300016, 10.1590/s0034-89102005000300016]
   Rocco Iray M., 2005, Rev. Inst. Med. trop. S. Paulo, V47, P281, DOI 10.1590/S0036-46652005000500008
   Sabattini MS, 1998, OVERVIEW ARBOVIROLOG, P113
   Spinsanti L, 2003, EMERG INFECT DIS, V9, P271
   SPINSANTI Lorena Ivana, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P59, DOI 10.1590/S0036-46652002000200001
   Vasconcelos P., 1998, OVERVIEW ARBOVIROLOG, P72
NR 10
TC 59
Z9 62
U1 0
U2 5
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JAN
PY 2007
VL 13
IS 1
BP 176
EP 178
DI 10.3201/eid1301.060905
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 128XH
UT WOS:000243692500037
PM 17370543
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Trindade, GS
   Lobato, ZIP
   Drumond, BP
   Leite, JA
   Trigueiro, RC
   Guedes, MIMC
   Da Fonseca, FG
   Dos Santos, JR
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF Trindade, Giliane S.
   Lobato, Zelia I. P.
   Drumond, Betania P.
   Leite, Juliana A.
   Trigueiro, Ricardo C.
   Guedes, Maria I. M. C.
   Da Fonseca, Flavio G.
   Dos Santos, Joao R.
   Bonjardim, Claudio A.
   Ferreira, Paulo C. P.
   Kroon, Erna G.
TI Short report: Isolation of two Vaccinia virus strains from a single
   bovine vaccinia outbreak in rural area from Brazil: Implications on the
   emergence of zoonotic orthopoxviruses
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; RIO-DE-JANEIRO; SEQUENCE ALIGNMENT;
   DNA-SEQUENCE; CATTLE; POXVIRUS; HUMANS; REGION; GENOME; STATE
AB Outbreaks of bovine vaccinia disease caused by circulation of Vaccinia virus (VACV) strains have been a common occurrence in Brazil in the recent years, being an important emergent zoonosis. During a single outbreak that took place in 2001, two genetically different VACV strains were isolated and named Guarani P1 virus (GP1V) and Guarani P2 virus (GP2V). Molecular diagnosis was done through restriction fragment length polymorphism (RFLP) of ati gene (A26L) and by sequence analysis of a group of five VACV genes including the C11R, J2R, A56R, B18R, and E3L genes. These findings confirmed the co-circulation of two different Vaccinia virus strains during the same outbreak, raising important questions about the origin, emergence, and circulation of VACV strains in Brazil.
C1 Univ Fed Minas Gerais, Virus Lab, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Escola Vet, Dept Med Vet Prevent, BR-31270901 Belo Horizonte, MG, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Inmunol Celular & Mol, Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Virus Lab, Dept Microbiol, Inst Ciencias Biol, Av Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Bonjardim, Claudio A/J-2601-2014; Kroon, Erna
   Geessien/B-3631-2015
OI Kroon, Erna Geessien/0000-0003-2721-3826; Lobato,
   Zelia/0000-0002-9399-3691
CR da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Lobato ZIP, 2005, ARQ BRAS MED VET ZOO, V57, P423, DOI 10.1590/S0102-09352005000400001
   Malkin AJ, 2003, J VIROL, V77, P6332, DOI 10.1128/JVI.77.11.6332-6340.2003
   Marques JT, 2001, VIRUS GENES, V23, P291, DOI 10.1023/A:1012521322845
   Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   Neubauer H, 1997, LAB ANIM, V31, P201, DOI 10.1258/002367797780596275
   PEARSON W, 2006, LALIGN FIND MULTIPLE
   ROOP SL, 1995, J CLIN MICROBIOL, V33, P2069
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
NR 22
TC 75
Z9 77
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 2006
VL 75
IS 3
BP 486
EP 490
DI 10.4269/ajtmh.2006.75.486
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 083RR
UT WOS:000240476400019
PM 16968926
OA Bronze
DA 2020-12-08
ER

PT J
AU Leite, JA
   Drumond, BP
   Trindade, GS
   Lobato, ZIP
   da Fonseca, FG
   dos Santos, JR
   Madureira, MC
   Guedes, MIMC
   Ferreira, JMS
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF Leite, JA
   Drumond, BP
   Trindade, GS
   Lobato, ZIP
   da Fonseca, FG
   dos Santos, JR
   Madureira, MC
   Guedes, MIMC
   Ferreira, JMS
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
TI Passatempo virus, a vaccinia virus strain, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID SEQUENCE ALIGNMENT; COWPOX VIRUS; GENE; SMALLPOX; POXVIRUS; HUMANS;
   FOREST; CATTLE
AB Passatempo virus was isolated during a zoonotic outbreak. Biologic features and molecular characterization of hemagglutinin, thymidine kinase, and vaccinia growth factor genes suggested a vaccinia virus infection, which strengthens the idea of the reemergence and circulation of vaccinia virus in Brazil. Molecular polymorphisms indicated that Passatemoo virus is a different isolate.
C1 Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, BR-31270901 Belo Horizonte, MG, Brazil.
   Fdn Inst Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   Inst Mineiro Agropecuaria, Belo Horizonte, MG, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, Av Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM kroone@icb.ufmg.br
RI Kroon, Erna/V-5444-2019; Bonjardim, Claudio A/J-2601-2014; Kroon, Erna
   Geessien/B-3631-2015
OI Kroon, Erna Geessien/0000-0003-2721-3826; Lobato,
   Zelia/0000-0002-9399-3691
CR CROUCH AC, 1995, EPIDEMIOL INFECT, V115, P185, DOI 10.1017/S0950268800058258
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   da Fonseca FG, 1999, VIRUS GENES, V18, P151, DOI 10.1023/A:1008072720217
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6
   Morellato LPC, 2000, BIOTROPICA, V32, P786, DOI 10.1111/j.1744-7429.2000.tb00618.x
   Nagasse-Sugahara Teresa Keico, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P315, DOI 10.1590/S0036-46652004000600004
   ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trindade GD, 2003, EMERG INFECT DIS, V9, P155
   Trindade GS, 2004, J GEN VIROL, V85, P2015, DOI 10.1099/vir.0.79840-0
   UNIVERSAL VIRUS DATA
NR 14
TC 79
Z9 81
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2005
VL 11
IS 12
BP 1935
EP 1938
DI 10.3201/eid1112.050773
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 990UI
UT WOS:000233768300021
PM 16485483
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Trindade, GD
   da Fonseca, FG
   Marques, JT
   Nogueira, ML
   Mendes, LCN
   Borges, AS
   Peiro, JR
   Pituco, EM
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
AF Trindade, GD
   da Fonseca, FG
   Marques, JT
   Nogueira, ML
   Mendes, LCN
   Borges, AS
   Peiro, JR
   Pituco, EM
   Bonjardim, CA
   Ferreira, PCP
   Kroon, EG
TI Aracatuba virus: A vaccinialike m virus associated with infection in
   humans and cattle
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; RIO-DE-JANEIRO; MOLECULAR CHARACTERIZATION;
   POXVIRUS; ORTHOPOXVIRUS; STATE; DIFFERENTIATION; BEAN-58058; SMALLPOX;
   PROTEIN
AB We describe a vaccinialike virus, Aragatuba virus, associated with a cowpoxlike outbreak in a dairy herd and a related case of human infection. Diagnosis was based on virus growth characteristics, electron microscopy, and molecular biology techniques. Molecular characterization of the virus was done by using polymerase chain reaction amplification, cloning, an DNA sequencing of conserved orthopoxvirus genes such as the vaccinia growth factor (VGF), thymidine kinase (TK), and hemagglutinin. We used VGF-homologous and TK gene nucleoticle sequences to construct a phylogenetic tree for comparison with other poxviruses. Gene sequences showed 99% homology with vaccinia virus genes and were clustered together with the isolated virus in the phylogenetic tree. Aragatuba virus is very similar to Cantagalo virus, showing the same signature deletion in the gene. Aragatuba virus could be a novel vaccinialike virus or could represent the spread of Cantagalo virus.
C1 Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, BR-31270901 Belo Horizonte, MG, Brazil.
   NIH, Bethesda, MD 20892 USA.
   Univ Estadual Paulista, Sao Paulo, Brazil.
   Inst Biol, Sao Paulo, Brazil.
RP Kroon, EG (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Virus Lab, Av Antonio Carlos 6627,Caixa Postal 486, BR-31270901 Belo Horizonte, MG, Brazil.
RI Mendes, Luiz Claudio/B-8095-2012; Peiro, Juliana/C-4880-2012; Marques,
   Joao T/F-7683-2012; Borges, Alexandre S/B-5506-2013; Bonjardim, Claudio
   A/J-2601-2014; Mendes, Luiz Claudio Nogueira/N-2232-2019; Nogueira,
   Mauricio L/B-7599-2012; Kroon, Erna/V-5444-2019; Pituco, Edviges
   Maristela/J-2424-2012; Kroon, Erna/B-3631-2015
OI Mendes, Luiz Claudio/0000-0002-7696-6018; Marques, Joao
   T/0000-0002-3457-3320; Mendes, Luiz Claudio
   Nogueira/0000-0002-7696-6018; Nogueira, Mauricio L/0000-0003-1102-2419;
   Pituco, Edviges Maristela/0000-0003-1469-9257; Kroon,
   Erna/0000-0003-2721-3826; Secorun Borges, Alexandre/0000-0001-6256-8089
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   BLOOD DC, 1979, CAN VET J, V20, P341
   BRENNER S, 1959, BIOCHIM BIOPHYS ACTA, V34, P103, DOI 10.1016/0006-3002(59)90237-9
   CAMPOS MAD, 1993, REV MICROBIOL, V24, P104
   da Fonseca FG, 2002, J GEN VIROL, V83, P223, DOI 10.1099/0022-1317-83-1-223
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   DUMBELL K, 1993, ARCH VIROL, V128, P257, DOI 10.1007/BF01309438
   ESPOSITO JJ, 1980, J GEN VIROL, V47, P37, DOI 10.1099/0022-1317-47-1-37
   FENNER F, 1989, ORTHOPOXVIRUSES, P317
   Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365
   GIBBS EPJ, 1973, VET REC, V92, P56, DOI 10.1136/vr.92.3.56
   JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1
   LAUDER IM, 1971, VET REC, V89, P571, DOI 10.1136/vr.89.22.571
   LUM GS, 1967, AM J TROP MED HYG, V16, P332, DOI 10.4269/ajtmh.1967.16.332
   Marques JT, 2001, VIRUS GENES, V23, P291, DOI 10.1023/A:1012521322845
   MAZUR C, 1989, VET REC, V125, P419, DOI 10.1136/vr.125.16.419
   Mazur C, 2000, VET MICROBIOL, V73, P253, DOI 10.1016/S0378-1135(99)00151-0
   Meyer H, 1997, J VIROL METHODS, V64, P217, DOI 10.1016/S0166-0934(96)02155-6
   MEYER H, 1994, J GEN VIROL, V75, P1975, DOI 10.1099/0022-1317-75-8-1975
   Moss B, 1996, FIELDS VIROLOGY, V2, P2637
   REIS R, 1970, ARQUIVOS DA ESCOLA DE VETERINARIA UNIVERSIDADE FEDERAL DE MINAS GERAIS, V22, P213
   ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schatzmayr HG, 2000, MEM I OSWALDO CRUZ, V95, P625, DOI 10.1590/S0074-02762000000500007
   SILVA P L D, 1986, Arquivo Brasileiro de Medicina Veterinaria e Zootecnia, V38, P323
   Topciu V, 1976, Virologie, V27, P279
   Tryland M, 1998, J WILDLIFE DIS, V34, P240, DOI 10.7589/0090-3558-34.2.240
   UEDA Y, 1978, J GEN VIROL, V40, P263, DOI 10.1099/0022-1317-40-2-263
   VANBRESSEM MF, 1993, J WILDLIFE DIS, V29, P109, DOI 10.7589/0090-3558-29.1.109
   VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569
NR 30
TC 103
Z9 106
U1 0
U2 0
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2003
VL 9
IS 2
BP 155
EP 160
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 646KR
UT WOS:000181034600002
PM 12603984
OA DOAJ Gold
DA 2020-12-08
ER

EF